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ABSTRACT
Insulin resistance is associated with a number of metabolic abnormalities that increase 
the risk of developing coronary heart disease. Dietary fat has been linked with insulin 
resistance, with alterations in the quality as opposed to the quantity of dietary fat now 
thought be more important in instigating improvements in insulin resistance. The aim 
of this work was to investigate the effect of alterations in the dietary fat intakes of 
middle-aged men (n = 32) on the insulin sensitivity of glucose disposal and 
postprandial lipid metabolism and to explore the mechanistic links between these 
insulin responsive pathways. Three separate dietary interventions were conducted; the 
first involved an increase in the intake of «-3 polyunsaturated fat, the second a 
decrease in saturated fat and an increase in carbohydrate and the third a decrease in 
saturated fat and an increase in monounsatuiated fat intake. Compliance was 
monitored by the measurement of red blood cell phospholipid fatty acid composition, 
postprandial lipid metabolism was measured over 9 hours following a high-fat 
breakfast (80 g fat), and insulin resistance was measured using the short insulin 
tolerance test. The results of the study showed that while insulin sensitivity was 
inversely correlated with red blood cell saturated fatty acid concentration at baseline, 
the insulin sensitivity of glucose disposal was unaffected by any of the dietary 
interventions conducted. In measurements of postprandial lipaemia, improvements 
were observed following the low-saturated fat / high-monounsaturated fat diet and the 
n-3 polyunsaturated enriched diet, however the low-satuiated fat/ high-carbohydrate 
diet was associated with a worsening of postprandial lipaemia through an increase in 
the concentrations of triglyceride-rich-lipoproteins. Changes in fasting biochemical 
measurements were most evident in the low-saturated / high-monounsaturated diet, 
with an 11 % reduction in total cholesterol and a 15.4 % reduction in fasting 
triglycerides. There were no observed changes in the activity levels or the gene 
expression of lipoprotein lipase. There was an unexpected positive association 
between the degree of insulin sensitivity and the extent of postprandial lipaemia, 
indicating that the link between these pathways is complex and warrants further 
investigation. Overall this work supports the view that dietary guidelines should be 
diiected towards a change in the composition of fat, to a lower saturated fat intake, a 
higher monounsaturated fat intake and a lower «-6 : n-3> ratio thiough an increase in 
the intake of long chain n-3 polyunsaturated fatty acids.
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CHAPTER 1.0 
INTRODUCTION
1.1 INSULIN RESISTANCE
1.1.1 DEFINITION OF INSULIN RESISTANCE
A composite definition, which describes insulin resistance (IR) in its entirety, has not 
yet been agreed. What is evident however, is that IR plays a major role in the 
aetiology of many metabolic disorders. Obesity and type II diabetes are two of the 
most common morbidities associated with IR, but notably around 25 % of the 
apparently healthy population are also thought to be insulin resistant and therefore 
considered to be at greater risk of coronary heart disease (CHD) (Reaven, 1993). This 
has lead to a great deal of interest in increasing our understanding of the mechanisms 
involved in developing IR and its associated metabolic complications.
In broad terms, IR can be defined as an impaired biological response to either
exogenous or endogenous insulin (American Diabetes Association: Consensus
Development Conference on Insulin Resistance, 1997). The term insulin insensitivity
is used synonymously with IR. Insulin promotes a wide variety of actions in the
human body and has effects on lipid, glucose and protein metabolism, vascular
endothelial function and gene expression. An impaired biological response to one or
more of these could, in theory, be classed as a resistance to insulin. In practice
however, most definitions of IR have been confined to parameters of glucose
metabolism. The most classic definitions of IR refer to an impairment in the ability of
insulin to lower plasma glucose both by stimulating glucose uptake in insulin-
sensitive tissues (predominantly skeletal muscle) and by inhibiting hepatic glucose
output (Tooke & Hannemann, 2000). As stated by Kruszynska & Olfesky (1996) IR
should be understood to represent most fimdamentally an impairment in insulin
signalling, evoked by an impairment in the binding of insulin to the receptor. Among
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the first to characterise IR was Himsworth & Kerr (1939) who noted considerable 
differences in the glucose response to insulin administered to young lean male 
diabetics and obese older non-diabetic males.
1.1.2 THE INSULIN RESISTANCE SYNDROME
The ‘insulin resistance syndrome’ is a term that has been used to describe a number of 
metabolic abnormalities associated with IR including:
> Elevated plasma triglyceride (TG) concentration.
> Decreased plasma high-density lipoprotein (HDL) cholesterol concentration.
> Elevated plasma non-esterified fatty acid (NEFA) concentration.
> Increased small dense low-density lipoprotein (LDL) cholesterol concentration.
> Increased plasminogen activator inhibitor 1 (PAI-1) concentration.
> Hyperuricaemia.
> Impaiied vasodilation of the endothelium.
> Hypertension.
Reaven (1988) was the first to describe the insulin resistance syndrome, which he
coined ‘Syndrome X’. He postulated that the syndrome was central to the
development of CHD and was characterised by glucose intolerance,
hyperinsulinaemia, decreased HDL-cholesterol concentration, increased plasma TG
and high blood pressure. A World Health Organisation (WHO) expert committee has
recently proposed that the insulin resistance syndrome be referred to as ‘The
Metabolic Syndrome’ and that it’s definition should focus mainly on its relationship
to cardiovascular disease (Alberti & Zimmet for the WHO consultation group, 1998).
Bonora et al. (1998) examined the prevalence of IR in the most common metabolic
disorders. They observed that higher rates of IR were found in those with type II
diabetes, hypertriglyceridaemia and low levels of HDL-cholesterol (~85 % of
subjects), whereas lower prevalence rates were found with hypercholesterolaemia,
hyperuricemia and hypertension (30 -6 0  % of subjects). They concluded that IR is
extensive when several metabolic abnormalities cluster within the same individual,
whereas it is rarer when the metabolic disorders (in particular hypertension and
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hyperuricemia) are isolated. These findings highlight the strong association between 
disorders of lipid metabolism and IR and lend credence to the concept of a metabolic 
syndrome.
1.1.3 RISK FACTORS FOR INSULIN RESISTANCE
In Reaven’s original paper it was acknowledged that while there was evidently a 
genetic component to the development of IR, environmental influences were also 
important (Reaven, 1988). In particular he observed that the more obese and 
sedentary an individual, the greater the degree of IR. Since then a growing number of 
studies have tried to examine the effect of various environmental factors, including 
diet, on the development and progression of IR. The risk factors thus far associated 
with IR are outlined in table 1.1.
Table 1.1. Risk factors associated with insulin resistance
Obesity -  in particular central adiposity 
Low levels of physical activity 
High fat diets 
Low birth weight 
Genetic factors
Beck-Nielsen, (1999).
It is not currently known whether IR is the result of obesity, the cause of obesity, or 
whether the two conditions arise independently from each other (Bessesen, 2000). It is 
known that the prevalence of IR is greater among the obese, however there are normal 
weight individuals who are equally insulin resistant (Ruderman et al. 1998). Without 
question reduction in weight is associated with improvements in insulin sensitivity 
(Torjesen et al. 1997; Markovic et al. 1998). It is also clear that regular physical 
activity improves insulin action, although the exact mechanisms involved are not 
clear. It is thought that exercise effects on insulin action, while related to changes in 
body composition, may also work independently of decreases in fat mass and 
increases in muscle mass (DeFronzo et a/. 1987). The pioneering work by Barker and
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colleagues suggests that low birth weight was associated with many of the features of 
IR in adult life (Barker et al. 1993). Data are also available to indicate a strong genetic 
contribution to the determination of insulin action in any given individual (Pedersen, 
1999). However, attempts to identify the relevant genes have not been successful to 
date. It is also difficult to separate genetic factors from environmental influences. 
Several studies have pointed to the detrimental effects of a high fat intake on IR 
(Lovejoy & DiGirolamo, 1992; Mayer et al. 1993). However, there is a paucity of 
human dietary studies that have provided clear evidence that alterations in the intake 
of dietary macronutrients alter insulin action. A number of studies have focused on 
the ratio of carbohydrate to fat effects, however greater interest in the types of dietary 
fat rather than total fat intakes per se has developed (Mann, 2000).
1.1.4 MEASUREMENT OF INSULIN RESISTANCE
Most investigators measure insulin action by its ability to modulate glucose 
metabolism. A variety of techniques have been employed including, the euglycaemic 
clamp, the insulin suppression test, the frequently sampled intravenous glucose 
tolerance test (FSIVGTT) with minimal modelling, the homeostatic model assessment 
(HOMA) and the insulin tolerance test (ITT). The most widely accepted research 
method or ‘gold standard’ is the euglycaemic insulin clamp technique originally 
developed by DeFronzo et al. (1979). With this procedure, exogenous insulin is 
infused, to maintain a constant plasma insulin level (above fasting), while glucose is 
fixed at basal level by infusing glucose at variable rates. The total amount of glucose 
infused over time (M value) is an index of insulin action on glucose metabolism. The 
more glucose that has to be infiised per unit time, the more sensitive the individual is 
to insulin. Conversely, the insulin resistant patient requires much less glucose to 
maintain basal plasma glucose levels. This technique has generated the largest amount 
of reliable information regarding IR. However, the clamp technique has a number of 
limitations, not least the complexity and cost of the procedure, which limits its use as 
a clinical diagnostic tool.
A more practical method of measuring IR, which could be applied to a larger
population, is the ITT. The ITT involves intravenous administration of a bolus dose of
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insulin, generally calculated on the basis of body weight, with the subsequent rate of 
decline in blood glucose taken as a measure of insulin sensitivity. Two major 
disadvantages to the ITT have been proposed. The first is that pharmacological doses 
of insulin are used and therefore there is a threat of insulin-induced hypoglycaemia 
(Del Prato, 1999). Secondly, counter-regulatory hormones are secreted in response to 
hypoglycaemia blunting the fall in plasma glucose (Harrison & King-Roach, 1976). 
However, as pointed out by Akinmokun et a l (1992), follovmg intravenous insulin 
injection, blood glucose reaches its lowest point by 20 minutes and counter regulatory 
hormone response occurs only after this time. The ITT has been foimd to compare 
favourably with other measures of IR including the euglycaemic clamp (Akinmokun 
et a l 1992) and in practice most investigators have found the method to be both safe 
and reliable (Chen, 1998). Several studies have examined the reproducibility of the 
test, with the intra-subject coefficient of variation (CV) varying fi*om 6 to 13 % 
among the studies conducted (Hirst et a l 1993). In contrast however, a recent study 
by Hermans et a l (1999) concluded that the short ITT performs less well against 
other methods of measuring insulin sensitivity including the FSIVGTT, the HOMA 
and the 2-h continuous infusion of glucose with model assessment due to it’s poor 
reproducibility however, there was no comparison with more complicated measures 
of insulin sensitivity including the euglycaemic clamp techmque. The majority of the 
studies conducted thus far (with the exception of the study of Hermans and 
colleagues) have concluded that the test is adequately reproducible in normal subjects 
and recommended its use particularly in large-scale epidemiological studies.
Studies involving the measurement of IR have highlighted the fact that there is a great 
deal of variation in insulin sensitivity within population groups. Hollenbeck & Reaven 
(1987) demonstrated a wide range of insulin sensitivities in 100 individuals with 
normal glucose tolerance. On the basis of rates of glucose uptake in response to 
insulin, subjects were divided into quartiles. They observed that those falling into the 
lowest quartile had insulin sensitivities as low as those observed in the most insulin 
resistant category of patients with type II diabetes. In the database collected by the 
European Group of Insulin Resistance (EGIR), approximately 1500 euglycaemic 
hyperinsulinaemic clamp studies in non-diabetics were performed across 9 European 
countries. A similar pattern was observed and even in the lean segment of the cohort
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(Body mass index (BMI) < 25), insulin sensitivity was found to vary over a wide 
range (Beck-Nielsen, 1999). Ultimately it is the response to IR and the accompanying 
metabolic abnormalities that determines the impact of the defect and the question 
remains as to whether measurement of IR is a definitive marker with which to predict 
future development of diseases such as diabetes and CHD.
From a clinical perspective, the most practical way of assessing IR would seem to be 
the measurement of insulin concentration m the plasma. However debate exists as to 
whether fasting plasma insulin levels are a useful predictor of IR. In the EGIR, Beck- 
Nielsen (1999) found that the degree of IR was positively correlated with fasting 
plasma insulin levels. One prospective study conducted by Haf&ier et al. (1992) 
showed that elevated fasting insulin concentrations were predictive of multiple 
metabolic disorders. Eight years following the measurement of fasting insulin, those 
individuals occupying the upper quartile were 5.6 times more likely to develop type II 
diabetes, 3.5 times more likely to develop hypertriglyceridaemia, 1.6 times more 
likely to develop low levels of HDL-cho lesterol, and 2 times more likely to develop 
hypertension than those in the lower quartile. In addition, as pointed out by Reaven 
(1999) insulin-resistant individuals can only remain glucose tolerant if the pancreas is 
able to respond to this defect by secreting large amounts of insulin. Type II diabetes 
will inevitably develop when insulin-resistant individuals can no longer sustain the 
compensatory state of hyperinsulinameia. It is important to remember that festing 
hyperinsulinaemia is not synonymous with IR, however its measurement may be of 
value in risk factor analysis (Jensen, 2000). Therefore, while fasting insulin level 
alone is an inadequate method of measuring IR it may prove useful in the predicting 
the development of IR related abnormalities such as type II diabetes and CHD. 
Genetic phenotyping, combined with measures of fasting insulin may prove to be 
more predictive of IR.
1.1.5 INSULIN RESISTANCE AND LIPOPROTEIN METABOLISM
The relationship between lipids and IR has been intensively investigated. It is
presumed that the association between CHD risk and IR is to a large extent mediated
via its effects on lipoprotein metabolism. However, other components of the
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metabolic syndrome including raised PAI-1 levels, alterations in endothelial function 
and hypertension also contribute to the atheroslcerotic risk (Festa et al. 1999). In 
recent years the description of the Atherogenic Lipoprotein Phenotype (ALP) has 
aided our understanding of the link between IR and lipoprotein metabolism. Central to 
the ALP is a moderately raised fasting TG level. Hypertriglyceridaemia has also been 
consistently found to correlate with measures of IR, with much weaker associations 
for hypercholesterolaemia. The traditional characteristics of the ALP include a normal 
to marginally raised cholesterol level, a TG level above 2.0 mmol/1 and a HDL- 
cho lesterol level below 1.0 mmol/1 (Packard, 1996). The lipoprotein profile described 
in the ALP has been shown to be associated with a preponderance of small dense 
LDL- cholesterol (LDL subclass III, paiticle size < 26 nm, density > 1.04 g/ml), an 
increase in very-low-density lipoprotein (VLDL)i TG (particle size >35 nm, density 
< 1.006 g/ml) and an increase in small HDL3 (particle size < 8.8 nm) as outlined in fig
1.1. More recently it has been recognised that increased LDL particle number as well 
as postprandial TG metabolism is important in the portrayal of the ALP (Griffin, 
1999). Small dense LDL are unfavourable in terms of CHD risk and they have been 
shown to be as present in 40-50 % of all patients with CHD (Griffin, 1999). The 
correlation between CHD incidence and small dense LDL is explained by the fact that 
small dense LDL is highly atherogenic. Small dense LDL exhibit a reduced binding to 
the LDL receptor and have a greater susceptibility to oxidation. Reduced receptor- 
binding leads to an increase in the residence time of small dense LDL in serum, 
allowing greater filtration across the endothelium. Oxidised LDL is more easily taken 
up by macrophages to create foam cells (Parthasarathy et al. 1989), thereby aiding in 
the formation of an atheromatous plaque.
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Atherogenic VLDL & 
chylomicron remnants
TG > 2.0 mmol/l
ALP
HDL < 1.0 mmol Small non-protective HDL,
Small dense LDL
Figure 1.1. Lipoprotein associations of the ALP
It has been found that the measurement of LDL particle size and distribution is more 
predictive of CHD risk than measuiement of serum total cholesterol alone and the key 
determinant to the generation of small dense LDL is the TG concentration (Austin et 
al. 1988). A fasting serum TG value of 1.5 mmol/l is thought to represent a threshold 
value, beyond which LDL becomes small and dense (Griffin, 1999). The importance 
of TG in the generation of atherogenic small dense LDL is most clearly understood by 
recognising the postprandial metabolic effects of a raised TG. At serum TG values >
1.5 mmol/l, VLDL synthesized in the liver, become enriched with TG and are 
secreted into the circulation as larger lighter paiticles known as VLDLi. In the 
postprandial state, VLDLi is a weak competitor (with chylomicrons) for removal from 
the plasma by lipoprotein lipase (LPL) resulting in a greater residence time of VLDLi 
in plasma. The residence time of chylomicrons in the blood is normally about 5 min, 
whereas that of VLDL-TG is several fold longer (Havel, 1997). Lipoproteins are 
continually exchanging their lipid components, catalysed by cholesterol ester transfer 
protein (CETP). The accumulation of VLDLi leads to a greater transfer of TG to LDL 
and HDL. The TG-enriched LDL and HDL act as good substrates for hepatic lipase 
(HL) resulting in the formation of small dense LDL and small dense HDL. VLDLi is 
typically over-produced in insulin resistant states such as obesity and type II diabetes. 
It is obvious therefore that treatment strategies must aim to reduce the TG level in
26
States of IR in order to reduce the risk of CHD. Reduction in TG concentration can 
lead to a more favourable shift in the LDL profile of an individual, leading to the 
generation of larger and denser LDL particles, which are less of an atherogenic threat 
(Griffin, 1999). While reductions in TG can lead to an improvement in CHD risk, the 
question remains as to what leads to an increased TG concentration in IR in the first 
instance?
1.1.6 INSULIN RESISTANCE AND PLASMA NEFA LEVELS
It has been suggested that the link between hypertriglyceridaemia and IR is mediated 
by a defect in the suppression of NEFA. NEFA, also known as free fatty acids (FFA), 
are the form in which stored body fat is transported from adipose tissue to its sites of 
utilization (Frayn, 1998). Plasma NEFA concentrations are normally at their highest 
after an overnight fast or during aerobic exercise, as it is at these times that the body 
needs to draw upon its stored fuel. Conversely plasma NEFA concentrations are 
suppressed after a meal. Insulin is the hormone responsible for suppressing plasma 
NEFA levels. Suppression of plasma NEFA allows free glucose utilization by 
peripheral tissues, removes an important stimulus for hepatic glucose production, and 
likewise removes the major stimulus for hepatic VLDL-TG secretion (Frayn, 1998). 
Failure to suppress NEFA concentrations after a meal, will result in impaired glucose 
utilization at a time when it should be stimulated to increase glucose clearance, will 
stimulate hepatic glucose production at a time when it should be suppressed, and will 
drive hepatic VLDL-TG secretion so that VLDL will be competing with 
chylomicrons for peripheral clearance by lipoprotein lipase (LPL).
Higher fasting and postprandial NEFA concentrations are associated with IR (Frayn,
1993). It has been shown that IR within adipose tissue causes failure of NEFA
suppression to occui" in subjects resistant to insulin’s glucoregulatory action. Randle et
al. (1963) suggest that an increase in NEFA supply, by inhibiting glucose uptake and
oxidation in muscle cells, causes IR by substrate competition. In other words NEFA
will compete with glucose for utilization by insulin-sensitive tissues such as skeletal
muscle, leading to impaired glucose utilization. Interaction between NEFAs and
glucose at a hepatic level is another proposed mechanism, as an increase in the
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delivery rate of NEFAs to the liver leads to stimulation of gluconeogenesis (Girard, 
1995; Saloranta & Groop, 1996). It has also been suggested by several investigators 
that the link between IR and central adiposity (or visceral fat) could be explained by 
an increase in the liberation of NEFA from intra-abdominal adipose into the portal 
vein (Arner, 1997; Frayn, 1998). An increased supply of NEFA in the portal vein 
leads directly to an increased supply of NEFA in the liver. The association is 
strengthened by the fact that intra-abdominal adipose tissue seems to be more 
lypolyticallly active than subcutaneous adipose tissue. The idea that IR, or at least 
many of its deleterious features, could arise from visceral adipose tissue has attracted 
much attention and has been called the ‘Portal Theory’ (Arner, 1997). However, at 
present it is no more than a theory and as recently discussed by Frayn (2000) there is a 
lack of evidence in vivo to support the theory. He suggests that an alternative link 
between visceral adiposity and IR is that both are associated with subcutaneous 
adipose tissue accumulation. The greater the subcutaneous depot the greater the 
potential for release of NEFA and subsequently the development of IR as a result of 
greater competition with glucose. A ‘toxic’ effect of high NEFA concentration on 
pancreatic cells has also been implicated as contributing to the development of IR 
however this has not been confirmed (Unger, 1995). It is clear that inappropriately 
elevated NEFA levels are central to the metabolic syndrome, however further work is 
needed to understand more about the mechanistic links between increases in NEFA 
concentration, TG metabolism, IR and the development of CHD.
1.1.7 TREATMENT OF INSULIN RESISTANCE
The treatment of the metabolic syndrome has to be targeted at improving insulin
sensitivity and correcting or preventing the associated metabolic and cardiovascular
abnormalities. Weight reduction and increased exercise improve insulin sensitivity
and have been shown to delay the onset of impaired glucose tolerance to diabetes (Pan
et ah 1997). Most of the individuals affected by the metabolic syndrome are
overweight and there is almost universal agreement that weight loss and regular
exercise should form the cornerstone of the treatment of the metabolic syndrome
(Riccardi & Rivellese 2000). Weight loss in the region of 5-10% is sufficient, in most
instances, to induce a clinically relevant effect (Weinstock et al. 1998). However,
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sustained weight loss is notoriously difficult to achieve and few interventions have 
proved successful in the long term (Kendall et al. 1991). Additional treatments could 
focus on the finding that altering the composition of the diet can influence insulin 
sensitivity, independent of weight loss. In particular, the specific effects of the 
components of dietary fat are of great interest. There are few dietary components 
other than dietary fet, which have been shown to influence insulin sensitivity, and for 
most of these the available evidence is inconclusive. In short there are some 
indications that alcohol might be beneficial if consumed in limited amounts and 
detrimental when the intake exceeds 30g/day (Facchini et al. 1994; Kiechl et al.
1996). Also, it has been suggested that a very high sodium intalce might impair insulin 
sensitivity (Donovan et al. 1993). In the following sections, the effect of various 
dietary components including, n-Z fatty acids, saturated fatty acids (SFA), 
monounsaturated fatty acids (MÜFA) and carbohydiate (CHO) on IR and its related 
metabolic abnormalities including CHD and postprandial lipaemia will be discussed. 
Also discussed is the way in which alterations in dietary fat intake can influence the 
membrane fatty acid composition of various tissues, thereby influencing insulin 
action.
1.2 N-3 FATTY ACIDS
1.2.1 SOURCE AND FUNCTION OF N-3 FATTY ACIDS
A vast amount of literature, studying the importance of n-3 fatty acids in human 
nutrition, has been assembled over the last 30-40 years, n-3 fatty acids are essential 
fatty acids, necessary fiom conception, which are derived from both marine and plant 
sources. They are so named because the first of the several double bonds occur three 
carbons away from the terminal end of the carbon chain. The two major n-3 fatty 
acids provided by marine sources are eicosapentaenoic acid (EPA, 20:5m3) and 
docosahexaenoic acid (DHA, 22:6m3). a-Linolenic acid (ALA, 18:3cd3) is derived 
from plant sources and although present in small amounts in unhydrogenated soybean 
oil and rapeseed oil it is most abundantly found in flaxseed and perilla seed oils 
(Harris, 1997). ALA is a metabolic precursor to EPA and DHA. N-3 fatty acids may
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be consumed in gram quantities in foods (predominantly fish) or in larger quantities in 
fish oil capsules. The reason why n-3 fatty acids have attracted so much attention is 
for their role in the prevention and modulation of certain disorders including;
> CHD and stroke
> Rheumatoid arthritis
> Autoimmune disorders e.g. lupus and nephropathy
> Cancers of the breast, colon and prostate
> Mild hypertension
> Crohns disease
> Essential fatty acid deficiency in infancy (retinal and brain development)
(Connor, 2000)
The greatest amount of work has focused on the cardiovascular effects of the 
ingestion of n-3 fatty acids. The beneficial effects of n-3 fatty acids in modulating 
CHD risk first became apparent in epidemiological studies of Greenland Eskimos, 
who despite having a high intake of dietary fat, had a low incidence of CHD. The 
majority of fat consumed by the Eskimos was polyunsaturated in nature, rich in EPA 
& DHA, the main sources of which were fish, shellfish and whale meat. Compared to 
Danish matched subjects, Eskimos were foimd to have lower levels of total 
cholesterol and TG and higher levels of HDL-cho lesterol (Bang et al. 1971). Other 
epidemiological studies seemed to support the suggestion that fish consumption was 
associated with a lower incidence of CHD (Norell et al. 1986; Kromhout et al. 1995; 
Stone, 1996). In the Seven Countries study there was an inverse relation between 
CHD and fish consumption (Keys, 1980). Protective effects of fish consumption were 
also observed in the Zutphen study, where men who consumed on average 30g of fish 
daily had a 50 % decrease in coronary mortality compared with men who did not 
include fish in their diet (Kromhout et al. 1985). Subsequently, it has been found that 
dietary n-3 fatty acids have cardio-protective actions through a variety of mechanisms 
as outlined in table 1.2.
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Table 1.2. Beneficial actions o f n-3 fatty acids in preventing CHD
Prevent ventricular arrhythmia and cardiac arrest
Hypolipidaemic properties with effects on plasma VLDL and TG concentrations 
Antithrombotic effects -  n-3 fatty acids inhibit synthesis of thromboxane Az 
Inhibit atherosclerosis
Promote nitric oxide induced endothelial relaxation 
Prostaglandin and leukotriene precursors
Adapted from Connor & Connor (1997)
In animal models and in tissue culture studies n-3 fatty acids have been shown to 
prevent the development of ventricular fibrillation (Charnock, 1994; Leaf & Kang,
1996). Results from the recent physicians health study in the United States showed 
that the consumption of one or more fish meals a week was associated with 52 % 
lower risk of sudden cardiac death compared with consumption of < 1 fish meal per 
week (Albert et ah 1998). In the Diet and Reinfarction Trial (DART), overall 
mortality was decreased by 29% in men with a positive history of CHD who 
consumed n-3 fatty acids from fish or fish oil, presumably because of the reduction in 
cardiac arrests (Burr et al. 1989). Recently, the results of the GISSI-prevention trial 
showed a clear reduction in fatal and non-fatal cardiovascular events in men who 
received fish oil supplementation following myocardial infarction compared with 
those receiving vitamin E supplements (Gruppo Italiano per lo Studio della 
Soprawivenza nellTnfarto miocardio, 1999).
Thrombosis is a major complication of CHD that can lead to myocardial infarction, n- 
3 fatty acids have been shown to have strong anti-thrombotic properties. 
Thromboxane Ai is a prostaglandin that causes platelet aggregation and 
vasoconstriction in platelets. EPA has been shown to inhibit the synthesis of 
Thromboxane A2 from arachadonic acid in platelets thereby causing an increase 
bleeding time and a decrease the stickiness of the platelets for aggregation (Goodnight 
et al. 1981). In addition, the ingestion of fish oil enhances the production of 
prostacyclin, a prostaglandin that produces vasodilation and less sticky platelets 
(Goodnight et al. 1981). In the original Eskimo studies, Dyerberg & Bang (1979) also 
showed that n-3 fatty acids were incorporated into the phospholipids of the Eskimos’
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platelet membranes leading to a prolonged bleeding time and decreased in vitro 
platelet aggregation.
The role of fish oils in the prevention and retardation of atherosclerosis has been 
reviewed by Israel & Gorlin (1992). They deliberate that EPA and DHA contained in 
fish oil produce a number of effects that inhibit the development of atherosclerosis, 
with evidence derived fi*om animal studies, in vitro studies, epidemiological studies 
and some human clinical studies. Atherosclerosis is a term used to describe the 
thickening (atherosis) and reduction in the elasticity (sclerosis) of vessel walls in the 
arteries of the heart (Nettleton, 1995). Evidence suggests that leukotrienes contribute 
to the acute inflammatory response produced by vascular injury and therefore aid in 
the formation of atheromatous plaques (Mullane et al. 1987). Fish oils exert beneficial 
effects on leukotriene metabolism by suppressing the formation of leukotriene B4, a 
powerfiil chemoattractant for neutrophils and monocytes. Furthermore, n-3 fatty acids 
may affect the synthesis of growth factors by platelets, endothelial cells and 
monocytes, including platelet-derived growth factor, interleukin-1 and tumour 
necrosis factor (TNF) (Fox & DiCorleto, 1991). The suppression of these growth 
factors by fish oil is thought to reduce atherosclerotic plaque formation. In addition, 
nitric oxide (NO) acts to enhance endothelial vasodilation and fish oil has been shown 
to stimulate the production of NO (Chaet et al. 1994). Animal studies have so fai* 
provided the most direct evidence that fish oil reduces atherosclerosis with the most 
notable results in pigs and monkeys (Weiner et al. 1986; Davis et al. 1987). In 
summary, n-3 fatty acids act to halt or reverse many of the deleterious processes 
associated with the development and progression of atherosclerosis and CHD. 
Another coronary-protective mechanism of n-3 fatty acids relates to their effects on 
lipoprotein metabolism.
1.2.1 N-3 FATTY ACIDS AND LIPOPROTEIN METABOLISM
The effect of n-3 fatty acids on lipoprotein metabolism has been investigated in
normal healthy individuals, those with CHD, those with type II diabetes and in those
with a family history of CHD. The most remarkable finding is that n-3 fatty acids
have potent hypotriglyceridaemic properties and as little as 3 g (1 % energy) can
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reduce serum TG levels by 30 % (Harris, 1997). There is evidence also of a dose 
response relationship (Blonk et al. 1990). The minimum effective dose of n-3 fatty 
acids appears to be a little over 1 g/d. In a review  ^by Harris (1997) the results of a 
total of 36 placebo-controlled studies v^ere combined. The data showed that a daily 
intake of approximately 4 g of n-3 fatty acids, TG concentrations decreased by 25 % 
in normal subjects and by 34 % in hypertriglyceridaemic (> 2 mmol/l) subjects. High 
TG concentrations are now widely recognised as an independent risk factor for CHD, 
however postprandial concentrations of TG have also been shown to be important in 
modulating CHD risk (Patsch et al. 1992). In addition to their effects on fasting TG n- 
3 fatty acids have also been shown to reduce postprandial lipaemia (Hands et al. 1988; 
Weintraub et <7/.1988). Fish oils are thought to affect lipoprotein metabolism through 
a variety of mechanisms including:
A reduction in VLDL-TG secretion as demonstrated by kinetic studies in humans and 
animals (Harris et al. 1990).
An increase in VLDL apolipoprotein B secretion leading to an impairment in VLDL 
assembly (Nestel et al. 1984).
Reduced TG transport, resulting in smaller VLDL, largely converted to LDL.(Harris 
et al. 1990)
An increase in VLDL clearance or in chylomicron clearance due to reduced 
competition with VLDL. (Harris et al. 1990)
It is also suggested that reduced TG synthesis following fish oil feeding could reflect 
a reduction in NEFA availability (Dagnelie et al. 1994). Studies have shown that fish 
oil may lead to reduction in fatty acid synthesis and fish oil also diverts fatty acids to 
phospholipids (Nestel, 2000).
With regard to the effect on other lipoproteins, supplementation with n-3 fatty acids 
has in some instances lead to an increase in LDL-cho lesterol concentration, 
particularly in hypertriglyceridaemic individuals (Harris, 1989). This may be due to a 
reduction in LDL removal mediated via a defect in the LDL receptor, although this 
has not been confirmed. HDL-cholesterol is essentially unaffected by n-3 fatty acid 
treatment (Harris, 1997) however some reports indicate a favourable effect of fish oil 
in increasing the number of large cholesterol rich HDLs. Serum total-cholesterol
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levels are generally not reduced by n-3 fatty acid supplementation (Wilt et al. 1989). 
While the effect of n-3 fatty acids on lipoprotein metabolism has been studied 
extensively fijrther research is needed to clarify the associated mechanisms of action 
(Harris, 1997; Toft et al 1997). Issues that need to be resolved include;
1) Whether the TG lowering effect of n-3 fatty acids can be ascribed more to EPA or
DHA? To date no trials comparing the effect of EPA to DHA have been
conducted.
2) The effect of n-3 fatty acids on other lipoprotein classes such as intermediate 
density lipoproteins (IDE), VLDL, HDL, and LDL subclasses.
3) There is a suggestion that LDL rich in n-3 fatty acids is more easily oxidised. In 
vivo studies are needed to explore this issue.
4) What is the exact role of n-3 fatty acids in the primary prevention of CHD?
In summary n-3 fatty acids exert a variety of effects that are beneficial in modulating 
the risk of CHD however further studies are needed to explore all of the associated 
mechanisms of action.
1.2.3 N-3 FATTY ACIDS AND INSULIN ACTION
Interest in the effects of n-3 fatty acids on insulin action are centred on the
observation that n-3 fatty acids can induce changes in the fatty acid composition of
membranes, particularly within skeletal muscle. Skeletal muscle is the principal site
of insulin-mediated glucose disposal therefore, the fatty acid composition of
membranes is one cellular factor that may influence the action of insulin within
skeletal muscle. Increasing the content of n-3 fatty acids within cell membranes in
cultured cells and in animal models has been shown to increases membrane fluidity,
the number of insulin receptors and the action of insulin (McCaleb et al. 1981;
Ginsberg et al. 1982; Gould et al. 1982). Animal studies have also demonstrated that
IR induced by high fat feeding can be prevented by the inclusion of n-3 fatty acids in
the diet, shown to have been incorporated into the phospholipid component of muscle
cells (Storlein et al. 1991). Further evidence comes from human studies and the
investigations of Borkman et al. (1993) showed that a high concentration of long
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chain n-3 PUFA in the skeletal-muscle phospholipids was associated with an 
increased insulin sensitivity. Data from Baur et al. (1998) also showed that the degree 
of IR in human subjects was negatively correlated to the amount of DHA within 
skeletal muscle phospholipid. The way in which PUFA may induce changes in 
membrane fluidity has been carefully described by Malasanos & Stacpoole (1991) 
and is depicted in figure 1.2. The improvement in glucose uptake that occurs when 
membranes are enriched with long chain PUFA could be due to the fact that glucose 
transporter-4 (GLUT-4) protein resides within the plasma membrane for a prolonged 
period of time (Clandinin et al. 1993). The increase in residence time of GLUT-4 is 
associated with an enlargement of the intracellular pool of glucose-6-phosphate 
(Podolin et al. 1998). Clarke (2000) hypothesises that the enlargement of the glucose-
6-phosphate pool could potentially explain the increase in skeletal muscle glycogen 
synthesis that is observed in rats fed fish oil. Dietary fish oils have also been shown to 
reduce the intra-muscular content of triglyceride (Storlein et al. 1991). A decrease in 
lipid droplet size and number has been found to be associated with an improved 
insulin sensitivity, presumably due to the fact that fish oils induce skeletal muscle 
fatty acid oxidation (Power & Newsholme, 1997; Baillie et al. 1999).
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Figure 1.2. Effects of PUFA on membrane fluidity
Enrichment of membrane phospholipids with PUFA leads to increased fluidity 
because the irregular shape of PUFA keeps phospholipids from packing tightly 
against each other. The increase in fluidity allows membrane proteins (A, B, 
and C) to move more readily, thus potentially changing rates of signal 
transduction, hormone-receptor interaction or substrate transport.
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Despite the intense interest in «-3 fatty acids relatively few studies have examined the 
effect of «-3 fatty acids on insulin sensitivity. Animal studies have convincingly 
shown that supplementation with «-3 fatty acids enhances insulin sensitivity (Behme, 
1996; Luo et ah 1996). Podolin et al. (1998) also showed that as little as 6 % fish oil 
in the diets of rats prevented the development of IR. Such convincing evidence is yet 
to emerge from human studies. To date, few have measured insulin sensitivity directly 
but several have examined the effect of «-3 fatty acids on glucose and insulin levels 
(Zak et al 1989; Fasching et al 1991). In addition, the studies have tended to 
concentrate on the effect of «-3 fatty acids in those with type II diabetes. There is a 
lack of evidence therefore of the effect of fish oil feeding on insulin sensitivity in 
normal healthy individuals. Of the studies that have been conducted several have 
demonstrated an improvement in insulin sensitivity with w-3 fatty acid ingestion 
(Popp-snijders et a l 1987) with others showing either no response (Pelikanova et a l 
1993) or a worsening of insulin sensitivity (Stacpoole et a l 1989). It is evident that 
the effect of «-3 fatty acid supplementation on insulin sensitivity has not yet been 
determined and further studies are imperative.
1.3 SATURATED FATTY ACIDS
L3.1 DESCRIPTION OF SATURATED FATTY ACIDS
SFA contain the maximum hydrogen atoms that they can hold. A fatty acid becomes 
unsaturated when a pair of hydrogen atoms is removed, thereby creating a double 
bond between the adjacent carbon atoms. Saturated fatty acids are associated mainly 
with animal foods such as meat and dairy products. They are also abundantly found in 
tropical oils such as coconut, palm and palm kernel oil. Saturated fats vary in their 
constituent fatty acids. Individual SFA vary in carbon chain length and the various 
types of SFAs found in foods are shown in table 1.3. The average daily consumption 
of SFA in the UK is approximately 16 % of energy and expert bodies have advised 
that this level is reduced to 10 % of dietary energy (Department of Health, 1994).
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Table 1.3. Description and source o f saturatedfatty acids.
Common name Systematic
name
Carbon
atoms
Melting
point
(°C)
Typical fat source
Butyric Butanoic 4:0 -7.9 Butterfat
Caproic Hexanoic 6:0 -3.4 Butterfat
Caprylic Octanoic 8:0 16.7 Coconut oil
Capric Decanoic 10:0 31.6 Coconut oil
Laurie Dodecanoic 12:0 44.2 Coconut oil
Myiistic Tetradecanoic 14:0 54.4 Butterfat, coconut oil
Palmitc Hexadecanoic 16:0 62.9 Most fats and oils
Stearic Octadecanoic 18:0 69.6 Most fats and oils
Arachidic Eicosanoic 20:0 75.4 Peanut oil
Behenic Docosanoic 22:0 80.0 Peanut oil
Adapted from Dupont et a/. (1991)
1.3.2 SATURATED FAT AND CHD
The effects of consuming saturated fats on levels of plasma lipids and lipoproteins 
and on the incidence of CHD have been extensively studied since the 1950’s. Interest 
in the total fat content and SFA composition of the diet in the pathogenesis of 
atherosclerosis originated from the observed decline in mortality from CHD that 
occurred during periods when the consumption of milk, butter, cheese and eggs fell 
such as a during the rationing of World War II (Malmros, 1970). The Seven Countries 
study was one of the first epidemiological studies that attempted to relate the 
incidence of CHD to SFA intake. In that study it was found that there was a high 
correlation between the average percentage of energy from SFA and the 10-year 
incidence of, and mortality from CHD (Keys, 1980).
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It is thought that the association between the level of SFA in the diet and 
atherosclerosis is mediated by an increase in circulating total and LDL-cholesterol 
levels. In the Seven Countries study there was a significant correlation between 
percentage of calories from SFA and median serum cholesterol. Of the individual 
fatty acids it was observed that myristic acid (14:0) had a potent 
hypercholesterolaemic effect, with stearic acid (18:0) neutral and palmitic acid (16:0) 
intermediate. This confirmed the findings of a previous study where it was shown that 
SFA with 12-14 carbon atoms in chain length had slightly greater serum cholesterol- 
raising effects, than SFA with 16-18 carbon atoms (Grande et al. 1961). The principal 
SFA in most human diets is palmitic acid, followed by stearic, myristic and lauric 
acids (12:0). The view that palmitic acid may have neutral or intermediate 
cholesterol-raising properties has been contested by the results of several well- 
controlled studies in which palmitic acid was shown to raise LDL cholesterol relative 
to the effects of oleic acid (Denke & Grundy, 1992; Zock et al. 1994). It is thought 
that individual SFAs, notably lauric, myrisitic and palmitic acids, raise total and LDL- 
cholesterol by decreasing LDL-receptor-mediated clearance as a result of a down- 
regulation of LDL receptor activity (Dietschy et al. 1993).
The postprandial effects of SFA have also been investigated. In a study by Weintraub 
et al. (1988) it was shown that postprandial levels of lipoproteins in addition to fasting 
lipoprotein levels were raised following a diet (25 days duration) consisting of 67 % 
SFA, 28 % MUFA and 5 % PUFA as fat. Shepherd et al. (1980) examined the 
composition of LDL-cholesterol particles following high SFA feeding and found that 
the relative proportion of cholesterol increased and the relative percentage of 
phospholipid decreased in the LDL particle with the high SFA diet.
Several primary and secondary drug trials have demonstrated the clear benefit of 
plasma cholesterol reduction in both the prevention and treatment of CHD 
(Scandinavian Simvastatin Survival Group, 1994; Shepherd et al. 1995). It is 
therefore not disputed that reduction in total and LDL-cholesterol has beneficial 
effects on CHD mortality. Nor is it disputed that individual SFAs have the ability to 
raise serum cholesterol concentration and several studies have shown that the 
development and progression of CHD may be related to the intake of SFA (Watts,
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1995; Hu et al. 1997) What is lacking however is the evidence from long-term clinical 
primary and secondary intervention trials that a reduction in total and SFA results in a 
reduction in CHD mortality. Oliver (1997) reviewed the outcomes of several large 
trials where total and satuiated fats were reduced. He concluded that controlled 
clinical trials of the primary prevention of CHD (six trials in total) showed no 
significant reduction in either all-cause or CHD mortality. Exceptions were in trials in 
which the polyunsaturated to saturated ratio was increased to =1.5 (Tuipeinen et al. 
1979) or where current cigarette smoking was almost halved (Hjermann et al. 1981). 
There have been only two small trials of the secondary prevention of CHD with diets 
low in SFA and cholesterol alone (Research Committee to the Medical Research 
Council, 1965; Woodhill et al. 1978). In neither trial was there a significant effect on 
the rate of recurrence of CHD. In contrast in secondary prevention trials where SFA 
has been replaced by unsaturated fats, CHD and to a lesser extent all-cause mortality 
have been reduced (Dayton & Pearce, 1969; Leren, 1970; Burr et al. 1989; Singh et 
al. 1992; de Lorgeril et al. 1994). There is evidence to suggest therefore that it is 
more beneficial to change the proportion of dietaiy fat so that the amount of 
unsaturated fat is increased than to decrease the amount of satuiated fat alone. Keys et 
al. (1984) and Hegsted et al. (1965) have developed predictive equations based on the 
results of a variety of feeding studies in order to predict serum cholesterol responses 
to changes in the saturated and polyunsaturated components of the diet. The equations 
have since been employed in a wide range of studies. However, the use of standard 
equations to estimate effects of SFA must be cushioned by the realisation that there is 
considerable variation in response. Some people appear- to be hyper-responders, 
whereas others are hypo-responders to SFA (Denke, 1994). In addition, the absolute 
response may depend on an individual’s baseline cholesterol concentration (Hayes & 
Khosla, 1992). Possible explanations for hyper- and hypo-cholesterol responses to a 
reduction in SFA intake are discussed in greater detail in section 1.7.1.
1.3.3 SATURATED FAT AND INSULIN ACTION
There is considerable evidence from experimental animal studies that SFA in the diet
may lead to IR. It has been reported that IR is greater in rat adipocytes obtained from
animals with diets high in SFA compared with those from animals with diets rich in
40
MUFA- or PUFA (Ip et al. 1976; Olefsky, 1978; van Amelsvoort et al 1988). Fewer 
insulin receptors have also been foxmd in animals fed a high SFA diet (Nagy et al 
1990). Work by Clandinin et al (1993) demonstrated that in rats, in which the SFA 
content of the diet has been reduced, adipocyte insulin binding is significantly 
increased. Several mechanisms for the adverse effect of high SFA feeding have been 
suggested including, down regulation of the insulin receptor in muscle and adipose 
tissue (Hedeskov et al 1992), a decrease in the expression of glucose transporters 
(GLUT 4) in fat cells (Pedersen et al 1991) and reduced oxidative glucose disposal 
(Grundleger & Thenen, 1982).
In man there is indirect evidence for the same effect i.e. that a higher SFA intake is 
associated with impaired insulin action (Maron et al. 1991; Marshall et al. 1997) 
however, since the classic study of Himsworth (1935) in which it was concluded that 
high fat feeding induced IR, human studies have produced conflicting reports as to the 
effect of dietary fat on insulin sensitivity. Earlier studies seemed to confirm the 
finding that individuals fed a high-fat diet had lower insulin action compared to those 
consuming a low-fat diet. Subsequently, as methods for measuring insulin action 
improved several studies showed no effect of high fat feeding on insulin sensitivity in 
subjects both with and without diabetes (Nestel et al 1984; Borkman et al. 1991). A 
study by Riccardi & Parillo (1992) also showed that insulin sensitivity was higher on 
a high-fat diet (38% energy) compared to a diet high in CHO and dietary fibre in a 
group of subjects with diabetes. In contrast however, Lovejoy & DiGirolamo (1992) 
showed that insulin sensitivity was inversely associated with total fat and SFA intake 
and positively associated with fibre intake in a group of lean and obese men and 
women. Similaily Marshall et al. (1997) found that habitual consumption of SFA and 
total fat was positively related to hyperinsulinaemia in a sample of 1069 Hispanic and 
non-Hispanic white persons living in Southern Colorado. Intervention studies have 
proved less conclusive and when the degree of saturation of fatty acids is increased or 
decreased, the effect on insulin sensitivity is equivocal (Fasching et al. 1996). Also 
contested is the effect of replacing SFA with either and unsaturated fat or CHO on 
insulin sensitivity. Fukagawa et al. (1990) demonstrated that high-CHO, high-fibre 
diets improve glucose disposal rates in young individuals with a stronger effect 
observed by Chen et al (1988) in older subjects but with much higher levels of CHO
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feeding. In contrast, Ginsberg and colleagues reported no difference in substituting 
either CHO or MUFA for SFA on postprandial glucose and insulin excursions 
(Ginsberg et al. 1994). However, other studies have shown that replacing SFA with 
either MUFA- or PUFA improves insulin sensitivity to a greater extent than high- 
CHO feeding (Riccardi & Parillo, 1992; Garg, 1998). These issues are explored in 
greater detail in both chapters 4.0 and 5.0.
1.4 MONOUNSATURATED FATTY ACIDS
1.4.1 THE MEDITERRANEAN DIET
The ‘Mediterranean diet’ has received a great deal of attention since the 1950’s and is 
principally a term used to represent the food patterns of those living in Greece and 
Southern Italy. The evidence for the beneficial effect of consuming diets based on the 
Mediterranean pattern of eating were founded on the observation that adult life 
expectancies for populations in these areas was among the highest in the world, and 
rates of CHD and certain cancers were among the lowest. This was despite a high 
incidence of smoking among this population group and also an inferior health care 
system compared to that available in Northern Europe or m the US (Kushi et al. 
1995). In general the Mediterranean diet can be described by the following 
characteristics.
> An abundance of fresh fruit and vegetables.
> Considerable consumption of breads, cereals, beans, nuts and seeds.
> Dairy products consumed in low to moderate amounts.
> Red meat consumed in low amounts.
> Red wine consumed in low to moderate amounts, normally with meals.
> Olive oil as the principal source of fat.
42
Of the many dietary patterns that prevail in the Mediterranean region, the 
consumption of olive oil occupies a central position in all of them. The greatest 
amount of research has therefore focused on the beneficial effects of olive oil 
consumption. Olive oil contains a large proportion of monounsaturated fat, is 
relatively low in satui'ated fat and is a source of the antioxidant vitamin E (Ascherio & 
Willett, 1995). Monounsaturated fats are characterised by having one double bond in 
theii’ fatty acid carbon chain. The most common monounsaturated fatty acid is oleic 
acid (18:lco9). Its single double bond is located nine carbons from the methyl end of 
the fatty acid chain giving rise to an n-9 fatty acid. The main sources of oleic acid 
apart from olive oil are rapeseed oil, peanut oil and high-oleic containing sunflower 
and safflower oil. Other food sources include avocados, meat, rice bran, soybeans and 
olives as well as processed foods such as margarine’s and shortenings. The reasons 
why monounsaturated fats are thought to be beneficial in the prevention of CHD are 
summarised in table 1.4.
Table 1.4. Beneficial effects o f MUFA consumption
Oleic acid is considered to be antithrombotic compared with SFA.
Diets rich in MUFA are less likely than diets high in PUFA to cause oxidation of 
LDL.
MUFA can cause HDL-cholesterol levels to increase, when substituted for CHO. 
Evidence of TG lowering properties.
MUFA have been shown to lower total cholesterol concentrations.
Olive oil facilitates the consumption of large amounts of vegetables by enhancing 
taste.
(Ascherio & Willett, 1995)
1.4.2 MONOUNSATURATED FAT AND CHD
The Seven Countries Study initially ascribed the lower incidence of CHD to a lower 
intake of SFA in the Mediterranean region, however it is now clear that the higher 
intake of MUFA is a more likely explanation for the reduction in CHD mortality. 
MUFA have been shown to be effective in lowering both total cholesterol and LDL-
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cholesterol concentration (Mensink, 1994) as well as TG concentrations (Gai'g et al. 
1992). MUFA are also thought to have antithrombotic effects (Storlein et al. 1997). 
Blades & Garg (1995) investigated the mechanisms of TG lowering with a high 
MUFA diet in patients with type II diabetes and reported that TG lowering was not 
due to increased lipolysis or postprandial clearance of triglyceride-rich-lipoproteins 
(TRL) but was primarily due to a reduced hepatic secretion of VLDL-TG. Further 
studies are needed to explore the proposed mechanisms of TG-lowering with high 
MUFA diets.
There has been some controversy as to whether MUFA is as effective at lowering 
cholesterol as PUFA. Increasing the PUFA content of diets has been consistently 
shown to decrease total and LDL-cholesterol levels (Beynen & Katan, 1985). In 
addition, long chain «-3 PUFA have clear hypotriglyceridemic properties. Linoleic 
acid is the predominant fatty acid of the PUFAs. Recent analysis of available data 
suggests that linoleic acid lowers total and LDL-cholesterol concentrations slightly 
more than does oleic acid but not as much as was previously reported (Grundy, 1997). 
There is therefore, negligible difference in the cholesterol lowering effects of MUFAs 
and PUFAs (Nydahl et al. 1994), however there are greater concerns about increasing 
PUFAs than MUFAs above current amounts. Chiefly, no populations have consumed 
large amounts of linoleic acid with any proven safety. This contrasts with high intakes 
of oleic acid in the Mediterranean region, where people have used olive oil for 
hundreds of years with no evidence of harm. The main cause for concern is that high 
intakes of linoleic acid are associated with an increased susceptibility of LDL to 
oxidation, a process thought to increase the risk of atherogenesis and CHD (Schwab et 
al. 1998). Also in laboratory animals’, high intalces of linoleic acid can promote 
chemical carcinogenesis (Rose, 1997); the same has not been found with oleic acid. 
Finally, limited epidemiological data fiirther suggest that high PUFA consumption 
can increase the risk for human cancer although no firm conclusions have been 
reached (Zock & Katan, 1998).
It is also thought that among the MUFA-rich oils there are some differences in their 
cholesterol lowering properties (Truswell & Choudhury, 1998). Animal studies have 
addressed this question and in a study of hamsters, rapeseed oil was found to be as
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effective at lowering cholesterol concentration as sunflower oil, whereas olive oil 
failed to produce a cholesterol lowering effect (Trautwein et al. 1997). Another 
animal study using guinea pigs also demonstrated that rapeseed and olive oil differed 
in their effect on plasma total and LDL cholesterol (Fernandez et al. 1997). A number 
of human studies have also indicated that rapeseed oil (Valsta et al. 1992) as well as 
high-oleic sunflower oil (Perez-Jimenez et al. 1995) caused lower plasma cholesterol 
concentrations than olive oil. This finding is further endorsed by the observation that 
not all studies using an olive oil intervention have had effects on serum cholesterol 
concentration. The differing cholesterol-lowering effects of monounsaturated oils 
could be related to differences in their overall fatty acid composition. As shown in 
table 1.5. rapeseed oil, high-oleic sunflower and high-oleic safflower oil contain only
7-8 % SFA as compared to 14 % in olive oil. In addition rapeseed oil contains a 
relatively high amount of ALA, which could also contribute to its cholesterol- 
lowering potential. Differences in nonsaponifiable lipids within the MUFA-rich oils 
e.g. the squalene and phytosterol content, may also account for their diverse effects on 
plasma cholesterol. Squalene is a precursor to cholesterol synthesis while phytosterols 
can reduce cholesterol absorption (Westrate & Meijer, 1998). Olive oil contains more 
squalene, while rapeseed oil and oleic-rich sunflower oils have higher concentrations 
of phytosterols than olive oil (Truswell & Choudhury ,1997).
Table 1,5. Composition o f monounsaturated-rich oils.
Olive oil Rapeseed oil
High-oleic 
sunflower oil
High-oleic 
safflower oil
18:1 cis (% total F As) 76 63 80 73
SFA (% total F As) 14 7 7 8
PUFA (% total F As) 10 30 9 18
Squalene (mg/lOOg) 500 Small amount 30 Small amount
Phytosterols 110 250 350 440
(mg/lOOg)
Adapted from Truswell & Choudhury (1997)
45
L4.4 MONOUNSATURATED FAT AND INSULIN ACTION
Few studies have examined the effects of increasing MUFA intakes on insulin 
sensitivity. Several studies have reported improvements in the metabolic 
abnormalities associated with IR such as raised TG level and LDL-cholesterol 
concentration, however only a small number have measuied insulin sensitivity 
directly. Furthermore, the studies that have been conducted have concentrated on 
those with type II diabetes or impaired glucose tolerance. Therefore, a consensus has 
not been reached as to the effect of high-MUFA feeding on insulin sensitivity with 
some studies reporting no effects (Garg et al. 1992b) and other studies reporting an 
improvement in insulin mediated glucose disposal with consumption of a high-MUFA 
fat diet (Parillo et al. 1992). These studies involved a small number of subjects and 
were essentially designed to compare the effects of high-carbohydrate diets with high- 
MUFA diets on insulin sensitivity. Neither study supported the notion that high-CHO 
diets improve insulin sensitivity and in the study of Parillo and colleagues superior 
improvements in insulin mediated glucose disposal was reported with the high-MUFA 
diet. It is evident therefore that more investigations are required to confirm whether 
high-MUFA diets improve insulin sensitivity in those who are insulin resistant.
1.5 CARBOHYDRATES AND INSULIN RESISTANCE
The cornerstone of many national and international dietary guidelines is a reduction in 
dietary fat and an increase in dietary CHO. The main reason why low-fat, high-CHO 
diets are recommended is because of their cholesterol lowering effects and in the case 
of diabetes because of improvements in glycaemia. Coupled with this low-fat, high- 
CHO diets are thought to promote weight loss, although long term studies have 
generally reported minor reductions in weight which are not easily maintained (Katan,
1997). The disadvantages of replacing dietary fat with CHO is that a high-CHO diet 
may increase plasma TG and decrease HDL-cholesterol concentrations. Numerous 
studies have confirmed the finding that high-CHO feeding induces
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hypertriglyceridaemia (Ginsberg et a l 1976; Coulston et al 1983; Borkman et al 
1991; Katan, 1997; Parks et a l  1999). Several studies have also demonstrated the 
detrimental effects of high-CHO feeding in the postprandial state (Garg et a l 1988; 
Garg et a l 1994; Chen et a l  1995). An increased TG and a decreased HDL- 
cholesterol concentration are central to IR, and treatment with a high-CHO diet could 
potentially exacerbate the condition rather than affect an improvement. Garg (1998) 
has recently completed a meta-analysis of all studies comparing a high-CHO and a 
high-MUFA diet in diabetics and concluded that high-MUFA diets are preferable in 
the treatment of IR. High-CHO diets have also been shown to be associated with an 
increase of PAI-1 levels, thereby causing a decrease in fibrinolysis (Lopez-Segura et 
a l 1996). Despite this there is a reluctance to promote high-unsaturated fat diets over 
low-fat, high-CHO diets.
L 5J  COMPONENTS OF DIETARY CARBOHYDRATE
Measurement of carbohydrate and its components is more difficult than measurement 
of fat, as carbohydrate in the diet is not a single entity. This may account for the 
discrepancy in the results of studies, which have examined the effects of CHO feeding 
on IR. There is increasing awareness that the examination of total carbohydrate is not 
sufficiently accurate to detect relations between CHO components and disease. Figure 
1.4. outlines the components of CHO in the diet. Sugars, dietary fibre and starch have 
been the major focus of studies in which CHO has been examined. Interest in the 
‘sugars’ group has tended to focus on sucrose, glucose, and fructose. Studies in 
humans suggest that moderate amounts of sucrose and fructose have no deleterious 
effect on insulin resistance (Daly et a l  1997).
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CARBOHYDRATE
Frœ sugars Oligosaccharides Dextrlns
Glycogen
Avail£Ü3le ŒO
Starch Non-starch polysaccharides
fivctose Sugar alcohols
galactose raEBnose readily digestible
glucose stachyose slowly digestible
lactose vetascœe resistant
maltose
sucrose
non-cellulosic
polysaccharide
Unavailable CHO
Figure 1.3. Components of carbohydrate in the diet
The terms ‘available’ and ‘unavailable’ CHO relate to the availability 
for digestion. Adapted from Stephen et al. (1995)
1.5.2 CARBOHYDRATES AND INSULIN SENSITIVITY
There is discrepancy among the results of dietary trials that have attempted to address 
the question of whether replacement of dietary fat with CHO has a beneficial effect on 
insulin sensitivity. The studies in non-diabetic subjects generally show beneficial 
effects of a high-carbohydrate diet on insulin sensitivity (Chen et al. 1988; Fulcagawa 
et al. 1990; Borkman et al. 1991), while those in diabetics show a deleterious effect 
(Parillo et al. 1992; Garg et al. 1992a). The new classification of carbohydrate rich 
foods based on their glycaemic index (GI) however, has aided our understanding of 
the specific effects of CHO on insulin sensitivity. GI represents the plasma glucose
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response to a food, expressed as a percentage of the glucose response to a reference 
food. A growing number of studies have confirmed the finding that the detrimental 
effects of a high-CHO diet on plasma glucose, insulin, and lipoproteins occur only 
when CHO foods with a high GI index are consumed, while they are abolished if the 
diet is based largely on fibre-rich, low-GI foods (Riccardi & Rivellese, 1991; Frost et 
al. 1994; Rivellese et al. 1994; Jarvi et al. 1999). Classification of foods using GI 
have more predictive physiological effects than classifications based on the fibre 
content of CHO-rich foods (Riccardi & Rivellese, 2000). Further work needs to be 
conducted before a firm conclusion can be drawn as to the optimal amount and type 
of dietary CHO for the treatment of JR.
1.6 LIPOPROTEIN LIPASE
1.6.1 STRUCTURE AND FUNCTION OF LPL
LPL is an insulin-sensitive hormone, which plays a central role in the regulation of 
lipid metabolism in the body. LPL is expressed in many human tissues including, 
adipose tissue (white and brown), skeletal muscle, and cardiac muscle and in the 
mammary glands (Bensadoun, 1991). Other members of the lipase family include 
pancreatic lipase and HL and all three enzymes have a number of structural features in 
common including their lipid-binding regions (Wion et al. 1987). Comparison of the 
coding sequences of the LPL, HL and pancreatic lipase genes indicate that each 
originated from a common ancestral gene (Raisonnier et al. 1992). Lipases are 
involved in the hydrolysis of endogenous and exogenous TG molecules. LPL is 
responsible for the hydrolysis of TG in the circulation, while pancreatic lipase acts 
principally in the small intestine. The site of action of LPL is on the surface of the 
capillary endothelium, however LPL is not synthesised by the endothelial cells but 
within the parenchymal cells of tissues such as adipose tissue (Olivecrona et al. 
1987). LPL is dependent on apolipoprotein C-II (Apo C-II) for its activation. Heparin 
administered intravenously (IV) causes the rapid release of LPL into the surrounding 
fluid, which stimulates synthesis of the lipase (Quinn et al. 1983). The exact 
mechanism of how heparin affects the release of LPL is unclear. In the endothelium,
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LPL is bound by heparan sulfate proteoglycans integrated into the glycocalyx on the 
plasma membrane (Olivecrona et al. 1987). The enzyme is found near* the luminal end 
of the proteoglycan complex where it can best bind and hydrolyze circulating TG. 
Binding to heparan sulfate is thought to stabilise the enzyme but does not activate it 
(Eckel, 1989) In the circulation TG are carried within chylomicrons or VLDL 
particles, collectively known as TRL. The presence of LPL on the capillary 
endothelium allows the TG in the TRL particles to be hydrolysed into FF A and 
glycerol. FF A are either esterified for storage in adipose tissue or oxidised for fiiel as 
in skeletal tissue. It has been shown that about forty LPL molecules may act on a TRL 
particle simultaneously to achieve the rates of TG hydrolysis observed (Scow et al. 
1977). The lipolysis mediated by LPL also promotes the exchange of lipids between 
lipoproteins.
The synthesis and secretion of LPL has been studied most extensively in adipose 
tissue. As observed by Frayn et al. (1995) not all of the fatty acids released by LPL 
are directed into adipose tissue for estérification and storage; a proportion leaves in 
the venous plasma as NEFA. The generation and inhibition of NEFA is part of a co­
ordinated system between LPL and hormone-sensitive lipase (HSL) both of which are 
effected by circulating insulin levels. Acylation stimulating protein (ASP), a potent 
stimulator of fatty acid uptake and estérification in adipocytes is another component 
of this highly co-ordinated system for the regulation of the deposition of dietary fatty 
acids (Sniderman et al. 1997). Thus, while LPL is important in the regulation of fatty 
acid metabolism it is only part of a highly co-ordinated pathway.
1.6.2 REGULATION OF LPL
The regulation and expression of LPL has been investigated in a range of in vivo and
in vitro models. It has been found that the extent of LPL expression in different
tissues is dictated by the metabolic state of the tissue. In the fed state LPL is activated
in adipose tissue and down-regulated in skeletal muscle and heart, thereby allowing
fatty acids to be directed to adipose tissue for re-esterification and storage in a time of
energy surplus. In contrast in the fasting state LPL is up-regulated in muscle tissue
and suppressed in adipose tissue so that fatty acids are directed to the tissue in which
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they are needed as an oxidative fuel (Enerback & Gimble, 1993). The highest levels 
of tissue LPL activity are seen in the mammary tissue of the lactating female 
(Kinnunen et al. 1980). The LPL gene has been observed at the molecular biology 
level in a number of species including, chicken, bovine, guinea pig, rat and human 
(Raisonnier et al. 1995). In each of these species, the complementary 
deoxyribonucleic acid (cDNA) has been sequenced and the amino acid sequence 
described (Raisonnier et al. 1995). The gene is highly conserved across species. The 
human genomic LPL gene spans approximately 30Kb and contains 10 exons coding 
for a 475 amino acid protein. The gene for LPL has been located to the short arm of 
chi'omosome 8 (Spai’kes et al. 1987). Studies in cultured rat adipocytes show that 
increases in LPL-specific messenger ribonucleic acid (mRNA) precede increases in 
the activity of LPL (Dani et al. 1990). Insulin is known to increase the synthesis of 
LPL but exactly how insulin increase the level of mRNA is unclear (Ranganathan et 
al. 1995). It is also unclear whether the rapid effect of insulin on mRNA levels is due 
to changes in gene transcription, to an enhancement of the stability of LPL mRNA or 
both (Ranganathan et al. 1995). It is thought that the effect of insulin on adipocyte 
LPL levels is mediated at the post-transcriptional level (Enerback & Gimble, 1993).
1.6.2 LPL AND INSULIN RESISTANCE
Since LPL is central to TG metabolism, decreases in LPL activity will inevitably
contribute to hypertriglyceridaemia. There are a number of conditions in which a
decrease in the level of post-heparin plasma or tissue LPL activity can lead to a
defective catabolism of TRL in humans (Taskinen & Kuusi, 1987). These conditions
include, diabetes mellitus, hypothyroidism, chronic renal failure, and nephrotic
syndrome. Excessive alcohol ingestion is also associated with decreases in LPL
activity. Obesity is associated with increased levels of LPL, mainly due to an increase
in the number of fat cells. Both genetic and acquired deficiencies of LPL activity aie
associated with low levels of HDL-cholesterol (Karpe et al. 1993). This suggests that
the low HDL levels associated with CHD and IR may be in part due to LPL
deficiency. In the presence of hypertriglyceridaemia, the reduction in HDL-
cholesterol could represent a reduction in the number of HDL particles (i.e. fewer
HDLs generated by the lipase reaction), a change in HDL composition such as TG
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enrichment to generate small dense HDL3, or both. Low levels of LPL in post-heparin 
plasma and adipose tissue have been found in both type I and type II diabetes. In 
general the more severe the insulin deficiency or resistance, the greater the likelihood 
that decreases in LPL contribute to the associated hypertriglyceridaemia, as opposed 
to increases in VLDL synthesis (Taylor et ah 1980; Levy et al. 1990). The association 
between plasma lipid levels and LPL activity has been investigated in several studies. 
In a recent study by Henderson et al. (1999) levels of post-heparin LPL were found to 
be lower in a group of patients with existing CHD compared with normolipidaemic 
control subjects. Furthermore they were able to demonstrate that post-heparin LPL 
activity in male CHD patients was inversely correlated with fasting TG level and 
positively correlated with HDL-cholesterol levels. The apolipoprotein (apo) E 
genotype was found to be of little significance in determining the relationship 
between post-heparin LPL levels and lipid levels in this group of subjects.
Levels of LPL increase with exercise, certain drugs, or with insulin treatment in the 
case of type I diabetes, and lead to a reduction in TG and an increase in HDL- 
cholesterol. Of interest also is the effect that alterations in diet composition, 
particularly dietary fat, can have on LPL activity and expression. Studies of LPL 
activity after an oral high fat load have shown that LPL activity is increased in 
response to an increase in chylomicron TG levels (Karpe et al. 1993). Animal studies 
have shown that meal fatty acid composition effects on postprandial lipaemia may 
depend in part on differences in chylomicron size, with PUFA producing 
chylomicrons of larger size, which appear to act as better substrates for the LPL 
enzyme (Groot et al. 1988; Levy et al. 1991). Animal studies have also suggested that 
PUFA and MUFA can enhance the activity of LPL and thereby improve TG 
clearance. Several animal studies have demonstrated clearly that increases in the 
intake of MUFA or PUFA increase post-heparin LPL activity (Groot et al. 1988; van 
Heek & Zilversmit, 1990) adipose tissue LPL activity (Levy et al. 1991; Murphy et 
al. 1993) or skeletal muscle LPL activity (Baltzell et al. 1991). A study by Murphy et 
al. (1993) has also demonstrated an increase in LPL gene expression in rats fed a fish 
oil enriched diet. In general, human studies have failed to demonstrate any 
relationship between alterations in dietary fat composition and LPL activity. One 
study (Zampelas et al. 1994) showed an increase in post-heparin LPL activity nine
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hours following a meal eniiched with «-3 PUFA, however studies in which n-2> PUFA 
were fed as part of the background diet failed to show any effect (Harris et ah 1988; 
Weintraub et al, 1988; Nozaki et al. 1991; Harris & Muzio, 1993). Williams (1997) 
deliberates that the reason for the lack of effect observed in these studies may be due 
to the non-specific measurement of post-heparin LPL activity i.e. LPL measuiements 
were not specific to either adipose tissue or skeletal muscle tissue. Further studies are 
required to examine the relationship between changes in lipoprotein levels as a result 
of alterations in dietary fat intake and LPL activity and expression.
1.7 GENETICS OF INSULIN RESISTANCE
IR has a definite genetic component and is known to cluster in families. For example, 
45 % of first-degree relatives of patients with type II diabetes are insulin resistant 
compared with 20 % of people without a family history of diabetes (Groop & Tuomi,
1997). Abdominal obesity, which is strongly associated with IR, also has a genetic 
component. Variations in abdominal fat accumulation have been attributed to genetic 
factors (up to 60 %) in post-menopausal women. Furthermore, first-degree relatives of 
patients with type II diabetes have increased waist to hip ratio compaied with their 
spouse without a family histoiy of diabetes (Groop et al. 1996). This suggests that the 
inheritance of type II diabetes seems to favour fat accumulation in the intra-abdominal 
region. Among the genes thought to contribute to the metabolic syndrome, genes 
regulating lipolysis and thermogenesis remain as prime candidates. The ‘thrifty gene’ 
hypothesis was put forward by Neel (1962) as an explanation as to why the metabolic 
syndrome develops in individuals switching from a harsh rural environment to a 
plentifiil urban environment. The hypothesis was that within an austere environment 
individuals would increase their potential of surviving if they could maximise storage 
of surplus energy. When exposed to a more plentiful environment these evolved genes 
could lead to obesity and potentially IR. However the search for ‘thrifty’ genes has 
yielded disappointing results. Other genes which have been studied in relation to IR 
include, leptin, p2-and p3-adrenergic receptors, lipases including LPL, uncoupling 
proteins, TNF-a, peroxisome proliferator-activated receptor y (PPAR y), glycoprotein
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PC-1, insulin receptor substrate-1 (IRS-1), and glycogen synthase (Groop, 2000). So 
far our knowledge of the role of these candidate genes and their interaction with 
envii'onmental factors is limited. Further studies, perhaps involving families with a 
clearly identifiable genetic risk of IR ai e required.
1.7.1 DIET AND GENE INTERACTIONS
Among the environmental influences that are thought to enhance the genetic risk of 
developing IR is diet. It is known that nutrients govern the tissue content of different 
proteins by functioning as regulators of gene transcription, nuclear RNA processing, 
mRNA stability and mRNA degradation (Clarke, 2000). The nutrient, which has a 
strong influence on cell differentiation, growth and metabolism, is fat. The fatty acid 
component of dietary lipid not only influences hormonal signalling events by 
modifying membrane lipid composition but fatty acids have a direct influence on the 
molecular events governing gene expression (Clarke et al. 1997). It is believed that 
the regulation of gene expression by dietary fats has an impact on the development of 
IR and obesity. In a review by Clarke (2000) it is summarised that dietary n-2 PUFA 
may exert greater benefit in the prevention and treatment of IR than MUFA and «-6 
PUFA. The author attributes this to a genomic influence at the level of gene 
transcription. It is proposed that «-3 PUFA inhibit lipid synthesis and decrease 
malonyl-CoA production by suppressing the expression of lipogenic genes. 
Concomitantly, «-3 PUFA induce the genes of lipid oxidation and induce 
thermogenesis by increasing the expression of uncoupling proteins.
It has also become evident that the relationship between responses to dietary
manipulations and lipoprotein levels is influenced at least in some part by genetic
factors (Williams et al. 1995; Ordovas & Schaefer, 2000). It is important to consider
this when interpreting the results of dietary intervention studies. Other factors such as
age, gender and baseline lipid levels will influence an individual’s response to a
dietary change however gene-environment interactions are thought to play a
significant role. To date studies have focused on genes known to play a central role in
lipoprotein metabolism. The candidate genes include, apo E, apo Al, apo A4, apo B,
apo C3, LPL and CETP (Ordovas & Schaefer, 2000). The apo A, apo E and apo C
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genes are located on chromosome 11 and are closely linked (Bruns et al. 1984). 
APOB is found on chromosome 2 (Law et al. 1985), LPL on the short arm of 
chromosome 8 (Oka et al. 1990), while CETP has been located on chromosome 16, 
adjacent to the lecithin-cholesterol acyl transferase (LCAT) gene (Ordovas & 
Schaefer, 2000). Apo A and apo E genes have secured the greatest attention and they 
have been examined under a variety of different experimental conditions.
Apo Al is the major protein of HDL, the major activator of the enzyme LCAT and 
constitutes a key component of the reverse cholesterol transport process (Reichl & 
Miller, 1989). A common variant due to adenine (A) to guanine (G) transition has 
been described from the apo Al gene transcription site. It has been reported that 
individuals with the A allele, have HDL-cholesterol levels that are higher than those 
homozygous for the most common G allele (Pagani et al. 1990; Jeenah et al. 1990). 
Several studies have demonstrated that the A allele appears to be associated with a 
hyper HDL-response to changes in the amount and saturation of dietary fat in 
normolipidaemic subjects (Lopez-Miranda et al. 1994; Mata et al. 1998). Genetically 
determined isoforms of apo A4 have also been detected in human subjects. The two 
most common iso forms are apo A4*l and apo A4*2 (Menzel et al. 1990; de Knijff et 
al. 1992). The effect these isoforms on dietary response has been examined by several 
investigators. Studies by Mata et al. (1994) have shown that the apo A4 *2 allele is 
associated with hypo-responsiveness of LDL-cholesterol to dietary therapy consisting 
of reductions in total fat and cholesterol. In addition, it was observed that subjects 
with the apo A4*2 allele tended to have greater decreases in HDL-cholesterol 
following a low fat low, cholesterol diet. Jansen et al. (1997) have also examined the 
effect of this polymorphism on HDL-cholesterol response in 41 healthy male subjects. 
They observed that after the consumption of a high saturated fat diet, carriers of the 
apo A4*2 allele had a greater decrease in HDL cholesterol. They also observed that 
compared to carriers of the apo A4* 1 allele, these subjects showed a greater increase 
in HDL-cholesterol with a high MUFA diet than a diet low in fat and high in CHO. 
These results suggest that these subjects may benefit particularly from a diet high in 
monounsaturated fat as opposed to a diet low in fat and high in CHO.
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Apo E in serum is associated with chylomicrons, VLDL and HDL, and serves as a
Iligand for the LDL receptor and the LDL-receptor-related protein (Mahley, 1988; j
Beisiegel et al. 1989). When apo E deficiency is present, there is a marked |
Iaccumulation of cholesterol-enriched lipoproteins of density < 1.006 g/ml (Schaefer |
et al. 1986). Moreover, with this disorder there is delayed cleaiance of both apo B- I
100 and apo B-48 within TRL (Schaefer et al. 1986). Genetic variation at the apo E I
locus results from three common alleles in the population, E*4, E*3, and E*2 
(Davignon et al. 1988). Population studies have shown that plasma cholesterol, LDL- 
cholesterol and apoB levels are highest in subjects carrying the apo E4 isoform, I
intermediate in those with the apoE3 isoform and lowest in those with the apo E2 
iso form (Ordovas et al. 1987; Wilson et al. 1994). The most common apo E allele is 
the apo E3 allele with a relative frequency of 78 % (Davignon et al. 1988; Hixson et 
al. 1991). The relationship between LDL-cholesterol and apo E genetic variation is 
not independent of environmental and ethnic factors. The association of the apo E4 
isoform with elevated cholesterol is greater in populations consuming diets rich in 
saturated fat and cholesterol than in other populations (Williams et al. 1995; Ordovas 
& Schaefer, 2000). These findings indicate that the higher LDL-cholesterol levels 
observed in subjects carrying the apo E4 isoform are manifested primarily by the 
consumption of a high fat diet, and that the response to dietary saturated fat and 
cholesterol may differ among individuals with different apo E phenotypes. A study by 
Loktionov et al. (1998) observed that elevated plasminogen activator inhibitor (PAI- 
1) activity was higher in apo E4 subjects than in apo E3/3 or apo E3/2 subjects, j
suggesting that elevated PAI-1 activity may be an additional factor involved in the 
increased CHD associated with the apo 4 allele. The link between apo E4 gene 
variability and PAI-1 may be mediated by the LDL- receptor-related protein receptor.
It has also been observed that carriers of the apo E2 allele have a hyper TG response 
to low fat and high CHO diets (Ordovas et al. 1995). The apo E gene has also been 
implicated as one of the genetic factors responsible for variable postprandial 
responses to dietary manipulations (Williams et al. 1995). The apo E2 isoform is 
considered to decrease remnant clearance because of decreased affinity for the 
receptors (Ordovas & Schaefer, 2000). Conversely the apo E4 isoform should induce 
a faster clearance. However, studies that have compared postprandial TG responses 
across different apo E genotypes have produced conflicting reports, especially
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regarding the effects associated with the apo E4 allele (Brown & Roberts, 1991; 
Boerwinkle et al. 1991; Nikkila et al. 1994). Interestingly in the Multiple Risk Factor 
Intervention Trial (MRFIT), fasting hyperinsulinaemia was a risk factor for coronary 
artery disease only in men with apo E 3/2 phenotype (Orchard et al. 1994).
A degree of caution is necessary when interpreting the results of diet-gene 
interactions. Studies conducted to date have produced conflicting results therefore 
fuifher studies are still required to reconcile the available information. Most of the 
studies reported were not initially designed to examine diet-gene interactions, and 
conclusions were drawn from re-analysis as advancing genetic techniques facilitated 
this possibility. Some allele effects may be apparent during the postprandial state as 
compared with the fasting state and future studies of diet and lipoprotein response 
should take this into consideration. We know that magnitude of plasma lipid 
responses to diet therapies varies considerably among individuals and future studies 
may be able to use genetic technology to increase our understanding of the effects of 
dietary manipulation on lipoprotein and insulin response, within those at greater 
genetic risk of developing CHD. Further studies are also required to establish the 
genetic components of IR.
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1.8 AIMS AND OBJECTIVES OF THE STUDY
CHD remains a major cause of premature death despite a dramatic decline in many 
Western countries over the past 25 years. IR is strongly associated with the risk of 
developing CHD. Treatment of IR is focused on the environmental factors thought to 
contribute to the development of the condition, including diet. The nutrient, which is 
thought to have a strong influence on the development and progression of IR, is 
dietary fat. Thus, both quality and quantity of dietary fat are potential targets for 
dietary manipulation in the treatment of IR and it’s associated lipid abnormalities. In 
addition to the lack of clear dietary information, the mechanistic links between 
improvements in IR and lipid metabolism including postprandial lipaemia are poorly 
defined. Against this background, dietary intervention studies were planned with the 
objective of providing a stronger scientific base for advising changes in population 
dietary fatty acid intake likely to be associated with reduced risk of cardiovascular 
disease.
The hypotheses to be investigated were:-
> Insulin resistance with respect to glucose disposal also extends to 
deranged postprandial fat metabolism, with consequent increased risk of 
CHD.
> The insulin sensitivity of these pathways is improved by either increased 
dietary «-3 PUFA or reduced SFA in normal adults.
To address these hypotheses a series of intensive metabolic studies were designed and 
conducted in middle-aged men exhibiting characteristics of IR with the following 
specific objectives and methodologies employed.
1. To determine the effects of reduced dietary SFA and increased dietary 
n-3 PUFA on the insulin sensitivity of :
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a) fasting glucose disposal and NEFA suppression, by the short ITT test measuring 
glucose and NEFA disposal rate.
b) adipose tissue LPL by adipose tissue lipoprotein lipase gene expression, and 
heparin releasable LPL activity during postprandial lipid clearance after a high fat 
breakfast.
c) glycerol release and NEFA suppression by stable isotope studies of the insulin 
sensitivity of hormone sensitive lipase as the reduction in the fasting glycerol 
appearance rate in response to a low level insulin infusion
To relate all these determinants of insulin sensitivity to:
a) Dietary lipid tolerance in terms of the metabolic and hormonal sequellae of 
postprandial lipid clearance after a high fat breakfast: i.e. triglyceride, cholesterol 
fi*actions, NEFA, apo B-48, glucose and insulin concentrations.
b) Altered membrane FA composition by assessment of the fatty acid composition of 
RBC membranes.
This research programme was supported by the MAFF lipids programme and 
involved several investigators working together during two dietary interventions, 
which formed the basis of the MAFF research contract: i.e.
1 : increased fish oil: 2-3 g long chain w-3 fatty acids/d in food.
2: reduced saturated fat by isoenergetic exchange with carbohydrate.
However during the execution of the second intervention, concern was expressed that 
although most National and International dietaiy guidelines emphasise the need to 
reduce total and saturated fat intakes and increase the intake of CHO, too much 
emphasis on reduction of total fat intake could result in excessive increases in CHO 
consumption. This is important since high-CHO diets have in some instances been 
shown to be detrimental in the management of IR Thus, a third intervention was 
carried out which was additional to the MAFF contract.
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3: reduced saturated fat by isoenergetic exchange with monounsaturated fat.
To ensure that the results of the study could be applied to the free-living situation, all 
of the dietary studies were conducted using normal foods, in which the fatty acid 
composition had been modified.
In this thesis only those aspects which I was directly involved with are described, 
namely all the above procedures excepting for the stable isotope studies which formed 
part of interventions 1 & 2. A brief summary of the main findings from the stable 
isotope studies is included in appendix 1. In the case of the third intervention I was 
solely responsible for its design and execution and no stable isotope studies were 
performed.
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CHAPTER 2.0 
MATERIALS & METHODS
2.1 MATERIALS
Chemicals, compounds and consumables used are presented under the heading of the 
company from which they were obtained.
□ Antigen Pharmaceuticals Ltd (Roscrea, Co.Tipperary, Ireland).
Lignocaine hydrochloride injection B.P.
□ BDH Laboratory Supplies (Poole, Dorset, BH15 ITD, UK).
N-Lauroylsarcosine, sodium salt, CigHzgNOgNa
□ Gibco BRL [Produced By Life Technologies Ltd] (Paisley, UK).
Guanidine thiocyanate (CHsNa^HSCN)
Primers
□ Greiner Labortechnik Ltd
(Brunei way, Stonehouse, Gloucestershire, GLIO 3SX).
Falcon tubes, sterile (14 ml)
□ LIP Equipment & Services Ltd
(Dockfield rd., Shipley, W. Yorkshire, BD17 7SJ)
EDTA tubes (1, 5 & 10 ml)
Fluoride oxalate tubes (1 ml & 5 ml)
Glass blood tubes (without anticoagulant)
Lithium Heparin tubes (5 & 10 ml)
LP3 tubes
□ Nycomed Amersham Pic.
(Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK). 
Glycerol Tri (9, lO(n)-^H) oleate
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^^ I^-Insulin
□ PROMEGA UK Ltd
(Delta House, Cliilworth Research Centre, Southampton, S016 7NS, UK).
Access RT-PCR system
RNAgents® Total RNA isolation system
□ Roche Products Ltd (Welwyn Garden City, Hertfordshire, AL7 3AY).
Calibrator H
Cholesterol kit (Unimate 5)
Control-serum N 
Glucose kit (Unimate 5 HK)
HDL reagent
TAG analysis kit (Unimate 5)
□ Randox Laboratories (Co. Antrim, Northern Ireland, UK).
HDL direct
□ Sarsted Ltd. (Leicester, UK).
Centrifuge tubes, opaque, 15 ml
□ Sigma-Aid rich Company Ltd
(Fancy road, Poole, Dorset, BH12 4QH, UK).
Acetic acid, glacial (C2H4O2)
Albumin,bovine (essentially fatty acid free)
Chloroform (CHCI3)
Diethyl pyrocarbonate (CeHioOs)
Ethidium bromide (C21H20N3BR)
Glycerol AR (C3H8O3)
Heparin (porcine, sodium salt)
Heptane
Isoamyl alcohol (C5H12O)
DNA ladder, 1 Kb
Lauryl sulfate sodium salt (Ci2H2504SNa)
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L-a-phosphatidyl choline (L-a-Lecithin; l,2-Diacyl-sn-glycero-3- 
phosphocholine).
Methanol (CH3OH)
2-mercaptoethanol (CaHeOS)
Phenol (CôHôOH)
Polaroid black and white print film 667 
Polaroid positive/negative print film 665 
Polyethylene Glycol (PEG)
Potassium carbonate (K2CO3)
Sodium Chloride (NaCl)
Triolein (C18:l,[cis]-9)
Trizma base (C4H11NO3)
□ Wallac UK Supplied By Fisons Chemicals (Leicester, UK).
Optiphase safe
□ WAKO Chemicals supplied by Alpha Laboratories (Eastleigh, UK).
NEFA C kit
2.2 METHODS
2.2.1 COLLECTION AND TREATMENT OF BLOOD SAMPLES
Blood samples were collected into tubes containing a suitable anticoagulant for the 
analysis requiied.
Sample Analysis Collection tube type
Glucose - Fluoride oxalate tube
Lipids - EDTA tube
Insulin - Lithium heparin tube
Blood tubes were centrifiiged immediately after sample collection at 553 x g for 10 
minutes in a bench top centrifuge. For the analysis of glucose, insulin and lipids.
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plasma was removed, aliquoted into LP3 tubes and stored at -20®C. HDL-cholesterol 
samples, were stored at 4°C and analysis conducted within 48 hours.
2.2.2 PREPARATION OF BLOOD SAMPLES FOR THE ANALYSIS OF RED 
BLOOD CELL FATTY ACIDS
After the separation of blood by centrifugation, plasma was removed and the red 
blood cells were washed with 10 ml of 0.9 % saline solution. The washed solution 
was centrifuged at 553 x g for 10 minutes in a bench centrifuge and the top saline 
portion removed. The washing procedure was repeated a further two times. Finally the 
blood cells were transferred to a glass tube , were wrapped in para-film and stored at -  
20°C until required for analysis.
Another investigator measwed the fatty acid composition of red blood cell 
phospholipids. Lipids were extracted with a mixture of chloroform and methanol (2:1 
vol/vol), containing 0.01 % BHT as an antioxidant, according to the Folch method 
(Folch et al. 1957). The fatty acids were separated and quantitated using gas 
chromatography, with peak areas expressed as % of total peaks. Fatty acids were 
identified by comparing retention times with those of a known standard mixture.
2.2.3 AUTOMATED ANALYSIS ON THE COBAS MIRA PLUS
2.2.3.1 Measurement o f plasma Glucose
Plasma glucose concentrations were measuied using the Unimate 5 GLUC HK in- 
vitro kit (Roche Diagnostic Products Ltd, UK). The method involves an enzymatic 
UV test and uses the enzymes, hexokinase (HK) and glucose-6-phosphate 
dehydrogenase (G6P-DH). The principle of the assay is described in the following 
equations:-
D-glucose + ATP ___  ^ D-glucose-6-P + ADP
D-glucose-6-P + NAD"^  , D-gluconate-6-P + NADH + iT
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The formation of NADH is directly related to the glucose concentration of the sample 
and is measured photometrically at 340 nm.
2.23.2 Measurement o f total plasma cholesterol
Plasma total cholesterol was measured using a kit and QC supplied by Roche 
diagnostic products Ltd, UK. The principle of the system is outlined below:-
, , _  Cholesterol esterase  ^  ^ ,Cholesterol ester + H2O ____________ ^  cholesterol + fatty acids
Cholesterol oxidase
Cholesterol + O2 -------------------^  cholest-4-en-3-one + H2O2
peroxidase
H2O2 + 4-chlorophenol + 4-aminophenazone------------- ► quinoneimine derivative
The coloui* intensity of the red-coloured quinoneimine derivative is directly 
proportional to the concentration of cholesterol in the sample.
2.2.3.3 In-direct measurement o f HDL-cholesterol
For the fish oil (chapter 3.0) and the low SFA / high CHO (chapter 4.0) interventions 
HDL cholesterol was measured using a kit and QC supplied by Roche Diagnostic 
products Ltd, UK. Prior to cholesterol analysis, samples and QCs were treated with a 
reagent containing phosphotungstic acid and magnesium chloride to precipitate out 
apoB containing lipoproteins (LDL and VLDL). The samples were centrifiiged at 
5955 X g for 2 minutes in a microcentrifuge. The supernatant was removed and 
analysed for cholesterol concentration using the total cholesterol kit described in 
section 2.2.3.2. The standard used for this assay was diluted (1: 2.5) with 0.15 M 
NaCl prior to cholesterol analysis, to allow for the diluting effect of the precipitating 
reagents on the samples.
2.2.3.4 Direct measurement o f HDL-cholesterol
For the MUFA intervention (Chapter 5.0) HDL-cholesterol samples were measured 
using the direct HDL-cholesterol kit, supplied by Randox. The kit allows dhect 
measurement of HDL-cholesterol, without sample pre-treatment. The assay consists 
of 2 distinct reaction steps catalysed by two enzyme reagents. The first step facilitates 
the elimination of chylomicron, VLDL-cholesterol and LDL-cholesterol, while the
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second step allows the specific measurement of HDL-cholesterol after release of 
HDL-cholesterol by detergents in reagent 2. The principle of the assay is outlined in 
the equations below.
Step 1
cholesterolesterase
Cholesterol ester -------------------► cholesterol + fatty acids
Cholesterol oxidase 
Cholesterol + 0% ^  cholest-4-en-3-one + H2O2
peroxidase2H2O2  ► 2H202 + 02
Step 2
cholesterolesterase
Cholesterol ester -------------------► cholesterol + fatty acids
Cholesterol oxidase 
Cholesterol + O2 ► cho lest-4-en-3 -one + H2O2
Peroxidase
2H202 + 4AA + HD AOS -------------------► Quinone pigment + 4H20
The intensity of the quinoneimine dye produced is directly proportional to the 
cholesterol concentration when measured at 600 nm.
4AA = 4- Aminoantipyrine
HD AOS = (2 - hydroxy -  3 -  sulfopropyl) -  3,5 - dimethoxyaniline
2.2.3.5 Measurement o f LDL-cholesterol
LDL-C was calculated from the measurement of total cholesterol, HDL-Cholesterol 
and triglyceride according to Friedewald’s formula (Friedewald et al. 1972).
LDL-C (mmol/L) = Total serum cholesterol -  [HDL-cholesterol + ]
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2.2.3.6 Measurement o f plasma NEFA
Plasma NEFA concentrations were measured using a kit supplied by WAKO 
Chemical GmbH, Germany and supplied by Alpha Laboratories Ltd, Eastleigh, UK. 
The QC employed in the assay was supplied by Randox laboratories Ltd, UK. The 
principle of the system is outlined below
Acyl-CoA synthetase
RCOOH (NEFA) + ATP +CoA -------------------► Acyl-CoA + AMP + Ppi
Acyl-CoA oxidase
Acyl-CoA + O2 -------------------► 2,3-trans-Enoyl CoA + H2O2
Hydrogen peroxide, in the presence of peroxidase permits the oxidative condensation 
of 3-methyl-N-ethyl-N-(B-hydroxyethyl)-aniline with 4-aminoantipyrine to form a 
purple colour adduct which can be measured colorimetrically at 550 nm. The intensity 
of the colour formed is proportional to the NEFA concentration. If left to stand at 
room temperature, the level of NEFA within a sample will increase. Therefore, 
samples were prepared for analysis as quickly as possible, working on ice at all times.
2.2.3.7 Measurement o f Plasma Triglyceride
Plasma TG levels was measured by an automated, enzymatic, spectrophotometric 
technique on the Cobas Mira Plus analyser (Roche products Ltd, UK). The principle 
of the assay is described in the following equations.
Lipase
Triglyceride ^  glycerol + fatty acids
Glycerol kinase
Glycerol + ATP -------------------► glycerol-3 -phosphate + ADP
Glycerol phosphate oxidase 
Glycerol-3-phosphate + O2-----------------► dihydroxyacetone phosphate + H2O2
In the presence of peroxidase, the hydrogen peroxide formed effects the oxidative coupling of 4- 
chlorophenol and 4-aminotipyrine to form a red-coloured quinoneimine derivative. The colour intensity 
measured is directly related to the TG concentration in the sample and is measured photometrically at 
500 nm. 2.2.3.8 Variability of the Cobas Mira automated spectrophotometric techniques
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The intra- and inter-assay coefficient of variation (CV) for the assays employed on the 
Cobas Mira plus autoanalyser were as follows:-
Sample analysis
Mean QC value 
(mmol/1)
Intra-assay CV 
(%)
Inter-assay CV 
(%)
Glucose 4.51 1.56 2.53
Total cholesterol 6.54 2.43 5.61
HDL-cholesterol
- indirect method 1.04 1.89 4.94
direct method 0.79 0.69 1.82
NEFA 1.25 1.62 2.71
TG 1.19 1.05 3.45
2.2.4 SEPARATION OF TRL AND TPL FRACTIONS FROM PLASMA USING 
ULTRACENTRFIUGATION
At the time of blood separation, 5 ml of plasma was transferred to an anticoagulant- 
free glass bottle and stored at 4°C overnight. Using thick-walled polycarbonate tubes 
(38 ml), 3.5 ml of plasma was overlayered with 3.5 ml of NaCl solution (density 
=1.006 g/ml) using an automated Finnpipette (Lifesciences International, UK). The 
tubes were ultracentrifuged in a 50.2 Ti rotor (Beckman, UK.) at 4.83 x 106 gmax.min 
in a Beckman L7-65 ultracentrifuge (MSE Scientific Instruments, UK.) at 24°C.
The TRL fraction appears as a fine, cream layer on the surface of the plasma. At least
1.2 ml of the TRL layer was isolated using a glass Pasteur pipette and aliquoted into 
LP3 tubes. The TPL fraction was mixed and aliquoted. All samples were stored at -  
20°C until analysis.
2.2.5 MEASUREMENT OFAPO-’B48
ApoB-48 was measured by another investigator according to a method previously 
described by Lovegrove et al. (1996). The method is a competitive, enzyme-linlced 
immunosorbent assay (ELISA), employing the use of an antiserum, specific for apo
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B-48. An heptapeptide-thyroglobulin conjugate consisting of the terminal residues of 
the apo B-48 molecule is used as the coating material in this ELISA assay. 
Chylomicron samples from the postprandial studies were incubated with the specific 
antisera to apo B-48 before addition to the ELISA plate. An horse radish peroxidase 
conjugated antibody is used to detect antibodies attached to the coating material 
through its action with the tetramethylbenzidine substrate. Absorbance was measured 
at 450 nm. A standard curve was constructed and the amount of apo B-48 within the 
QCs and samples was determined by reading from this curve.
2.2.6 MEASUREMENT OF PLASMA INSULIN CONCENTRATION
Insulin was measured by a radioimmunoassay method developed at the University of 
Surrey (Hampton & Withey, 1993). The insulin radio label was produced by other 
reseai’chers in the Nutrition laboratory at the University of Surrey. Antibodies against 
insulin were raised by immunising guinea pigs with porcine insulin conjugated to egg 
albumin via carbodimide and aliquots were kindly supplied by Dr. S. Hampton at the 
University of Surrey. Separation of the assay was carried out by a double antibody 
plus polyethylene glycol method. The assay procedure is outlined in table 2.1.
The assay was conducted over a three-day period. The reagents were added in the 
order shown in table 2.1. Tubes were set up in duplicate. R.O. water was used in the 
preparation of all reagents. At the end of the incubation period on day 3 the tubes 
were centrifuged in a Beckman J-6B at 1300 x g for 30 minutes at 4°C. The resulting 
supernatant was aspirated and the tubes counted on the Wallac 1470 Wizard, 
automatic gamma counter using a pre-set programme. A low (mean, 71 pmol/1) and 
high (mean, 580 pmol/1) QC was run in each assay. The intra-assay CV was 5.2 % 
and 4.8 % for the low and high QCs respectively, while the inter-assay CV was 7.6 % 
for the low QC and 9.2 % for the high QC.
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Table 2.1. Outline o f the insulin assay procedure.
Standards of 23, 47, 94, 188, 375, 750 and 1500 pmol/1 are prepared in buffer.
Tu )es
i
c/3
1 i i
a lN M 1So jz; o ocx
gm B 
§  § 1
DAY 1
Assay
buffer . 350 pi 250 pi 200 p,l 350 pi 250 pi 350 pi 250 W
Insulin
standard 50 nl _ . .
CSS . 50 pi 50 pi 50 nl
QC plasma 50 pi 50 pi _
Plasma
sample . . . . 50 pi 50(11
Antisemm 100 Hi 100 pi 100 pi 100 (il
Tubes were vortex-mixed and incubated at 4°C for 24 houis
DAY2
^^^I-Insulin 100 Hl 100 pi 100 ni 100 pi 100 pi 100 pi 100 pi 100 (il
Tubes were vortex-mixed and incubated at 4°C for 24 hours
DAY3
NGPS 100 pi 100 |4l 100 pi 100 pi 100 pi 100 pi 100 (il
DAGP . 100 pi 100 ni 100 pi 100 pi 100 pi 100 pi 100 (il
4% PEG 700 pi 700 Hl 700 pi 700 pi 700 pi 700 pi 700 (il
Tubes were vortex-mixed, incubated at 4°C for 2 hours and then centrifuged at 
1300 X g  for 30 min. Tubes were aspirated and the pellet counted for radioactivity.
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2.2.7 MEASUREMENT OF POST-HEPARIN PLASMA LIPASE ACTIVITY
LPL and HL activity was measured by a modified method of that described by 
Nilsson-Ehle & Schotz (1976). The method involves the detection of ^ H-labeled free 
fatty acids, formed by hydrolysis of a ^H-labelled triolein-substrate emulsion, 
catalysed by the lipase enzymes LPL and HL as depicted in the equation below.
Lipase enzymes
Glycerol ^H-triolate ---------- ^  ^H-oleic acid + glycerol.
Selective measurement of LPL and HL was achieved by selecting assay conditions 
favourable to the activity of HL.
1 M NaCl can readily suppress the activity of LPL, and the activity recorded (in the 
absence of apo CII) is a good measure of HL. Salt inactivation of LPL is due to an 
irreversible dénaturation of the enzyme molecule (Olivecrona & Olivecrona, 1989)
In this assay post heparin samples were assayed simultaneously in the presence of 0.2 
M NaCl, to give a measure of total lipase activity and 4 M NaCl, to give a measure of 
HL activity. The difference in total lipase and HL activity was taken as a measure of 
LPL activity.
Both LPL and HL are inhibited by fatty acids. It was therefore necessary to include 
albumin in the lipid emulsion to bind any fatty acids present.
The LPL -heparin complex is more stable and soluble than the enzyme alone and is 
catalytically active (Olivecrona & Olivecrona, 1989). Heparin was therefore included 
in the Tris-buffer used for the incubation of the enzyme. With a high concentration of 
NaCl, the interaction between HL and heparin will be disrupted and the presence of 
heparin will be of no importance.
Finally, with triglyceride emulsions as substrates the activity of LPL, but not the 
activity of HL, has been shown to be increased several fold by apo-CII. Purified apo- 
CII was therefore added to the samples assayed for total lipase activity.
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2.2.7.1 Preparation of^H-triolein-glvcerol emulsion
50 pi of labelled (^H-triolein [9,10(n) oleate]) and 250 pi unlabeled triolein were 
mixed and 80 pi of L-a-phosphatidyl choline added. The solvents were evaporated 
under a stream of nitrogen in a darkened fiime cupboard. The dried lipids were 
emulsified in 5 ml of glycerol by homogenisation for 5 minutes continuously, using a 
Black and Decker drill to which a pestle had been attached. The homogenisation was 
carried out in a glass homogenising tube, immersed in an ice bath. The emulsion was 
transferred to a glass tube, wrapped in foil (to prevent photolytic destruction) and 
double contained in a Perspex box until required. The emulsion, which is optically 
clear due to the similar refractive indices of the lipid and glycerol, could be stored at 
room temperature for at least six weeks. It will be referred to as the ‘concentrated 
substrate’.
2.2.7.2 Preparation o f Tris buffer
50 mM Trizma base containing 2 lU/ml heparin and either 0.2M or 4M NaCl was 
made up in a volumetric flask with R.O. distilled water. The pH was corrected to 8.4 
using 1 M HCL or NaOH and the solutions stored at 4°C until required for use.
2.2.7.3 Preparation o f the substrate emulsion
Substrate emulsions for assay were prepared daily by dilution of 1 volume of 
concentrated substrate with 4 volumes of 0.2 M or 4 M NaCl-Tris buffer (pH 8.4) 
containing 3% (w/v) bovine serum albumin. The substrate emulsion was shaken 
vigorously on a vortex mixer for 10 seconds and incubated at 37°C before being 
added to the reaction tubes.
For the assay of total lipase activity 1 pi of apo-CII (0.5pM) per sample of post­
heparin plasma was added to the substrate emulsion. Apo-CII was not added to the 
substrate emulsion for the assay of hepatic lipase activity.
2.2.7.4 Assay procedure
An outline of the assay procedure is shown in table 2.2.
Using a total assay volume of 200 pi, 10 pi of post-heparin plasma, 100 pi of the 
appropriate substrate emulsion and 90 pi of either 0.2 M NaCl-Tris buffer or 4 M
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NaCl-Tris buffer was added to the reaction tubes. Outside of the incubation period, 
the reaction tubes were kept on ice at all times.
In addition, blank incubations (without lipase) and a reference sample of post-heparin 
plasma were included in the assay procedure as a measure of background free fatty 
acid levels and to monitor inter-assay valuation respectively. All samples were 
assayed in duplicate
Incubation of the reaction tubes was carried out in a shaking water bath at 37°C for a 
period of 30 minutes. The extraction of fatty acids produced during the incubation 
was by a modification of the method described by Belfrage & Vaughan (1969). The 
enzymatic reaction was stopped by the addition of 3.25 ml of 
methano 1:chloro&rm:heptane (1.41:1.25:1.00 v/v/v) followed by 1.05 ml of 0.1 M 
K2CO3 (adjusted to pH 7.4 with saturated boric acid) in order to extract free fatty 
acids into the methanolic upper phase.
The tubes were vortex mixed and centrifuged at 1700 x g for 10 minutes in a 
Beckman J6 centrifuge to separate the upper alkaline/water phase containing the fatty 
acids from the lower chloroform heptane phase, containing triglycerides and partial 
glycerides. All procedures subsequent to the extraction were performed at room 
temperature.
A 0.5 ml sample from the upper phase was added to a scintillation counting vial 
containing 4 ml of optiphase safe and 75 pi of glacial acetic acid. Glacial acetic acid 
reduced chemiluminescence by neutralising the alkaline sample.
The vials were inverted several times and left in the dark for a minimum of 1 horn* 
before being counted for specific radioactivity on a Wallac 1410 beta counter. Each 
vial was counted for 5 minutes using a pre-set programme.
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Table 2.2. Outline o f LPL assay procedure
Reagents
Tubes
0.2 M/4 M 
NaCl-Tris 
buffer
Substrate
Emulsion
P o st-
heparin
sample
Reference
sample
K2C03 Organic
solvent
Totals 2.45 ml 100 pi - - - -
Blanks 100 pi 100 ul - - 1.05 ml 3.25 ml
Samples 90 ul 100 ul lOul - 1.05 ml 3.25 ml
References 90 ul 100 ul - 10 ul 1.05 ml 3.25 ml
2.2.7.5 Calculation o f Enzyme Activity
Enzyme activity was calculated according to the formula:
Enzyme activity = Net DPM x x x 3 x 4.9 x
Net DPM = DPM-blank
Sp Act. = Specific radioactivity of triolein expressed as DPM per nmol of triolein.
3 = Number of fatty acids released per molecule of triglyceride hydrolysed.
4.9 = Dilution factor (0.5 ml taken from 2.45 ml upper phase).
0.76 = Partition of oleic acid in the extraction system.
The results were expressed in units of activity equivalent to pmoles of oleate released 
per ml per hour.
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2.2.8 OPTIMISATION OF LPL ASSAY
The method of measuring LPL in this laboratory was based on the method originally 
described by Nilsson-Ehle & Schotz (1976). When post-heparin samples collected 
during the first dietary intervention study (chapter 3.0) were analysed using the 
established method, it was found that the activity values obtained were below 
published values using the same method of analysis. LPL activity values were also 
lower than had previously been attained by other investigators in the laboratory using 
the same method of analysis.
Several experiments were undertaken in an attempt to optimise the assay. The 
components of the assay as well as the method of collecting blood samples were 
examined.
2.2.8.1 Collection o f post-heparin blood samples
When heparin is administered IV, to stimulate the release of LPL from the endothelial 
surface, it is recommended that that blood samples are subsequently collected from a 
site distal to that from which the heparin is administered. Post-heparin samples were 
collected at the end of a 9-hour postprandial study during this investigation. Subjects 
had a cannula inserted at the beginning of the study to facilitate the collection of 
blood samples. To minimise any further potential discomfort for the subjects it was 
decided to administer heparin via the cannula and to collect blood samples from the 
same cannula.
To investigate whether collecting blood from the same site through which heparin has 
been administered has an effect on levels of LPL activity, a small study was set up. 
The aim of the study was to establish whether there was any difference in LPL 
activity, measured in blood samples collected from a distal site or from the same site 
through which heparin was administered.
Six subjects (4 females and 2 males) participated in the study. Blood samples were 
collected four hours after consuming a high fat breakfast (60 g fat). Blood samples 
were collected on two occasions 5 and 15 minutes following heparin administration, 
one week apai't. For each study a cannula was inserted into the antecubital vein of the
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non-dominant arm and blood samples collected from here. Heparin (7500 lU) was 
administered via the cannula on one occasion and via an IV injection in the opposite 
arm on another occasion. Subjects were randomized in the order of the method of 
heparin administration.
Four subjects completed the study. For one subject when it was attempted to 
administer heparin by IV injection in the opposite arm, the vein was missed and blood 
sample collection was therefore not possible. This served to highlight the 
disadvantage of administering heparin in this fashion.
The levels of LPL activity measured 5 and 15 minutes following heparin administered 
via either the cannula or the opposite arm are presented in fig 2.1. It was observed that 
there was no difference in the method of administering heparin on LPL activity levels, 
either in the 5 minute or 15 minute sample. However it was noted that the results 
obtained by either method were still lower than published values for normal control 
subjects. It was concluded therefore, that the method of administration of heparin did 
not impact on the levels of LPL activity and was not accounting for the low levels 
being obtained in the fish oil study samples.
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■  Opposite arm 
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5 minute sample 15 minute sample
Figure 2.1. Comparison of post-heparin LPL activity levels using different 
methods of heparin administration
Data are means of 4 subjects ± SE.
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2.2.8.2 Method o f preparing substrate emulsion
The established method of emulsifying the 3^-triolein glycerol emulsion in this 
laboratory was by sonication using a Soniprep 150 ultrasonic disintegrator (MSE 
Scientific Instruments). After removal of solvents firom the triolein mixture described 
in section 2.2.1.3 , émulsification was carried out by intermittent sonication (10 
second bursts of sonication) over a period of 4-5 hours, cooling the emulsion for at 
least 15 minutes on ice between sonications. The emulsifying procedure was 
considered complete when no trace of oil was visible on the surface of the emulsion.
An alternative method of emulsifying is by homogenisation as described by 
Olivecrona et al. (1979). An experiment was set up to investigate the effect on the 
assay performance when an emulsion was prepared by homogenisation as described 
in section 2.2.7.4. The samples analysed were those collected during the heparin study 
described in section 2.2.S.2. The results obtained and a comparison with the values 
obtained using a sonicated emulsion are presented in figure 4.3. The LPL activity 
values measured using the homogenised emulsion were within previously published 
values with a range of 9.8 -  24.2 U and were greater than the results obtained 
previously using a sonicated emulsion. The intra-asay CV was 6.2% at 47.2 U using 
the homogenising method and was determined by repeated measure of a bovine milk 
standard. The inter-assay CV was 30% at 17.1 U and 30.5% at 8.5 U using post­
heparin plasma samples.
It was concluded therefore that preparing emulsions by homogenisation as opposed to 
the established method of sonication would improve the validity of the LPL assay.
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Figure 2.2.
PH5 = 5 minute post-heparin sample, PH 15 = 15 minute post-heparin sample.
Comparison of LPL activity levels measured in individual subjects 
using a homogenised emulsion and a sonicated emulsion.
2.2.8.4 Source o f Apo C-II in the LPL assay
Apo C-II is a co-factor necessary for LPL activation, therefore its inclusion is 
recommended in assays measuring LPL activity. Traditionally heat-inactivated serum 
has been used as a source of apo C-II. Previous studies however, have reported 
variable LPL activity values based on the source of serum, the length of time that 
substrates are incubated with serum and the amount of serum added (Bengston- 
Olivecrona & Olivecrona, 1992; Henderson, 1993). In addition, apo C-III present in 
the serum has the potential of inhibiting the activity of HL, thereby obscuring the 
measurement of LPL activity. An experiment was therefore set up to examine the 
effect on LPL activity of the exclusion of serum from the assay system and replacing 
this with a purified source of apo C-II.
Postheparin plasma samples (5 and 15 minute samples) previously obtained from 4 
subjects were analysed in duplicate. Within the assay, one set of samples was 
analysed using the addition of heat-inactivated serum as the source of apo C-II, while 
a duplicate set of samples was analysed using a purified source of apo C-II. The 
results of the experiment are presented in fig 2.3 and show that the removal of serum
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from the assay procedure and replacement with a purified source of apo C-II has 
increased the LPL activity values (p = 0.05). All measurements of LPL activity in the 
intervention studies presented were subsequently conducted without the use of heat- 
inactivated serum.
12.00 ■ With serum 
□ Without serum
10.00
s  8.00
Q 6.00
^  4.00
o_ 2.00
postheparin sample
Figure 2.3. Post-heparin LPL activity of 8 samples assayed with serum and with 
pure apo C-II.
Data are presented as means ± SE.
2.3 HUMAN METABOLIC INVESTIGATIONS
For each intervention study the following investigations were conducted.
2.3.1 POSTPRANDIAL STUDY
The study was conducted in the Clinical Investigation Unit at the Royal Surrey 
County Hospital. Each postprandial investigation began between 8:00 am and 9:00 
am, following an overnight fast. All subjects had refrained from strenuous exercise 
and abstained from alcohol on the day prior to the investigation.
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On arrival a 19 gauge, 32-mm venous cannula (Abbott Ireland Ltd,) was inserted in 
the antecubital vein of the non-dominant forearm, and 22 ml of fasting blood was 
taken. The test meal consisting of a cheese sandwich, orange juice and a chocolate 
milkshake, providing 80 g of fat was consumed. The nutrient composition of the test 
meal is provided in table 2.3. The subjects consumed the test meal within 20 minutes. 
No other food was allowed throughout the 9-hour test period, although energy-free 
and caffeine-free fluids were allowed ad libitum.
Following the test meal 10 ml of blood was dravm every 30 min for the first two 
hours and hourly thereafter for the remaining 7 hours. The cannula was flushed with 
1-2 ml of saline solution after sampling to ensure that the cannula remained patent. At 
each sampling point the first 1-2 ml of blood was therefore discarded to eliminate any 
traces of saline solution.
Blood samples were collected for the analysis of triglyceride, cholesterol, NEFA, 
insulin, glucose, and chylomicron fractions. The collection and treatment of blood 
samples was as described in section 2.2.1.
Six hours into the postprandial investigation an adipose tissue biopsy was taken from 
the par-umbilical region of the stomach. The procedure is outlined in detail in, section 
2.3.3. Adipose tissue was stored at -80°C until required for analysis of LPL mRNA 
levels, the results of which are described in chapter 6.0.
At the end of the 9-hour study, volunteers were given a bolus dose of 7500 lU of 
heparin, via the cannula. Blood samples (5 ml) were collected 5 and 15 minutes 
following heparin administration for the analysis of plasma LPL enzyme activity as 
described in section 2.2.7.
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Table 2.3. Nutritional content o f test meal
FOOD Quantity Energy
(kJ)
Fat
(g)
Protein
(g)
CHO
(g)
White bread 70 g 630 0.9 5.4 35
Margarine 10 g 300 8.2 - -
Cheddar cheese 30 g 510 10.4 7.7 -
Chocolate powder 10 g 170 0.5 - -
Whole miUc 130 ml 350 5.1 4.2 6
Double cream 120 ml 2220 57.6 2.0 4
Orange juice 200 ml 300 trace 1.0 18
Total 4480 82.7 20.3 72.5
2.3.2 SHORT INSULIN TOLERANCE TEST
The investigation was conducted in the Clinical Investigation Unit at the Royal Surrey 
County Hospital under the supervision of the project Clinician. Upon arrival at the 
investigation unit subjects were asked to place their non-dominant hand into a hand- 
warming unit. The hand-warming unit was set to a temperatuie of 60*^ C and was 
designed to enable the collection of ‘arterialised’ venous blood samples. Subjects had 
fasted overnight following the consumption of a standardised ready meal at 20:00 
hours on the evening prior to the investigation. No strenuous exercise had been 
undertaken or alcohol consumed in the previous 24-hour period.
A long arm butterfly cannula was inserted into an antecubital vein on the dorsum of 
the hand and a 4-ml fasting blood sample taken. The cannula arm was fixed with a 
thiee-way tap and positioned to facilitate the collection of blood samples without
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having to remove the hand from the hand-warming unit. The insulin (Human 
Actrapid, Novo laboratories, Basingstoke, UK) was prepared by diluting 100 units in 
100 ml of saline (1 unit/ml) and a bolus dose (O.lU/Kg body weight) was 
administered via the cannula. Following insulin administration, 1-ml blood samples 
were drawn at timed one-minute intervals over a period of 15 minutes. The cannula 
was flushed with a 0.9% saline solution between samples and at each sampling point 
the first 1 ml of blood was discarded to remove any traces of saline solution from the 
sample for assay. Giving a concentrated glucose drink (Hycal) terminated the test. 
Volunteers were provided with a breakfast before leaving the investigation unit.
Blood samples were collected and analysed for glucose and NEFA levels as described 
section 2.2.3.1 and 2.2.3.6 respectively. Insulin sensitivity was determined from the 
slope in the fall of log-transformed glucose between 4 and 15 minutes following 
insulin injection.
2.3.3 COLLECTION OF HUMAN ADIPOSE TISSUE
Adipose tissue samples were collected during the postprandial study day of each 
dietary intervention study. The tissue samples were collected from the paiaumbilical 
region under local anaesthetic. The area was first cleaned using an alcohol swab and 5 
ml of lignocaine injected deep into the paraumbilical region. A small amount of skin 
was excised using a fine needle to allow the sterile biopsy needle to be inserted into 
the adipose tissue beneath the skin. Adipose tissue was manipulated using the biopsy 
needle and removed by aspiration using a 20-ml syringe. The procedure was stopped 
when sufficient tissue had been collected and the area was cleaned and fixed with a 
plaster.
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CHAPTER 3.0 
THE EFFECT OF A LONG CHAIN N-3 PUFA ENRICHED DIET 
ON INSULIN SENSITIVITY AND POSTPRANDIAL LIPAEMIA
3.1 BACKGROUND
As indicated in the introduction while there is little dispute regarding the role of n-3 
fatty acids in lowering serum TG and VLDL concentration there is less agreement as 
to the effect of n-3 supplementation on glycaemic control and insulin action. In terms 
of glucose tolerance, epidemiological observations suggest that the incidence of 
diabetes is lower in populations known to consume large amounts of fish and marine 
mammals (MouratofF et al. 1969; Ki*omarm & Green, 1980). Intervention studies 
which have examined the effect of n-3 PUFA on blood glucose levels have generally 
been conducted in individuals with abnormal glucose tolerance or diabetes and here 
contradictory results have emerged. While some have found an improvement in the 
regulation of blood glucose levels (Zak et ah 1989; Fasching et al 1991), several 
others report either no change (Kasim et al 1988; Puhakainen et al 1995) or a 
worsening of glycaemic control (Friday et a l, 1989; Hendia et al. 1990; Malasanos & 
Stacpoole, 1991; Zambon et a l, 1992). The suggested explanation for the 
hyperglycaemic response, is an increase in basal hepatic glucose output. Those studies 
which have reported an adverse effect of fish oil supplementation have been criticised 
on the grounds that large doses of n-3 fatty acids (5.5 -  8.0 g/d) have been used, that 
the studies were uncontrolled and involved small numbers. Popp-Snijders et al. 
(1990) also suggests that the baseline glycaemic control, body weight and the extra 
dietary energy provided by the fatty acid supplementation may well be responsible for 
the observed hyperglycaemic effects.
In terms of insulin sensitivity animal studies have clearly demonstrated a beneficial 
effect of fish oil feeding (Behme, 1996; Chicco et al 1996; Luo et al 1996) and it is 
hypothesised that the enrichment of tissue phospholipids with n-3 PUFA induce 
changes in membrane fluidity which in turn may enhance both insulin sensitivity and 
secretion. As with the glucose tolerance studies, results from human studies of insulin
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sensitivity are inconclusive. Stacpoole et al (1989) found that insulin sensitivity was 
impaired following a period of fish oil feeding while other investigators have found 
no change (Pelikanova et al 1993) or an increase in insulin sensitivity with fish oil 
feeding (Popp-snijders et al 1987).
In recognising the potential beneficial effects of the ingestion of long chain n-3 
PUFA, questions remains as to optimum levels of intake and how best to achieve such 
intakes. Bang et al. (1971) reported that it was customary for Eskimos to consume 
400-500 g of fish or whale meat daily, containing up to 7 g of n-3 PUFA. Such levels 
would be impossible to achieve within normal western style diets, however studies 
have shown that diets containing 1.6 -  2.8 g of long chain n-3 PUFA are sufficient to 
produce a 30 % reduction in serum triglyceride levels (Williams, 1997). Studies 
which have looked at the effect of n-3 PUFA supplementation on glucose tolerance 
and insulin sensitivity have used varying amounts of fish oil with a suggestion that 
larger doses of fish oils have lead to greater increases in blood glucose levels. In the 
UK, the average daily fish consumption is 26 g, providing approximately 0.2 g per 
day of long chain n-3 PUFA (Gregory et al 1990). From this platform achieving 
potent levels of supplementation would require taking 4-6 fish oil capsules, 10-ml (2 
teaspoons) of cod liver oil or 100 g of salmon daily. In the primary prevention of heart 
disease, manifested through insulin resistance, the implementation of such dietary 
measures presents a challenge.
Recent technological advances have made it possible to enrich a variety of common 
foods with long chain n-3 PUFA. This has opened up the possibility of increasing n-3 
PUFA intakes without increasing intakes of oily fish or without the need to take large 
amounts of fish oil supplements. Another advantage is that the commercial food 
industry, keen to promote their food products rich in n-3 PUFA, may be much more 
successful at achieving an increase in n-3 PUFA intakes than that procured by 
Government health messages alone. As pointed out by Gibney (1997) we have seen 
how the margarine industry, by providing «-6-rich PUFA spreads, has promoted a 
greater knowledge of the different types of dietary fatty acids than most government- 
funded interventions could ever achieve.
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3.1.1 STUDY OBJECTIVES
At the outset of the work described here the effect of consuming n-3 PUFA emiched 
diets on lipoprotein metabolism was well established, but less was known about the 
effect of such diets on glucose metabolism and insulin action. In particular, the 
mechanistic links between disorders of lipid and glucose metabolism were poorly 
defined. The aim of this study therefore, was to investigate the effect of ingesting a 
diet enriched with long chain n-3 PUFA on insulin sensitivity and postprandial 
lipaemia. The hypothesis of the study was that insulin resistance with respect to 
glucose disposal also extends to distuibances of lipid metabolism, thus contributing to 
an increased risk of CHD. It was postulated that the insulin sensitivity of postprandial 
lipid metabolism as well as glucose metabolism would be improved by an increase in 
long chain n-3 PUFA intake. The study used a combination of normal foods, which 
had been enriched with long chain n-3 PUFA, and fish oil capsules in order to 
increase the intake of EPA and DHA over a twelve-week period. The incorporation 
into red blood cell membranes, effects on fasting and postprandial lipoproteins and 
hormone levels including LPL activity and mRNA expression as well as the effects on 
insulin sensitivity were investigated in 11 middle-aged, insulin-resistant men.
3.2 STUDY DESIGN AND SUBJECTS
3.2.1 EXPERIMENTAL DESIGN
The study design was a randomised, controlled, single blind, crossover study 
comprising of two 10-week periods of feeding with control or fish-oil enriched foods, 
separated by a 3-month washout phase. Fish oil was incorporated into the diet of 
volunteers through a combination of foods made with a long chain n-3 PUFA 
enriched cooking fat (MD foods, Denmark), a fish oil enriched spread, PACT (MD 
foods, Denmark) and 1 g Pikasol fish oil capsules (LUBE, Germany). The control 
phase comprised foods made using an un-enriched cooking fat (MD foods, Denmark), 
an n-6 spread (MD foods, Denmark) as well as 1 g olive oil capsules (Lube, 
Germany). The fatty acid composition of the control and enriched cooking fat and 
margarine are shown in table 1.1. The food items provided were biscuits, cakes, pâtés
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and pasta sauces. A local catering company, who was supplied with the cooking fat 
prepared the foods. Control foods were prepared and packaged in an identical form to 
the enriched products to allow a blind protocol. The volunteers were asked to 
incorporate the foods into their habitual diet, exchanging them for their usual snacks 
or main meals, in an attempt to maintain their habitual energy intakes.
Table 3.1. Composition o f n-3 enriched and control margarine and cooking fa t
Enriched
margarine
Control
margarine
Enriched 
cooking fat
Control 
cooking fat
Total fat (g) 60 60 99.3 99.3
SFA(g) 15 15 17.5 16.0
C18:0 (g) 1.5 1.5 7.0 7.0
MUFA (g) 30 30 26.3 21.3
C 18:1 (g) 27.6 27.6 23.0 21.3
PUFA(g) 15 15 42.5 48.9
Total n-6 (g) 9 10.5 37.3 48.5
Total n-3 (g) 6 4.5 4.4 0.4
n6: n3 1.5 2.3 8.5 121.3
C20:4(g) 0 0 0.3 0
EPA & DHA (g) 1.4 0 4.0 0
Trans FA (g) 0 0 13.0 13.0
The aim of the study was for volunteers to achieve a mean daily intake of 2-3 g of 
EPA & DHA per day on the enriched diet. A ‘unit’ system was devised to allow 
volunteers choice in the foods, that could be consumed, and to ensure that volunteers 
achieved the desired intake of long chain n-3 PUFA. Each food portion was assigned 
a unit value where one unit was equivalent to 0.4 g of EPA & DHA. The fish oil 
enriched-cooking fat provided 4 g of EPA & DHA per 100 g and each food item was 
made using either 10 g or 20 g of cooking fat i.e. equivalent to 1 or 2 units. The fish 
oil enriched-mai'garine, contained 1.4 g of EPA & DHA per 100 g and was packaged
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in 15-g portions. One portion of margarine was therefore equivalent to V2 a unit. 
Subjects were asked to consume 3 to 4 units per day, depending on their habitual 
energy intake. In addition to these foods volunteers were requested to consume two 
capsules per day, with each 1-g fish oil Pikasol capsule providing 310 mg of EPA and 
200 mg of DHA.
During the study, volunteer’s attended the University of Suirey every two weeks to 
meet with investigators and to collect foods. This allowed investigators to answer any 
queries, to resolve any problems encountered with the study foods and to aid 
volunteer motivation. During the two periods of dietary intervention, volunteers were 
asked to complete two 4-day food diaries, one at the beginning and one towards the 
end of the intervention period. These data were analysed using the FOODBASE 
nutrient analysis programme (Version 1.2; Institute of Brain Chemistry and Human 
Nutrition, London).
3.2.2 SUBJECTS
Twelve healthy middle-aged male volunteers, who were selected from 35 subjects 
initially screened, were recruited to the study. Volunteers had responded to 
advertisements placed with the local media in the Guildford area. The volunteers all 
satisfied the following inclusion criteria: they were aged between 35 and 60 years, 
with a BMI less than 35 Kg/m^ and a waist to hip ratio of less than 1.0. They were all 
non-smokers and did not take regular exercise i.e. more than thiee 20-minute aerobic 
sessions per week. All of the volunteers were free from medication and did not have 
any previous medical history of coronaiy artery, endocrine or liver disease. None of 
the volunteers were foUowing any type of therapeutic or specialised diet or taking any 
form of dietary supplements.
All subjects had a fasting blood sample collected prior to inclusion in the study for 
screening. The criteria for inclusion were: glucose < 7.0 mmol/1, total cholesterol < 
7.0 mmol/1, TG < 3 .0  mmol/1, insulin > 40 pmol/1 and haemoglobin > 130g/l. 
Volunteers were also asked to complete a 4-day food diary, at screening, to determine 
their habitual energy and fat consumption including their habitual long chain n-3 
PUFA intake.
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Ethical approval for the study was obtained from the University of Surrey and the 
Royal Surrey County Hospital Research Ethics Committees. Informed and witnessed 
consent was obtained from each subject before participating in the study.
3.3, METABOLIC INVESTIGATIONS
The metabolic investigations at the start and end of each dietary period required 
volunteers to attend on three study days i.e.
1. Fasting blood biochemistry and the short ITT: 3 subjects per day (work 
described in this thesis).
2. Postprandial lipid disposal, LPL activity and gene expression during a 9-hour 
study following a high fat breakfast : 5-6 subjects per day (work described in 
this thesis).
3. NEFA / glycerol suppression by insulin infusion and fasting proteolysis 
inhibition by postprandial insulin and amino acids: 9 hr stable isotope study of 
glycerol production rate and endogenous leucine production rate in response to 
insulin infusion: 2 subjects per day (work not described in this thesis, but 
results summarised in appendix 1)
A description of the metabolic investigations conducted are provided in chapter 2.0, 
section 2.3.
3.3.1 SUBJECT NUMBERS AND POWER CALCULATIONS
The intensity of the metabolic investigations, i.e. the need for subjects to attend on 
three separate study days at the start and end of each study and especially the study 
day 3 procedures, which only allowed two subjects to be investigated per day, limited 
the total numbers of subjects who could be realistically studied. Previous experience 
at Surrey of the short ITT indicated that an intra-individual variation (6 young men 
measured on 4 occasions) of 15 %, similar to fasting TG (14.5 %) and cholesterol (10 
%), but more than fasting glucose (3 %) and less than fasting NEFA (23 %). This
would allow a 20 % difference between diets to be detected by paired analysis with n 
= 12 at an error of p < or = 0.05, with a beta error (possibility of a type 2 error) of < 
0.05. Since 12 subjects was identified as the maximum number who could be taken 
through the complete protocol within a realistic time frame, an a 20 % change by the 
diets was estimated as the minimum likely response, the study number was set at n = 
12.
3.4 ANALYTICAL PROCEDURES
Analytical procedures are described in detail in chapter 2.0, section 2.2.3 - 2.2.7 with 
a brief outline provided in this section.
Plasma glucose concentrations, total cholesterol, HDL cholesterol, and triglycerides 
were assayed on a COBAS-MIRA autoanalyser (Roche Products Ltd, Welwyn 
Garden City, Herts) by enzymatic colorimetric methods using commercially available 
kits supplied by Roche Diagnostic Products Ltd (Welwyn Garden City, Herts). 
Plasma NEFA concentrations were also measured using the COBAS-MIRA analyser 
by a standard enzymatic colorimetric method (Wako Chemicals, GmbH, Germany 
supplied by Alpha laboratories Ltd., London). Appropriate quality controls with pre­
defined reference ranges were run with each assay in order to determine intra and 
inter assay variability.
Serum insulin levels were measured by radioimmunoassay as described in chapter 
2.0, section 2.2.6 Samples from each intervention period were analysed together in the 
same run at the end of the study period.
The fatty acid composition of red blood cell phospholipids was determined after the 
extraction of lipids with a mixture of chloroform and methanol (2:1 vol/vol), 
containing 0.01% BHT as antioxidant, according to the Folch method (Folch et al 
1957). The fatty acids were separated and quantitated using gas chromatography. 
Fatty acids were identified by comparing retention times with those of a known 
standard mixture.
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Triglyceride-rich and triglyceride poor fractions of plasma were separated using an 
adapted method of that described by Grundy & Monk (1976). 3.5 ml of plasma was 
overlayered with an equal volume of saline (1.006g NaCl/ml), and ultracentrifuged 
for 4.8 X 10^  g at 24°C in a 10-ml centrifuge tube. The top 1.2 ml of the upper layer, 
the TRL fraction was removed, aliquoted and frozen at ~20°C for later analysis. TG 
levels were measured in TRL fraction using an enzymatic, colorimetric kit supplied 
by Roche Diagnostic Products Ltd (Welwyn Garden City, Herts).
Lipoprotein lipase activity was measured in 10 pi portions of plasma taken 5 and 15 
minutes after the administration of an intravenous dose of heparin. LPL activity was 
measui'ed with LPL activity being inhibited with 4 M NaCl by a modified method 
described by Nilsson-Ehle & Schotz (1976) using the detection of liberated ^H- 
labelled free fatty acids from ^H-labelled triolein substrate emulsion (Amersham 
International, Bucks, UK) as the index of triolein hydrolysis.
3.5 STATISTICAL ANALYSIS
Statistical analysis was performed using the windows compatible computer package, 
Statistica (version 5, StatSoft Inc.) and the Excel (Microsoft Excel 97) computer 
programme.
For most data tabulated results are presented as mean values and standard deviations 
(SD). Individual time points on graphs are presented as mean values with then 
standard errors (SE).
The effect of treatment on fasting values was analysed by comparing the results 
within each individual during the n-3 enriched diet and the control diet using the 
student’s t test for paired data. Relationships between changes in insulin sensitivity 
and changes in postprandial lipaemia were analysed by the Pearson’s correlation. The 
postprandial data was expressed in summary form as an area under the postprandial 
response curve. Postprandial variations were determined by comparing area tmder the 
curve calculations from the control period and the n-3 enriched period. The are under
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the postprandial response cui'ves were calculated using the Trapezium rule (Matthews 
et al 1990). Values of P < 0.05 were considered statistically significant
3.6 RESULTS
Eleven subjects of the twelve subjects recruited to the study successfully completed 
both phases of the dietary intervention. One subject voluntarily withdrew at the end of 
the first intervention due to personal difficulties. All subjects remained healthy for the 
duration of the dietary intervention studies. Subjects reported that no difficulties were 
encountered in the consumption of the study foods or with any of the study day 
investigations. The results of the study are presented under the following sections.
5.6.1 ANTHROPOMETRY
There was no difference in the weight and subsequently the BMI of subjects at the 
beginning of the study compared with the end of the control period and the end of the 
n-3 enriched dietary period as shown in table 3.2.
Table 3.2. Weight and BMI o f subjects during the dietary intervention
Habitual diet Control diet n-3 enriched diet
Weight (Kg) 89.9 ± 11.2 90.7 ±11.9 90.0 ± 11.7
BMI (Kg/m’) 29.2 ± 3.1 29.4 ± 3.4 29.2 ± 3.2
Data are presented as means ± SD (n = 11).
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3.6.2 NUTRITIONAL ANALYSIS
The mean nutrient intakes of the volunteers on their habitual diet and during the n-3 
enriched diet period and the control diet period is shown in table 3.3. There were no 
significant differences in energy on the n-3 emiched and control diet compared with 
the habitual diet however, there was a significant difference in the protein and 
carbohydrate intake on the control diet compared to the habitual diet (p< 0.05). The 
two intervention periods did not differ in their macronutrient content.
Total fat intakes did not differ between the control and n-3 enriched diet however the 
% of energy from fat was increased from 39.8 (SD 5.0) % during the habitual diet to
43.6 (SD 4.3) % and 44.8 (SD 4.4) % during the n-3 enriched and control diets 
respectively (p = 0.07; p = 0.01). The proportion of fat from SFA, MUFA and PUFA 
was significantly different from the habitual to the control and n-3 enriched diets as 
shown in figure 3.1. The percentage of total fat composed of SFA was significantly 
reduced (p < 0.001) from 38.1 (SD 5.2) % to 28.0 (SD 1.8) % during the control diet 
and 28.9 (SD 2.7) % during the n-3 enriched diet. Intakes of PUFA were significantly 
increased (p < 0.001) from 16.0 (SD 5.1) % of total fat dming the habitual diet to 25.0 
(SD 2.3) % during the control diet and 24.3 (SD 2.9) % during the n-3 enriched diet. 
The ratio of n-3 to n-6 polyunsatmated fatty acids was also significantly increased as 
a result of the n-3 enriched diet when compared to the control and habitual diet (p < 
0.001).
The amount of EPA and DHA provided by the n-3 enriched diet was significantly 
greater (p < 0.0001) when compared to both the control and habitual diet. There was 
no difference in the amount of EPA and DHA ingested during the habitual diet and 
the control diet. The estimated average mtake of EPA & DHA during the n-3 emiched 
period was 3.1 g/d, assessed by two 4-day food records.
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Table 3.3. The mean daily macronutrient, and EPA + DHA intakes o f volunteers 
(n=ll) consuming habitual, control and n-3 enriched diets.
Nutrients Habitual diet n-3 Enriched diet Control diet
Energy (kJ) 11975 ± 1430.2 11183 ± 1231.0 11317 ± 1340.0
Protein (g) 105.6 ± 16.1 91.4 ± 12.9* 89.6 ± 18.7*
Carbohydrate (g) 306.4 ± 33.0 271.6 ± 54.4 269.3* ± 45.6
Total Fat (g) 127.8 ± 26.0 129.7 ± 20.0 134.7 ± 20.0
EPA + DHA (g) 0.2 ± 0.2 3.1 ± 0.3**^ 0.2 ± 0.1
n3 : n6 ratio 0.14 ± 0.05 0.23 ± 0.05**^ 0.10 ± 0.02
Data are expressed as means ± SD
*P < 0.05; ** P<0.01 Mean values were significantly different from those for the 
habitual diet.
P < 0.01 Mean values were significantly different from those for the control diet.
■  Habitual diet
■  Control diet
■  n-3 Enriched diet
40.0 -
35.0 -
30.0 -
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SFA MUFA PUFA
Figure 3.1. Intake of SFA, MUFA and PUFA as a percentage of total fat intakes 
during the Habitual, Control and n-3 Enriched diet.
P < 0.01 Mean values were significantly different from n-3 enriched 
and control diet compared to habitual diet.
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3.6.3PHOSPHOLIPID FATTY ACID COMPOSITION OF ERYTHROCYTE 
MEMBRANES
The phospholipid fatty acid composition of erythrocytes at baseline and at the end of 
the control and n-3 enriched diet periods are shown in table 3.4. Fatty acids aie 
expressed as a percentage of the total aiea of all fatty acids measured. Saturated, 
monounsaturated and polyunsaturated fatty acids did not change between the control 
and n-3 enriched diets, a finding that is in agreement with the results of the nutritional 
analysis.
The amount of EPA and DHA was increased fiom the control diet to the n-3 enriched 
diet however, this did not reach statistical significance. There was a significant 
increase in saturated fat and a significant decrease in polyunsaturated fat between 
baseline and the end of the control and the end of the n-3 emiched periods. 
Arachidonic acid levels were reduced from baseline both at the end of the control diet 
and the end of the n-3 emiched diet. There was also a significant decrease in EPA and 
DHA levels from baseline to the end of the control diet (p = 0.03).
Fatty acids were measured at week 0, week 4 and week 8 of the intervention periods. 
Figure 3.2. shows the increase in EPA & DHA in individual subjects from week 0 to 
week 4 of the n-3 emiched diet. The 0 week measurement in one individual was not 
available and in another individual the 0 week measurement was greater than 2 
standard deviations above the mean as highlighted in figure 3.2. using a shaded bar. 
When those individuals are excluded from the data there was a significant increase (p 
= 0.01) in the amount of EPA and DHA fr om 6.35 (SD 2.01) % to 11.31 (SD 5.2) %. 
The increase in EPA and DHA was not sustained through to week 8 of the 
intervention period. At week 0, week 4 and week 8 of control diet there was no 
change in any of the fatty acids measured.
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Table 3.4. Vatty acids (% area) measured at baseline and at the end o f the 
control and n-3 enriched diet periods.
Fatty acid (% area) Baseline Control n-3 enriched
Saturated 30.7 ± 1.5 40.8 ± 7.2** 43.1 ± 6.2^
Monounsaturated 15.1 ± 1.1 16.8 ± 6.7 18.8 ± 3.9
Polyunsaturated 51.6 ± 2.3 39.2 ± 12.9** 34.5 ± 11.0^
EPA + DHA 7.4 ± 1.8 4.9 ± 2.7* 6.4 ± 3.8
Polyunsaturated w-3 7.7 ± 1.8 5.4 ± 2.4* 6.9 ± 3.9
Arachidonic acid 20.6 ± 3.4 12.9 ± 6.3** 8.6 ± 4 j t
Values are expressed as the percentage of the total area of all fatty acids measured and 
are presented as means of 11 subjects ± SE.
*P < 0.05, **P< 0.01, mean control values are significantly different from baseline 
^P < 0.01, mean n-3 values are significantly different from baseline.
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Figure 3.2. EPA + DHA levels individual subjects at week 0 and week 4 of the n-3 
enriched diet.
Subjects are ranked in order of increasing levels of EPA + DHA at 
week 0. The shaded bar highlights an individual with a high level of 
EPA + DHA at week 0.
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3.6.4 FASTING BIOCHEMICAL DATA
The fasting plasma concentrations of lipids, glucose and insulin are shown in table 
3.5. There were no significant differences in the concentration of total cholesterol, 
HDL cholesterol, LDL cholesterol, glucose and insulin when measured at the outset 
of the study and at the end of the control diet and the n~3 enriched diet.
The concentration of triglyceride was reduced by an average of 23.2 % from 2.05 (SD 
0.65) mmol/1 on the habitual diet to 1.58 (SD 0.51) mmol/1 at the end of n-3 enriched 
period (p = 0.06). The reduction in the concentration of triglyceride becomes 
significant (p = 0.015) on the removal of the result of one individual who’s TG level 
increased as a result of the n-3 enriched diet (2.05 ± 0.69 mmol/1 Vs 1.44 ± 0.22 
mmol/1, n = 10). Comparing the triglyceride levels at the end of he control period and 
the end of the n-3 enriched period in the group overall, TG concentration was lowered 
but does not become significant (p = 0.049) until removal of the individual with a 
raised TG as a result of the intervention diet ( 1.91 ± 0.73 Vs 1.44 ± 0.22, n = 10).
There was a significant increase in the concentration of NEFA from 0.35 (SD 0.14) 
mmol/1 on the habitual diet to 0.57 (SD 0.18) mmol/1 at the end of the control diet and 
0.53 (SD 0.20) mmol/1 after the n-3 intervention period (p < 0.01).
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Table 3.5. Mean fasting plasma concentrations o f total cholesterol, HDL 
cholesterol, LDL cholesterol, triglyceride, NEFA, glucose and insulin 
o f male volunteers (n=ll) on their habitual diet and after consuming 
the control diet and the n-3 enriched diet.
Habitual diet Control diet n-3 Enriched diet
Total cholesterol (mmol/1) 6.23 ± 1.09 6.15 ± 1.04 5.96 ± 0.89
HDL cholesterol (mmol/1) 0.94 ±0.17 0.93 + 0.14 0.96 ± 0.14
LDL cholesterol (mmol/1) 4.52 ± 1.09 4.46 ± 1.30 4.39 ± 1.11
Triglyceride (mmol/1) 2.05 ± 0.65 1.89 ± 0.70 1.58 ± 0.50
NEFA (mmol/1) 0.35 ± 0.14 0.57 ± 0.18* 0.53 ± 0.20*
Glucose (mmol/1) 5.81 ± 0.64 5.61 ± 0.56 5.69 ± 0.61
Insulin (pmol/1) 81.5 ± 25.48 94.32 ± 25.89 95.10 ± 28.87
Data are presented as means ± SD.
* Mean values were significantly different from those for the habitual diet, p<0.01
3.6.5 POSTPRANDIAL DATA
Figure 3.3. shows that the mean postprandial levels of triglyceride were lower 
following the n-3 enriched diet when compared to the control diet, although this did 
not reach significance. The postprandial profiles show a mean peak TG at 256 (SD 
76.3) min and 229.1 (SD 52.4) min after the control and the n-3 enriched diet 
respectively. As with the fasting TG results one individual had a marked increase in 
postprandial TG concentrations following the n-3 enriched diet. When this individual 
is excluded from the data there was a significant reduction in the peak TG from 4.21 
(SD 0.95) mmol/1 on the control diet to 3.40 (SD 0.84) mmol/1 on the n-3 enriched diet 
(p = 0.04, n = 10). Fig 3.4. depicts the measurement of TG area under the curve in 
individual volunteers following the control diet and the n-3 enriched diet. It was 
observed that in those individuals with the highest area under the TG curve on the 
control diet (n -  6) there was a significant acceleration in the removal of postprandial 
TG fr om the plasma as measured by the AUC following the n-3 enriched diet (1934.4 
± 281.4 Vs 1318.6 ± 274.7, p -  0.008). In contrast, those with the lowest postprandial 
TG response (n = 5) had no change in the TG aiea under the curve following the n-3 
enriched diet (p = 0.19). Fig 3.5. depicts the relationship between the change
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postprandial lipaemia (control TG AUC / n-3 PUFA TG AUC) and the level of fasting 
TG during the control diet. This indicates that the change in lipaemia following the 
test meal was dependent on initial fasting TG level (p = 0.005).
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Figure 3.3 Total TG concentrations following the test meal (80-g fat) as measured 
at the end of the control and n-3 enriched diet periods.
Data are presented as means ± SE.
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Figure 3.4. Postprandial TG response in individual subjects as measured by the 
area under the curve (mmol/l.min).
Subjects are ranked in order of decreasing lipaemia during the control 
diet. The patterned bars, highlight a subject who had a marked increase 
in the TG AUC following the a? - 3  enriched diet.
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Figure 3.5. The association between fasting TG concentration measured during the 
control diet and the change in postprandial TG (r = 0.781, p = 0.005).
99
Fig 3.6. shows the postprandial TRL TG profiles following the «-3 and control 
intervention periods. As with the total TG profile the peak TG was later on the control 
diet at 261.8 (SD 90.1) min compared with 234.5 (SD 62.7) min on the «-3 enriched 
diet. There was no significant difference in the levels of postprandial TRL between 
the control and «-3 enriched diets when measured by the total area under the curve. 
However, in the late postprandial phase as measured by the 6-9 hour area under the 
curve the concentration of TRL TG was significantly attenuated on the n-3 enriched 
diet from 504.7 (SD 255.9) mmol/l.min during the control diet to 360.4 (SD 186.8) 
mmol/l.min on the n-3 enriched diet (p = 0.037). Fig 3.7 shows the postprandial apo- 
B48 concentrations in individual subjects, measured by the total area under the curve 
(AUC), following the control and the n-3 intervention diet. There was no difference in 
the mean concentrations of apo B-48 in the group overall. However, as with the 
postprandial TG response there was a significant attenuation of apo B-48 levels in 
those with the greatest apo B-48 AUC during the control diet (706.2 ±207.6 pg/ml/.hr 
(control) Vs 460.4 ± 180.5 pg/ml.hr («-3), n = 7) and is demonstrated by the 
correlation between apo B-48 AUC during the control diet with the change in apo B- 
48 concentration following the intervention diet (r = 0.77, p = 0.005) shown in figure 
3.8.
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Figure 3.6. Postprandial concentrations of TG in the TG-rich lipoprotein (TRL) 
fraction after the consumption of a test meal containing 80 g fat as 
measured at the end of the control and n-3 enriched intervention 
periods.
Data are presented as means of 11 subjects ± SE.
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Figure 3.7. Apo B-48 concentration in individual subjects as measured by the 
AUC (pg/ml.min).
Subjects are ranked in order of decreasing apo B-48 AUC during the 
control diet.
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Figure 3.8. The association between the change in apo B-48 AUC and the apo B- 
48 AUC during the control diet (r = 0.77, p = 0.005).
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Fig. 3.9. shows the postprandial NEFA profiles. They followed an expected contour, 
dipping sharply after the consumption of the test meal and gradually rising to a 
concentration almost twice that above fasting levels by 9 hours at the end of the study. 
From the fasting level the fall in NEFA at 30-min following the test meal was 
significantly lower (p = 0.02) on the «-3 enriched diet (0.32 ± 0.11 mmol/1) compared 
to the control diet (0.43 ± 0.02 mmol/1).
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Fig 3.9. The concentrations of NEFA following the test meal (80-g fat) as 
measured at the end of the control and «-3 enriched diet period.
Data are presented as means of 11 subjects ± SE.
Fig 3.10. shows the postprandial insulin response at the end of the control diet and at 
the end of the «-3 enriched diet. As expected the insulin levels increase sharply 
following the test meal and return to baseline levels at the end of the 9-hour test. 
There was no significant difference in the insulin AUC at the end of the n-2> enriched 
period and the end of the control period.
There was no difference in postprandial levels of glucose or total cholesterol between 
the control diet and the «-3 enriched diet as depicted in fig. 3.11.
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Figure 3.10. Postprandial insulin levels, following an 80-g fat meal. 
Data are presented as means of 11 subjects ± SE.
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Figure 3.11. Change in the glucose and cholesterol total AUC (mmol/l.min) 
measurements from the control diet to the «-3 enriched diet.
Data are means of 11 subjects ± SE.
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3.6.6 POST-HEPARIN LIPOPROTEIN LIPASE ACTIVITY
The effect of the n-3 enriched diet on post-heparin LPL activity 5 and 15 minutes 
following heparin administration is shown in figs 3.12. and 3.13. respectively. There 
was a wide range of LPL activity among the study group ranging from 1.41 to 8.21 
umole.oleate.ml.hr measured at the 15-minute time point during the control diet. As 
expected, the amount of LPL released into the plasma was increased from 5 to 15- 
minutes following the heparin administration. There was no significant difference in 
plasma post-heparin LPL activity at the 5 or 15-minute measurement between the 
control diet and the n-3 enriched diet.
The mean total lipase activity, HL activity and LPL activity 15 minutes following 
heparin administration is shown in figure 3.14. There was no difference in the levels 
of lipase activity following the n-3 enriched diet.
There was also no association between fasting TG levels and the level of LPL activity 
measured during the control diet as shown in figure 3.15.
Control diet 
n-3 enriched diet
3 . 4.0
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Subject number
Figure 3.12. 5-minute post-heparin LPL activity levels in individual subjects
measured at the end of the control diet and the end of the n-3 enriched 
diet.
Subjects are ranked in the order of increasing LPL activity during the 
control diet.
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Figure 3.13. 15-minute post-heparin LPL activity levels in individual subjects
measured at the end of the control diet and the end of the n-3 enriched 
diet.
Subjects are ranked in the order of increasing LPL activity during the 
control diet.
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Figure 3.14. Mean total lipase, HL & LPL activity (umole.oleate.ml.hr) levels, 15 
minutes following the administration of 7500 lU of heparin to 11 
subjects.
The vertical bars represent standard error bars.
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Figure 3.15. The association between fasting TG concentration and LPL activity 
levels (umole.oleate.ml.hr) measured during the control diet (r = 
0.065).
3.6.7 INSULIN SENSITIVITY DA TA
Linear regression was used to estimate the fall in log transformed blood glucose 
concentration following the administration of a bolus dose of insulin during the 
insulin tolerance test. The slope was multiplied by -100 to derive the rate constant 
( K i t t )  and by 60 to determine the percentage decline in blood glucose per minute (% 
min-'). Four minutes following intravenous injection of insulin, blood glucose levels 
began to decline as shown in fig 3.16. The glucose disappearance rate K i t t  was 
therefore estimated from the slope of the fall in glucose from 4-15 minutes. It was 
observed that the concentration of glucose was higher following the n-3 enriched diet 
at the 4 minute measurement when compared to the control diet (5.65 ± 0.73 mmol/1 
Vs 5.18 ± 0.56 mmol/1, p = 0.006). The mean plasma glucose concentration fell from 
5.38 (SD 0.54) mmol/1 to 3.78 (SD 0.87) mmol/1 during the control diet and from 5.64 
(SD 0.54) mmol/1 to 3.98 (SD 0.86) mmol/1 during the n-3 enriched diet following 
insulin administration.
The results of the short insulin tolerance test in individual subjects at the end of the 
control diet and at the end of the n-3 enriched diet are presented in fig 3.17. Subjects 
are ranked in the order of increasing insulin sensitivity on the control diet. There was
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a wide range of insulin sensitivity in the study group as measured during the control 
period, with Kut glucose varying from 1.19 to 6.16 % min (mean = 3.19 ±1.77) % 
min ■’). While there was no difference in insulin sensitivity as a result of the 
intervention in the group overall, it was observed that in the 7 least insulin sensitive 
subjects during the control diet, there was a significant improvement in insulin 
sensitivity from 2.07 (SD 0.85) % min '* to 3.52 (SD 0.95) % min as a result of the 
n-3 enriched diet (p = 0.009). There was no change in glucose Kut measurements in 
the 4 most insulin sensitive subjects as a result of the n-3 enriched diet (p = 0.106).
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Figure 3.16. Fall in blood glucose concentrations over 15 minutes following the 
administration of a bolus dose of insulin (0.1 U/Kg) at the end of the 
control diet and at the end of the n-3 enriched diet.
Data are means ± SE.
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Figure 3.17. Effect of the /?-3 enriched diet on Insulin sensitivity as measured by 
glucose Kitt (% min) in individual subjects.
Subjects are ranked in order of the least insulin sensitive during the 
control diet.
There was an inverse correlation between the fasting concentration of insulin and the 
degree of insulin resistance measured during the control diet as shown in fig 3.18. 
This indicates that fasting insulin was a good indicator of insulin resistance in this 
study group. Those subjects with a fasting insulin level greater than 90 pmol/1 group 
were the least insulin sensitive and had the greatest improvement in insulin sensitivity 
as a result of the n-3 intervention. Those with the greatest improvement in insulin 
sensitivity also had an initial K j t t  of less than 4.7 % min
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Figure 3.18. The association between fasting insulin concentration (pmol/1) and
insulin sensitivity (Glucose Kitt % min “*) measured during the control 
diet (r = -0.0779, p = 0.005).
The fractional rate of fall in plasma NEFA levels between 4 and 15 minutes following 
insulin administration served as a measure of insulin mediated inhibition of hormone 
sensitive lipase. The rate at which plasma NEFA levels fell was accelerated following 
the «-3 enriched diet as shown in fig 3.19. however this did not reach statistical 
significance.
In comparing lipase activity with measurements of insulin sensitivity, no association 
between LPL and activity and insulin sensitivity was observed, however as shown in 
fig 3.20. there was an inverse correlation between levels of HL activity and the degree 
of insulin sensitivity.
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Figure 3.19. Difference in the fall in log transformed NEFA (%/min'') from the 
control diet to the «-3 enriched diet.
Data are presented as means of 11 subjects ± SE.
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Figure 3.20. The association between levels of hepatic lipase activity and insulin 
sensitivity measured during the control diet (r = -0.613, p = 0.045).
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3.6.8 POSTPRANDIAL LIPAEMIA AND INSULIN SENSITIVITY
In comparing the results of the insulin tolerance test and the postprandial test, it was 
shown that there was no association between changes in insulin sensitivity and 
changes in postprandial lipaemia. Fig 3.21. shows the lack of association between the 
change in TAG AUC and the change in glucose Kitt following the n-3 enriched diet.
There was also no association between the extent of postprandial lipaemia and 
measures of insulin sensitivity i.e. those individuals who were most insulin resistant 
were not the subjects with the greatest degree of postprandial lipaemia. When the 
individuals who had the greatest improvement in insulin resistance (n = 7) are 
analysed separately there was in fact an inverse correlation between the extent of 
postprandial lipaemia and the degree of insulin resistance as shown in fig 3.22. Since 
insulin resistance has been shown to be associated with high fasting TG values this 
finding is contradictory to the expected relation between measures of lipid 
metabolism and insulin sensitivity.
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Figure 3.21. The relationship between the change in insulin sensitivity and the 
change in postprandial lipaemia measured by the TG AUC (n = 11) as 
a result of the n-3 enriched diet (r = 0.0656, p = 0.84).
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Figure 3.22. The association between measures of insulin sensitivity and 
postprandial lipaemia during the control diet in the 7 least insulin 
sensitive subjects (Kut < 4.74 % min ') (r = 0.743, p = 0.035).
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3.7 DISCUSSION
This study is one of the few studies to investigate the effect of foods supplemented 
with w-3 PUFA on postprandial lipaemia and one of the first to analyse the effect of 
consuming such foods on insulin sensitivity as measured by the short insulin tolerance 
test. The use of enriched foods as a means of increasing the EPA and DHA content of 
diets was used in conjunction with a modest fish oil capsule supplementation (two 1-g 
capsules per day). This offered an alternative to the use of an essentially 
pharmacological intervention where fish oil capsules alone are provided as a means of 
increasing EPA & DHA intakes. The data could also provide valuable information as 
to the impetus of such foods on improving insulin resistance if available for 
consumption in the free-living situation. Previous work in this research group in 
which foods alone had been used as a means of increasing EPA & DHA intakes 
highlighted that ‘a greater level of incorporation of EPA & DHA into the foods would 
be preferable for friture studies’ (Lovegrove et al. 1997). This observation was based 
on the finding that a moderate intake (1.4 g/d) of EPA & DHA given in the form of 
enriched foods did not yield the expected hypotriglyceridaemic effect in a group of 
male volunteers. The aim of the present study was to achieve an intake of between 2-3 
g EPA & DHA daily, of which 1.02 g was to be provided from two 1-g fish oil 
capsules. The addition of fish oil capsules therefore ensured that a potent dose of EPA 
& DHA would be consumed.
Analysis of the volunteers’ diets, calculated from a 4-day food record, revealed that 
the average intake of EPA & DHA achieved during the n-3 enriched intervention was
3.1 g/d. There was no change in average energy intakes between the habitual and the 
control and intervention diets, a finding reflected in the stability of the volunteers’ 
body weight throughout the study. The lack of change in energy intakes also indicates 
that volunteers were successful in substituting ‘study’ foods for the foods normally 
consumed in order to acliieve an increase in the levels of EPA & DHA.
The phospholipid fatty acid composition data is somewhat contradictory to the 
findings of the dietary analysis. Dietary analysis showed a decrease in the intake of 
SFA and an increase in the intake of dietary PUFA from the habitual to the 
intervention diets, whereas the analysis of membrane phospholipids demonstrated a
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fall in the levels of polyunsaturated fatty acids and an increase in the levels of 
saturated fatty acids. The erythrocyte membrane phospholipid levels of EPA & DHA 
were greater but not significantly increased at the end of the n-3 enriched period 
compared to the end of the control period. However, it was observed that EPA & 
DHA levels were significantly higher at week 4 compared to week 0 of the n-3 
intervention period, indicating that the enriched foods were being consumed. The fact 
that the increase in the enrichment of EPA & DHA was not sustained through to week 
8 of the intervention may be a reflection of diminishing volunteer compliance. 
However, this possibility is not supported by the analysis of food records. HaiTis et al 
(1991) have reported apeak level of fish-oil incorporation into platelet phospholipids 
after supplementation for one month, with various doses of fish oil, with no increase 
for the subsequent 5 months of supplementation. Measuiement of membrane 
phospholipids also showed that there was a significant reduction in aiachidonic acid 
levels from the habitual to the n-3 enriched diet. Carlson et al (1987) have shown that 
feeding fish oil to n-3 deficient animals, reduces the plasma and red cell phospholipid 
content of arachidonic acid and there has been a suggestion that fish oil may inhibit n- 
6 fatty acid metabolism (Innis et al 1991). Inhibition of arachidonic acid production 
and incorporation into membrane phospholipids may have a potentially 
antithrombotic effect (Heemskerk et al 1996).
The n-3 intervention did not result in the expected reduction in triglyceride levels in 
the group overall. Other studies have shown a hypotriglyceridaemic effect at lower 
doses of EPA & DHA in both normotriglyceridaemic and hypertriglyceridaemic 
subjects, however none of the studies have used foods as the vehicle of 
supplementation. Our findings are in agreement with other studies in which functional 
foods have been used, in that they also demonstrated an overall lack of effect on 
triglyceride levels, although the types of foods used and the level of supplementation 
was lower in both studies (Lovegrove et al 1997; Roche & Gibney, 1994). One 
subject had an increase in triglyceride levels following the n-3 enriched diet, which 
has masked the finding that triglyceride levels were significantly reduced in the 
remainder of the group (n= 10) at the end of the n-3 eniiched diet when compared to 
the habitual and the control diet. The reduction in plasma triglyceride levels 
associated with fish oil supplementation is thought to be as a result of a decrease in 
hepatic VLDL synthesis and/or an accelerated rate of VLDL removal. Animal studies
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have demonstrated that n-3 fatty acids inhibit fatty acid estérification to glycerol 
(Wong et al. 1989) and blunt the stimulatory action of insulin on hepatic lipogenesis 
(Topping et al. 1987). Human studies appear to agree ^vith these findings and 
lipoprotein kinetic studies in normal subjects indicate that VLDL synthesis and 
secretion are decreased by fish oil administration (Hands et al. 1990). The reduction 
in VLDL synthesis is thought to be due to an inhibitory effect of n-3 fatty acids on the 
estérification of glycerol.
No differences in the fasting concentration of other lipoproteins such as total, LDL 
and HDL-cholesterol levels as a result of the fish oil supplementation was observed, a 
finding consistent with other dietary intei'ventions of this nature. Studies observing 
effects on LDL and HDL-cholesterol levels as a result of fish oil feeding have been 
criticised by a failure to control the intake of other dietary fatty acids (Malasanos & 
Stacpoole, 1991). Increases in LDL cholesterol level have been reported but as Harris 
(1989) summarises, when saturated fat intake was held constant in dietary trials, LDL- 
cholesterol rose by 5 % but when fish oil replaced saturated fats LDL cholesterol fell 
by 5%. It has been reported that fish oil intervention in placebo-controlled trials 
generally increases HDL-cholesterol levels by 5-10 % (Harris, 1989). The response of 
HDL-cholesterol appears to be dependent on the quantity of fish oil administered 
because higher doses were associated with an increase of HDL-cholesterol levels 
whereas lower doses had a negligible effect.
Several studies with glucose intolerant and type II diabetic subjects have reported an 
increase in blood glucose levels following fish oil supplementation. Lovegrove et al. 
(1997) also reported an increase in fasting glucose levels following the consumption 
of manufactured foods enriched with EPA & DHA. In the present study there was no 
effect of fish oil feeding on fasting blood glucose levels however glucose 
measurements taken during the insulin tolerance test showed an increase in glucose 
levels at the 4 minute time point following insulin administration. Fasting insulin 
levels were also unchanged as a result of the intervention. In studies reporting plasma 
insulin concentrations, fish oils have not usually altered fasting levels. Few studies 
reporting an increase in blood glucose levels have reported a concomitant decline in 
the fasting levels of insulin making a diiect inhibitory action of n-3 fatty acids on the 
p-cell an unlikely explanation for the observed rise in blood glucose concentration.
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However, the failure of insulin to respond to elevated glucose levels could be 
interpreted as a deficiency in the response of the P-cell. Alternatively Glauber et al. 
(1988) and Friday et al. (1989) suggest that n-3 fatty acids may impair the insulin 
secretory response to hyperglycaemia.
While a large number of studies have looked at the effects of fish oil supplementation 
on fasting TG levels, fewer although a continually increasing number have 
investigated the postprandial effects of fish oil feeding (Harris et al. 1988; Weintraub 
et al. 1988). In this study it appears that the improvements in postprandial triglyceride 
concentrations as a result of the n-3 enriched diet occurred in those subjects who had 
the greatest degi’ee of postprandial lipaemia at the outset of the study. Postprandial 
response was also closely related to the baseline fasting TG concentration. Studies 
examining the effect of fish oils in NIDDM have also shown variable triglyceride 
responses, and in a study by Kasim et al. (1988) a significant hypotriglyceridaemic 
effect was observed in a group of NIDDM patients only when the subjects with the 
highest baseline TG levels were isolated. Harris et al. (1988) also demonstrated that in 
a group of non-diabetic hypertriglyceridaemic subjects, the higher the initial TG level 
the greater the fall as a result of fish oil administration. Similarly Connor et al. (1993) 
found that fish oil incorporated into the diet of hypertriglyceridaemic subjects had a 
more profound hypolipaemic effect than had been observed in normal subjects.
In this study while the concentration of TRL TG was not significantly attenuated over 
the entire 9-hour postprandial study there was a significant lowering of TRL TG in the 
late (6-9 horn*) postprandial phase. Elevations in late postprandial triglyceride levels 
have been identified as a significant risk factor for CHD in a number of case control 
studies (Groot et al. 1991; Patsch et al. 1992) and in a study of the offspring of 
subjects with CHD (Uiterwaal et al. 1994). Karpe (1997) and other investigators have 
highlighted that an accentuated profile in the late postprandial phase is potentially 
more atherogenic. Measurement of apo B-48 concentration showed no difference over 
the nine-hour postprandial study as a result of fish oil feeding. Studies in which fish 
oil was fed to healthy volunteers have demonstrated that n-3 fatty acids are 
incorporated into chylomicrons. The decrease in the late TRL-TG concentrations 
following fish oil administration could have resulted from slower synthesis of
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chylomicrons, and slower entry of chylomicrons into the circulation or, alternatively, 
from a more rapid removal of the chylomicrons in the circulation.
Post-heparin LPL activity was unaffected by the fish oil intervention in the present 
study. It is unlikely therefore that the decrease in TG concentrations were as a result 
of an increase in LPL mediated lipo lysis. Studies, which have examined the effect of 
fish oil feeding on LPL activity, have shown variable results. In general earlier studies 
have shown no effect in humans (Harris et a l 1988; Weintraub et al 1988; Nozaki et 
al 1991). A study by Zampelas et al (1994) reported an increase in post-heparin LPL 
activity following the consumption of a fish oil enriched meal. Kasim et al (1995) 
also reported an elevation in post-heparin LPL activity with fish oil enrichment of the 
background diet and Harris et al (1997) have shown increases in endogenous lipase 
activities following 3 weeks of fish oil feeding. A deeper understanding of the effects 
of fish oil eniiched diets on LPL activity is required before any firm conclusions on 
the mechanisms of n-3 TG lowering are made.
Plasma NEFA concentrations are usually unchanged as a result of fish oil feeding. In 
this study while fasting levels of NEFA were not altered there was a significant 
lowering of NEFA levels at 30 min postprandially following the n-3 enriched 
intervention. Elevation of NEFA and in particular postprandial NEFA levels is 
recognised as being unfavourable in terms of increasing atherogenic risk (Frayn, 
1998). The reduction in NEFA could indicate that in the early postprandial phase 
there was a greater suppression of insulin induced lypolysis following the n-3 
enriched diet however, the mechanisms of action of NEFA are not fully understood 
and the effect of fish oil feeding requires greater investigation.
Stronger evidence of the benefits of fish oil feeding on insulin sensitivity are provided 
by animal studies as opposed to human studies. The mechanism by which insulin 
sensitivity is improved by fish oil feeding in animals is thought to be via the 
incorporation of n-3 PUFA into membrane phospholipids. It is postulated that the 
induction of changes in membrane structuie and fluidity of cells as a result of fish oil 
feeding could influence insulin receptor binding as well as insulin action. 
Alternatively a change in the conformation of diacylglycerols, as a result of fish oil 
feeding, could increase their potency as secondary messengers to insulin (Luo et al
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1996). In addition, the association of n-3 fatty acids with prostaglandin and 
leukotriene production could secure changes in insulin secretion (Mori et al 1992). 
The discrepancy between human and animal studies with regard to changes in insulin 
sensitivity may be as a result of the way in which fatty acids are incorporated into the 
various classes of phospholipids. In humans, fish oil intake does not affect the 
phosphatidyl-inositol composition. As phosphoinositides have been implicated as 
secondary messengers in the insulin signal transduction this may explain the lack of a 
clear beneficial effect of fish oil consumption on insulin sensitivity in humans 
(Malasanos & Stacpoole 1991).
In the measurement of insulin sensitivity in this study the principal observation was 
that insulin sensitivity was improved only in individuals with the greatest degree of 
insulin resistance during the control diet. This indicates that fish oil feeding may be of 
greatest benefit to those with the lowest insulin sensitivity. In this study subjects were 
selected on the basis of fasting insulin levels. Fasting levels of insulin were 
subsequently shown to be a good indicator of the degree of insulin resistance in this 
group. The subject selection criteria included a fasting insulin greater than 40 pmoFl 
however the subjects who had the lowest insulin sensitivity all had a fasting insulin 
concentration greater than 90 pmol/1. In a recent study by Graci et al (1999) a Kitt 
value of less than or equal to 4.8 % min' identified a cluster of insulin resistance 
related abnormalities with an accuracy of 82 %. In this study we identified that the 
greatest improvement in insulin sensitivity as a result of the n-3 enriched diet 
occurred in subjects with a Kitt value of less than 4.7 % min Our findings contrast 
to that of Graci et al (1999) in that in this study we could find no association between 
improvements in insulin related lipid abnormalities and improvements in insulin 
sensitivity. From the results of this study it would appear that the link between 
pathways involved m the improvement of insulin sensitivity of glucose disposal and 
lipid tolerance as a result of increasing n-3 PUFA intake, are not clear cut and warrant 
further investigation. Baseline assessment of insulin sensitivity or selection of 
subjects with higher fasting insulin levels would be advisable in future studies to 
examine the effect of fish oil feeding on insulin sensitivity. Also a greater number of 
studies, involving direct measurements of insulin sensitivity are required to gain a 
clearer picture of the effect of fish oil feeding on improving insulin tolerance in 
humans.
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CHAPTER 4.0
EFFECT OF A REDUCED SFA AND INCREASED CHD INTAKE 
ON INSULIN SENSITIVITY AND POSTPRANDIAL LIPAEMIA
4.1 BACKGROUND
Dietary recommendations for the general public and in particular for those with type 
II diabetes advocate a reduction in total and SFA and an increase in the intake of 
complex CHO. Low-fat, high-CHO diets have been recommended for several reasons 
but were primarily based on the effect of such diets on total plasma cholesterol 
concentrations. Epidemiological observations have further endorsed the benefit of 
consuming such diets in that countries with higher intakes of fat and lower intakes of 
CHO have a higher prevalence of diabetes and obesity (West & Kalbfleisch, 1971).
Two main arguments have been used against the use of a high-CHO diet. The first 
relates to the effect of low-fat, high-CHO diets on serum lipoproteins. While there is 
little doubt that low-fat diets can lower total plasma cholesterol concentrations, it is 
now known that part of this reduction includes a fall in HDL-cholesterol levels. 
Lowering of HDL-cholesterol by a high-CHO diet was reported by Levy et al (1966) 
and has been a continual finding in such dietary interventions since (Turley et 
a/. 1998; Vélez-Carrasco et a/. 1999). Katan (1998) combined data from 27 trials and 
showed that HDL-cholesterol fell by 0.012 mmol/1 for every 1% of energy that was 
replaced by carbohydrates. HDL-cholesterol has been shown to be a protective factor 
against CHD (Miller & Miller, 1975), A reduction in HDL-cholesterol levels would 
therefore be unfavourable in terms of CHD risk. In addition, an abundance of 
evidence from metabolic trials has consistently pointed to the hypertriglyceridaemic 
effect of low-fat and high-CHO feeding (Mensink & Katan, 1992). It is thought that 
increasing the CHO content as a percentage of total calories in isocaloric diets 
increases TG levels as a result of increased synthesis of hepatic VLDL-TG particles. 
It has also been shown that low-fat, high-CHO diets can accentuate postprandial TG 
levels (Chen et a/. 1995). Higher fasting and postprandial TG levels are associated
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with an increased risk of atherosclerotic disease (Mamo et al. 1995; Hokanson & 
Austin, 1996).
The second main argument relates to the effect of high-CHO feeding on insulin and 
glucose responses. As pointed out by Reaven (1997) it would be expected that if 
dietaiy CHO intake is increased a greater postprandial insulin excursion must be 
secreted in order to maintain glucose homeostasis and thus may lead to impairment in 
insulin action in vulnerable individuals. While some early clinical studies suggested 
that high-CHO diets increased basal insulin concentrations (Grey & Kipnis, 1971) 
there has been little further evidence to support the view that high-CHO feeding is 
detrimental to insulin and glucose fiinction. In a study by Ginsberg et al. (1994) no 
significant differences in 8-hour excursions of glucose or insulin were demonstrated 
between individuals receiving a high-MUFA diet and those receiving a high-CHO 
diet. Similarly in a group of NIDDM patients no significant differences in fasting 
glucose or insulin levels following a high-CHO diet (55% energy) was observed 
(Garg et a/. 1994). In addition, greater insulin levels have been observed in those 
habitually consuming diets high in SFA compared to individuals consuming low-fat, 
high-CHO diets (Maron et al. 1991; Marshall et al. 1996).
Recommendations for Western countries advise that fat intakes be reduced in most 
cases to 30% of energy, and that CHO intakes be increased to at least 50% of energy. 
Emphasis is generally placed on the increase being in the form of stai'chy foods or 
complex CHO. In developing countries CHO intakes contribute 60-70% of total 
energy with corresponding low intakes of fat. It is well known that the incidence of 
CHD and diabetes is lower in developing countries but as pointed out by Katan (1997) 
the type of foods consumed in these countries is very different to the low-fat products 
available in supermarkets today. Dietaiy studies, which have looked at the metabolic 
effects of low-fat, high-CHO diets, have vaiied in the amounts and types of CHO 
ingested and in the duration of the low-fat, high-CHO feeding. Data is also limited by 
the fact that measurement of CHO and its components is more difficult than 
measurement of fat, as CHO in the diet is not a single entity. Increases in CHO intake 
have varied from 50% to 70-80% of total energy intake and have included CHOs of 
varying composition. It has been suggested that improvements in insulin action are 
observed only in diets extremely rich in CHO (70-80% energy) however these diets
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are not practical (Garg et al. 1992b). When changes in CHO intake aie restricted to a 
range typically consumed in a Western society there is less agreement as to the effect 
on insulin sensitivity. Variations in the type and composition of dietary CHO 
consumed may therefore account for some of the differences that have been observed 
in the metabolic outcomes of these types of dietary interventions.
4.1.1 STUDY OBJECTIVES
Although epidemiological studies have suggested that a high-fat diet results in obesity 
and IR, few studies have measured insulin sensitivity directly. In addition, it is 
difficult to extract firm conclusions about the effects of low-fat and high-CHO diets 
on insulin sensitivity from previous studies as they have varied considerably in terms 
of subject characteristics, dietary components altered and the techniques employed to 
measure insulin sensitivity. The purpose of this study therefore was to investigate the 
metabolic consequences, in particular the effect on insulin sensitivity, of replacing 
energy derived from SFA with energy derived from dietary CHO in 12 middle-aged 
insulin resistant men. The aim of the dietaiy intervention was to reduce SFA intakes 
to the recommended amount of less than 10% of energy intake, while increasing the 
intake of CHO fr om all dietary sources in order to maintain habitual energy intakes. 
Investigations included measurement of red blood cell membrane phospholipids, 
fasting and postprandial levels of plasma lipoproteins, insulin and glucose levels as 
well as measurement of insulin sensitivity using the short insulin tolerance test.
4.2 STUDY DESIGN AND SUBJECTS
4.2.1 EXPERIMENTAL DESIGN
The study design was a single dietary intervention with the subjects’ pre-intervention 
diet acting as a control phase. Thus a set of metabolic investigations was conducted 
on recruitment into the trial, prior to any dietary advice. On completion of these 
investigations advice was given on how to reduce the intake of SFA. Subjects then 
adhered to a low-saturated-fat diet for a period of 8 weeks, at the end of which the 
second set of metabolic investigations was conducted. The metabolic studies 
conducted pre- and post-diet were identical to those described in the fish-oil trial
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(chapter 3.0) i.e. three study days involving 1) Fasting blood biochemistry and the 
short ITT; 2) a 9 hr study postprandial study of lipid disposal and 3) a 9hr stable 
isotope study of NEFA/glycerol suppression by iusulin infusion and fasting 
proteolysis inhibition by postprandial insulin and amino acids. The stable isotope 
results are presented in appendix 1 but are not discussed further here.
In addition fasting blood samples were collected during the study at weeks 0,4 and 8 
and were analysed for TG, total cholesterol, HDL cholesterol, glucose, insulin and red 
blood cell phospholipid fatty acids.
4.2.1.1 Subject numbers and power calculations
As with the fish oil trial a cohort of 12 was established on the basis of feasibility and 
the short ITT variability (see section 3.2)
4.2.2 SUBJECTS
The study was approved by The Ethics Committee of the Royal Surrey County 
Hospital and the University of Surrey, Guildford. The study days were carried out in 
the Clinical Investigation Unit of the Royal Surrey County Hospital and all volunteers 
provided informed consent before participating in the trial.
30 subjects were recruited to the study via advertisements in the local media in the 
Guildford area for screening on the basis of a fasting blood sample, anthropmetric and 
dietary/lifestyle criteria i.e. glucose < 7.0 mmoFl, total cholesterol < 7.0 mmol/1, TG < 
3.0 mmol/1, insulin > 40 pmol/1 and haemoglobin > 130g/l. Volunteers also had a 
waist circumference greater than 100 cm. The screening biochemical and 
anthropometric data are shown in table 4.1.
Twelve healthy male volunteers were selected, all non-smokers with a low level of 
physical activity and they all habitually consumed at least 15% of energy as SFA. All 
of the volunteers were free from medication and did not have any previous medical 
history of coronary artery, endocrine or liver disease. None of the volunteers were
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following any type of therapeutic or specialised diet or taking any form of dietary 
supplements.
Table 4.1. Baseline Characteristics o f  the study volunteers.
Age (years) 44.2 ± 4.8
BMI (KgW ) 27.9 ± 2.6
Waist circumference (cm) 104.3 ±4.9
Total plasma cholesterol (mmol/1) 5.62+1.11
LDL cholesterol (mmol/1) 4.16 + 0.97
HDL cholesterol (mmol/1) 0.57 ±0.17
Triglyceride (mmol/1) 1.97 ±0.59
Insulin (pmol/1) 71.2 ±44.2
Glucose (mmol/1) 5.44 ± 0.36
Data are presented as the mean of 12 subjects ± SD
4.3 DIETARY INTERVENTION
Upon entry into the study each volunteer completed a seven-day food record, as used 
in the Epic study, to determine usual dietary intakes of energy, CHO and fat 
(Bingham et al. 1997). Nutritional analysis was completed using the FOODBASE 1.2 
nutrient analysis programme (Institute of Brain Chemistry and Human Nutrition, 
London). On the basis of their habitual intakes volunteers were given individual 
dietetic advice on how to reduce SFA and increase CHO in their diet, whilst 
maintaining their usual energy intake. SFAs were derived predominantly from dairy 
products, meat and meat products, and convenience foods. Commonly eaten foods 
were used in the intervention, and the volunteers were provided with low-fat dairy 
products and commercially available low-fat convenience snacks. Volunteers were 
provided with a list of CHO-rich food portions, each equivalent to 10 g of CHO.
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Volunteers were asked to consume 3-4 portions of these foods daily in addition to 
their normal food intake in an attempt to maintain habitual energy levels. The amount 
of CHO which volunteers consumed was adjusted throughout the intervention on the 
basis of volunteers weight measurements.
During the intervention volunteers attended the Nutrition Department at the 
University of Surrey weekly for the first two weeks and once every two weeks 
thereafter. Weight measurements were taken at each visit and volunteers were 
provided with low-fat foods.
At week 3 and week 7 of the intervention volunteers were asked to complete a 7-day 
food record in order to monitor compliance and to analyse the nutrient composition of 
the intervention diet.
4.4 ANALYTICAL PROCEDURES
All proceduies are described in detail in Chapter 2.0 with a brief outline of the general 
proceduies provided here.
Plasma glucose concentrations, total cholesterol, HDL cholesterol, and TGs were 
assayed on a COBAS-MIRA autoanalyser (Roche Products Ltd, Welwyn Garden 
City, Herts) by enzymatic colorimetric methods using commercially available kits 
supplied by Roche Diagnostic Products Ltd (Welwyn Garden City, Herts). LDL 
cholesterol concentration was estimated using the Friedewald equation (Friedewald, 
1972). Plasma NEFA concentrations were also measured using the COBAS-MIRA 
analyser by a standard enzymatic colorimetric method (Wako Chemicals, GmbH, 
Germany supplied by Alpha laboratories Ltd., London). Appropriate quality controls 
with pre-defined reference ranges were run with each assay in order to determine intra 
and inter assay variability. The inter and intra assay CV are outlined in Chapter 2.0 
section 2.1. Serum insulin levels were measured by radioimmunoassay. Samples 
ftom each intervention period were analysed together in the same run at the end of the 
study period.
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The fatty acid composition of red blood cell phospholipids was determined after the 
extraction of lipids with a mixture of chloroform and methanol (2:1 vol/vol), 
containing 0.01% BHT as antioxidant, according to the Folch method (Folch et 
a/. 1957). The fatty acids were separated and quantitated using gas chromatography. 
Fatty acids were identified by comparing retention times with those of a known 
standard mixture.
Triglyceride-rich and triglyceride poor fi*actions of plasma were separated using an 
adapted method of that described by Grundy & Monk (1976). 3.5 ml of plasma was 
overlayered with an equal volume of saline (1.006g NaCFml), and ultracentrifuged 
for 5.0 X 10^  g at 24°C in a 10-ml centrifuge tube. The top 1.2 ml of the upper layer, 
the TRL fraction was removed, aliquoted and frozen at -20°C for later analysis. The 
remaining TPL fraction was mixed, aliquoted and stored at ~~20°C for future analysis. 
TG levels were measured in TRL fractions using an enzymatic, colorimetric kit 
supplied by Roche Diagnostic Products Ltd (Welwyn Garden City, Herts). Apo B-48 
was assayed in the TRL fraction using an antiserum specific to apo B-48. The method 
used was as previously described by Lovegrove et al. (1996).
Lipoprotein lipase activity was measured in 10 pi portions of plasma taken 5 and 15 
minutes after the administration of an intravenous dose of heparin. LPL activity was 
measured by a modified method described by Nilsson-Ehle & Schotz (1976).
4.5 STATISTICAL ANALYSIS
For most data tabulated results are presented as mean values and standard deviations. 
Individual time points on graphs are presented as mean values with their standard 
errors.
Statistical analysis was performed using the windows compatible computer package, 
Statistica (version 5, StatSoft Inc.) and the Excel (Microsoft Excel 97) computer 
programme.
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The effect of the low SFA diet on fasting and postprandial values was analysed using 
the student’s t test for paired data. The postprandial data was expressed in summary 
form as an area under the postprandial response curve. The areas under the 
postprandial response curves were calculated using the Trapezium rule (Matthews et 
al. 1990). Relationships between study variables were analysed by the 
Pearson's’correlation. Values of P < 0.05  were considered statistically significant.
4.6 RESULTS
4.6.1 NUTRITIONAL ANALYSIS
Data for weight, energy and macronutrient intake are presented in table 4.2. A 
significant weight loss (mean of 1.7 Kg) was observed within the study group 
following the low-SFA intervention (p < 0.01).
Energy intakes were lower following the low-SFA / high-CHO. There was a 
significant reduction in the proportion of energy derived form fat (p < 0.0001) and a 
significant increase in the proportion of energy derived from CHO (p < 0 .0001). In 
conjunction with the increase in CHO there was also a significant increase in the 
intake of dietary fibre (Englyst method) as a result of the intervention diet. SFA levels 
fell from an average of 16.3 (SD 3 .0 ) % to 7.9 (S D l.6 ) % of total energy intake (p < 
0 .0001). There was also a significant reduction in MUFA levels from 14.3 (SD2.3) % 
to 8.9 (SD 1.7) % of energy intake as a result of the mtervention (p < 0 .0001) with no 
change in the intake of PUFA. No difference in the percentage of energy from alcohol 
was observed during the intervention.
The change in weight (pre-intervention weight/ post-intervention weight) as a result 
of the intervention diet was positively correlated with the change in energy intake 
(pre-intervention/ post-intervention) as well as the extent of the reduction in total fat 
intake as shown in figs 4.0. and 4.1. respectively.
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Table 4.2. Weight and nutrient intakes before and after low SFA intervention
Pre-intervention diet Intervention diet
Weight (Kg) 90.2 ± 9.7 88.5 ± 10.1**
Energy (MJ) 13.1 ± 2.2 11.9 ± 2.4
Protein (% energy) 13.0 ± 1.9 16.6 ± 2.0**
Carbohydrate (% energy) 41.0 ± 7.5 49.2 ± 5.2***
Alcohol (% energy) 3.7 ± 5.6 4.2 ± 4.8
Total fat (% energy) 42.0 ± 4.4 29.7 ± 4.0***
Saturated fat (% energy) 16.3 ± 3.0 7.9 ± 1.6***
Monounsaturated fat (% energy) 14.3 ± 2.3 8.9 ± 1.7***
Polyunsaturated fat (% energy) 6.5 ± 2.1 6.7 ± 2.0
Fibre (g) 14.4 ± 3.7 17.5 ± 5.5*
Values are presented as means ± SD. Significance of difference following 
intervention diet *p < 0.05, **p < 0.01; *** P < 0.0001.
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Figure 4.1. Relationship between the change in energy intake and the change in 
weight following the low-SFA / high-CHO diet (r = 0.6979, p = 
0 .012).
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Figure 4.2. The association between the percentage reduction in total fat intake 
and the percentage reduction in weight following the low-SFA / high- 
CHO intake (r = 0.7097, p = 0.010)
4.6.2 RED BLOOD CELL PHOSPHOLIPID FATTY ACID COMPOSITION
The phospholipid fatty acid compositions of erythrocytes measured prior to the 
intervention and at the end of the intervention period are presented in fig 4.3. The 
results are in agreement with nutritional analysis data in that there was a significant 
reduction in saturated (p = 0.015) and MUFA levels (p = 0.002) following the low 
SFA diet. There was also an increase in the PUFA content of phospholipids following 
the intervention (p = 0.01).
Pre-intervention data showed that there was a significant relationship between the 
level of SFA in phospholipid membranes and the weight of subjects as shown in fig 
4.4.
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Fig 4.3. Levels of principal red blood cell phospholipid fatty acids measured
pre-intervention and at the end of the intervention diet.
Values are expressed as a percentage of the total are of all fatty acids 
measured and are presented as means of 12 subjects ± SE.
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Figure 4.4. Correlation between weight (Kg) and red blood cell saturated fatty
acids (% area) as measured prior to the intervention diet (r = 0.6454, p 
= 0.023)
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4.6.3 FASTING BIOCHEMICAL DATA
The fasting plasma concentrations of lipids, glucose and insulin are presented in table 
4.3. No consistent alterations were observed in plasma cholesterol, HDL-cholesterol, 
LDL-cholesterol, TG, glucose or insulin levels as a result of the low SFA diet. NEFA 
concentrations were significantly reduced from the pre-intervention to the post­
intervention period.
In comparing the fasting biochemical data with the results of the nutritional analysis it 
was shown that there was a positive correlation between fasting insulin levels and 
SFA intake during the pre-intervention diet (r = 0.59, p = 0.042; Fig 4.5.). No other 
significant correlations were observed between biochemical measurements and the 
results of the nutritional analysis.
Table 4.3. Fasting concentrations o f plasma lipids, glucose (mmol/l) and insulin 
(pmol/l) pre, mid and post-intervention.
Biochemical
Measurement
Pre-intervention Mid-intervention Post-intervention
Triglyceride 1.85 ± 0.40 1.84 ± 0.64 1.93 ± 0.49
Cholesterol 4.71 ± 1.16 4.76 ± 1.16 4.89 ± 0.90
HDL-Cho lesterol 0.95 ± 0.21 0.94 ± 0.23 0.89 ± 0.06
LDL-Cho lesterol 2.92 ± 1.08 2.99 ± 1.22 3.12 ± 0.79
CHOL:HDL ratio 5.1 ± 1.4 5.3 ± 1.6 5.7 ± 1.3
NEFA 0.58 ±0.17 0.39 ± 0.17t 0.43 ± 0.13*
Glucose 5.47 ± 0.45 5.59 ± 0.30 5.49 ± 0.28
Insulin 92.81 ± 47.40 87.50 ± 33.98 91.84 ± 46.92
Data are presented as means ± SD.
*p < 0.01 Significance of difference pre and post intervention, 
tp  < 0.01 Significance of difference pre and mid intervention.
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Figure 4.5.. Relationship between fasting insulin concentration and SFA intake 
measured during the pre-intervention diet (r = 0.592, p = 0.042).
4.6.4 POSTPRANDIAL DATA
Postprandial TG data are presented in table 4.4. There was a 20% increase in TG 
AUC over the 9-hour postprandial study following the intervention diet although this 
was not statistically significant (p = 0.057). Taking account of the fasting TG values 
there was an increase in the TG incremental AUC (p = 0.025) as well as an 
augmentation in the 6-9 hour TG profile (p = 0.043) as a result of the low-SFA / high- 
CHO intervention diet. No differences were observed in the peak TG and the time to 
peak over the 9-hour study between the pre-intervention and the post-intervention 
diet.
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Table 4.4. Postprandial Triglyceride data, pre- and post-intervention
Pre-intervention Post-intervention P  value
TGAUC 1665.66 ± 406.02 1990.45 ± 646.73 0.057
(mmol/l. min)
Incremental TG AUC 645.51 ± 285.35 920.35 ± 400.29 0.025*
(mmol/l.min)
6-9 hour TG AUC 517.9 ± 200.46 653.70 ± 242.74 0.043*
(mmol/l.min)
Peak TG 4.28 ± 1.05 5.07 ± 1.61 0.094
(mmol/l)
Time to peak (hours) 4.75 ± 1.22 4.58 ± 1.24 0.551
Data are presented as means of 12 subjects ±SD.
Significance of difference pre and post intervention * p < 0.05.
Figure 4.6. shows the postprandial TRL TG profile prior to and at the end of the 
intervention diet. Concentrations of TRL TG were significantly augmented following 
the 80-g test meal as a result of the low-SFA and high-CHO diet as measured by the 
TRL TG AUC (p = 0.028). Incremental measurement of the TRL TG AUC and the 
late postprandial (6-9 hour) TRL TG phase also showed a significant reduction in the 
clearance of TRL TG following the low-SFA / high-CHO diet compared to the 
subjects habitual diet (p = 0.027; p = 0.047 respectively).
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Figure 4.6. Postprandial TRL TG concentrations (mmol/l.hr) following the test
meal (80-g fat) measured prior to and at the end of the low-SFA / high- 
CHO diet.
Data are presented as means of 12 subjects! SE.
Concentrations of apo B-48 are shown in fig 4.7. There was no variation in apo B-48 
concentrations as a result of the low-SFA/high-CHO diet. Apo B-lOO concentrations 
were calculated by subtracting apo B-48 fi’om total Apo lipoprotein B concentrations. 
There was no difference in Apo B-lOO AUC between the pre-intervention (7387.8 ± 
48457.7 pg/ml.min) and intervention diets (62301.9 ± 13521.5 pg/ml.min).
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Figure 4.7. Apo B-48 concentration (pg/ml) in individual subjects following the 
pre-intervention and low-SFA / high-CHO diet. The subjects are 
ranked in order of decreasing apo B48 concentration prior to the 
intervention diet.
Figure 4.8. shows the postprandial NEFA profile. As expected there was an inhibition 
of NEFA release directly after the consumption of the test meal with NEFA levels 
gradually increasing to a level almost twice that above baseline at the end of the 9- 
hour study. In agreement with the fasting NEFA data, there was a significant 
reduction in the total area under the NEFA curve following the low-SFA / high-CHO 
diet (303.3 ± 45.3 mmol/l.min Vs 280.5 ±51.5 mmol/l.min, p = 0.01). In separating 
the NEFA response curve into two phases, it was shown that there was a significant 
reduction in NEFA release during the later (4-9 hour) postprandial phase (232.0 ± 
31.3 mmol/l.min Vs 210.4 ± 37.05 mmol/l.min, p = 0.004) and no significant change 
in NEFA concentrations in the early (0-4 hour) postprandial phase (71.2 ± 19.1 
mmol/l.hr Vs 70.1 ± 20.1 mmol/l.hr, p = 0.85). This would indicate that the 
intervention affected late postprandial NEFA release to a greater extent than the 
inhibition of NEFA levels immediately following the test meal. The reduction in 
NEFA release was positively correlated with the change in energy intakes following 
the low-SFA / high-CHO diet as shown in fig 4.9. The greater the reduction in energy 
levels, the greater the fall in NEFA levels as a result of the intervention.
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Figure 4.8. NEFA concentrations following the test meal (80-g fat) measured prior 
to and at the end of the intervention diet.
Data are means of 12 subjects ± SE.
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Figure 4.9. Changes in energy intake and the association with change in the NEFA 
AUC measurements following the low-SFA/ high-CHO diet (r = 0.576, 
p = 0.050).
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Fig 4.10. shows the glucose and insulin levels following the test meal. They follow an 
expected contour with glucose rising, following ingestion of the test meal and insulin 
released in response to the rise in glucose. There was no change in overall glucose and 
insulin concentrations as measured by the area under the curve over the 9-hour study 
period. However, there was a significant reduction in the 60-min glucose 
measurement from 6.9 ± 1.5 mmol/l during the pre-intervention diet to 6.2 ± 0.9 
mmol/l during the intervention diet (p = 0.04). The fall in blood glucose was matched 
by a significant reduction in insulin release (p = 0.02) at the 60-min time point 
following the low-SFA / high-CHO diet. Glucose and insulin responses were also 
compared to the results of the nutritional analysis. As shown in fig 4.11. there was a 
positive association between the level of SFA in the subjects diets’ and the extent of 
the glucose response prior the low-SFA / high-CHO diet.
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Figure 4.10. Insulin (pmol/l) and glucose (mmol/l) responses, following the test 
meal (80-g fat) prior to and at the end of the intervention period.
Data are presented as means of 12 subjects ± SE.
136
24 1
22 
?  20 -
18 -
12 -
2400 2600 2800 34002200 3000 3200
G lu c o s e  AUC (m m o l/l.m in )
Figure 4.11 The relationship between the intake of saturated fat (% energy) and
glucose AUC measurements (mmol/l.min) prior to the intervention diet 
(r = 0.641, p = 0.025)
4.6.5 POST-HEPARIN PLASMA LPL ACTIVITY
The effect of the low SFA and high-CHO diet on post-heparin LPL activity is shown 
in fig 4.12. As expected, the amount of LPL released into the plasma was increased 
from 5 to 15 minutes following the heparin administration. There was no significant 
difference in plasma post-heparin LPL activity at the 5 or 15-minute measurement 
between the pre-intervention diet and the post-intervention diet.
In comparing plasma LPL activity and TG levels it was shown that there was an 
association between LPL activity at the 15-minute measurement and fasting TG levels 
at the end of the intervention diet. Figure 4.13. shows that those subjects with the 
highest fasting TG concentration also tended to have the highest enzyme activity (p = 
0.009). There was also a positive correlation between the extent of the increase in the 
area under the TG response curve and the level of post-heparin LPL activity (r = 
0.9320, p < 0.0001) following the low-SFA / high-CHO diet as shown in fig 4.14.
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Figure 4.12. LPL activity measured 5 and 15 minutes after heparin administration, 
prior to and at the end of the intervention diet.
Data are presented as means of 12 subjects with standard error bars.
20.00
18.00
16.00 
14.00
I  12.00
I 10.003
8.00 
6.00 
4.00
2 31 1.5 2.5
TG (m m o l/l)
Figure 4.13. The relationship between fasting TG concentration and plasma LPL 
activity following the low-SFA / high-CHO diet (r = 0.7118, p = 
0.009).
138
100.00 -I
80.00 -
O9  60.00 - 
40.00 -
20.00  -
oc 0.00
5.30 ♦ 10.00 15.00 20.00
- 20.00  -
-40.00 J
L P L  a c t iv i ty  ( u m o l .o i e a t e .m i .h r )
Figure 4.14. The association between post-heparin LPL activity levels and the % 
increase in TG AUC following the low-SFA / high-CHO diet (r = 
0.9320, p<  0.0001).
4.6.6 INSULIN SENSITIVITY DATA
The short insulin tolerance test determined insulin sensitivity in the study group. 
Linear regression was used to estimate the slope of the fall in log transformed blood 
glucose concentration following the administration of a bolus dose of insulin. The 
slope was multiplied by -100 to derive the rate constant ( K i t t )  and by 60 to determine 
the percentage decline in blood glucose per minute (% min'*). Following intravenous 
injection of insulin, blood glucose levels started to fall after 4 minutes as shown in fig 
4.15. The glucose disappearance rate Kitt was therefore estimated fi-om the slope of 
glucose disappearance from 4-15 minutes. Following the injection of insulin, the 
mean plasma glucose concentration fell from 5.84 (SD 0.43) mmol/l to 4.18 (SD 0.54) 
mmol/l during the habitual diet and from 5.73 (SD 0.11) mmol/l to 3.96 (SD 0.54) 
mmol/l during the intervention diet.
The results of the short insulin tolerance test in individual subjects prior to and at the 
end of the low-SFA / high-CHO diets are presented in fig 4.16. Subjects are ranked in
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the order of increasing insulin sensitivity as measured during the pre-intervention 
period. There was a wide range of insulin sensitivity in the study group, with K m  
glucose varying from 1.79 to 4.96 % min'* (mean = 3.25 ± 0.87 % min'* ) prior to the 
intervention. While there was no difference in insulin sensitivity as a result of the 
intervention in the group overall, it was observed that in the 7 least insulin sensitive 
subjects during the control diet, there was a significant improvement in insulin 
sensitivity as a result of the low-SFA / high-CHO diet (p = 0.005). In the 4 most 
insulin sensitive subjects there was a significant decline in insulin sensitivity as 
measured by the rate of fall in blood glucose, as a result of the low-SFA / high-CHO 
diet (p = 0.042).
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Figure 4.15. Mean fall in blood glucose concentrations over 15 minutes following 
insulin administration.
140
Pre-intervention diet 
Post-intervention diet
Figure 4.16. Glucose Kitt (% min'*), a measure of insulin sensitivity, in individual 
subjects prior to and following the low-SFA / high-CHO diet. Subjects 
are ranked in order of the least insulin sensitive subjects prior to the 
intervention.
In comparing the results of the insulin tolerance test with nutritional intakes it was 
observed that there was significant association between the reduction in SFA intake 
and improvement in insulin sensitivity (r = 0.785, p = 0.005) as shown in fig 4.17. 
This would indicate that the greater the reduction in SFA the greater the improvement 
in insulin sensitivity as measured using the short insulin tolerance test in the group 
overall. The association was also observed with total fat intake in that there was a 
positive correlation between the reduction in total fat intake following the intervention 
diet and the extent of the improvement in insulin sensitivity as a result of the low-SFA 
/ high-CHO diet (r = 0.634, p = 0.027) as shown in fig 4.18.
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Figure 4.17. The relationship between the reduction in saturated fat intake and the 
improvement in insulin sensitivity as a result of the intervention diet (r 
= 0.785, p = 0.005)
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Figure 4.18. The association between the reduction in total fat intake and the
change in insulin sensitivity as a result of the intervention diet (r = 
0.635, p = 0.027).
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The fractional rate of fall in plasma NEFA levels between 4 and 15 minutes following 
insulin administration served as a measure of insulin mediated inhibition of hormone 
sensitive lipase. Fig 4.19 shows the mean decline in NEFA levels following the 
administration of a bolus dose of insulin. The NEFA Kut data for individual subjects 
prior to and at the end of the intervention diet are shown in figure 4.20. There was no 
difference in the rate at which plasma NEFA levels fell following insulin 
administration as a result of the low-SFA / high-CHO diet.
As shown in fig 4.21. there was no association between changes in postprandial 
lipaemia as measured by the TG response and insulin sensitivity of glucose disposal 
as measured by the short insulin tolerance test (r = 0.011, p = 0.971).
0.700 Pre-intervention diet 
M— Low SFA / high CHO diet0.600 : =
0.500
E 0.400 -- 
E
<  0.300 -
I 0.200 -
0.100 - -
0.000
0 2 6 8 10 12 164 14
Time (minute^
Figure 4.19. Decline in plasma NEFA concentration over 15 minute following a 
bolus dose of insulin.
143
■  Pre-intervention diet
■  Post-intervention diet
0> ^  CM"  »  5
Figure 4.20. Individual NEFA Kitt (% min'*) levels measured prior to and at the 
end of the low-SFA / high-CHO dietary intervention.
Subjects are ranked in order of increasing Kitt values during the pre­
intervention diet.
§u3O)c0)O)cËo
60
50
40
30
20
10
0
-10
-20
-30
^0
-50
-20 20 40 60
7o change in TG AUC
80 100
Figure 4.21. The relationship between the change in postprandial lipaemia and the 
change in insulin sensitivity following the low-SFA / high-CHO diet (r 
= 0.01 l ,p  = 0.971).
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4.7 DISCUSSION
This study was designed to evaluate the effects of reducing intakes of SFA and 
increasing the intake of dietary CHO on vaiious metabolic outcomes including insulin 
sensitivity and measures of postprandial lipaemia. The study was conducted in a 
group of middle-aged men exhibiting characteristics of the insulin resistance 
syndrome and therefore considered to be at greater risk of developing CHD. Dietary 
advice directed at reducing risk of CHD has emphasised the need to reduce intakes of 
SFA and increase intakes of dietary CHO. The rationale for this approach appear to be 
based on the premise that such diets result in a decrease in total and LDL cholesterol 
and ultimately reduce the risk and incidence of CHD. Less emphasis has been placed 
on the effect of such diets on insulin sensitivity and the association with postprandial 
lipoprotein metabolism.
Results of the nutritional analysis demonstrated that the intervention was successful in 
reducing the intake of SFA from an average of 16 % to less than 8% of energy 
intakes. This was achieved by volunteers substituting high SFA foods in their diets for 
lower-fat, high-CHO alternatives. The intervention also led to a reduction in the 
intake of both total fat and of MUFA. It is expected that decreasing saturated fat 
intake without increasing the intake of unsaturated oils will produce a reduction in 
total and MUFA intake because of the reduction in high fat dairy products, meats and 
high fat snack foods. There was also a moderate increase in the intake of CHO from 
41% to 49% of energy, as a result of the intervention diet. Intakes of energy were 
lower but not significantly decreased as a result of the intervention.
Consumption of the reduced SFA diet was accompanied by a significant weight loss 
(mean 1.7 Kg) and is a reflection of the difficulty of the isocaloric substitution of 
dietary fat for dietary CHO. It was observed that the decrease in body weight was 
associated with a reduction in total energy intakes. Subjects commented throughout 
the intervention on the quantity of foods they had to consume in order to prevent 
weight loss, which was not unexpected as in order to match their habitual energy 
intakes, a lower-fat, higher-CHO diet would have a greater weight value. Assuming 
that all of the weight loss was fat loss it is estimated that a deficit of approximately 
890 kJ (213 Kcal) per day is required to shed 1.7 Kg of body fat in 8 weeks. Our
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findings are in agreement with other studies that have reported weight loss with the 
consumption of a low-fat and high-CHO diet. Higher fat diets have a higher energy 
density and it appears that under ad libitum conditions individuals will not 
compensate for the change in energy density when asked to consume a diet, which is 
lower in fat and higher in CHO. (Dougherty et al 1988; Kendall et al 1991; Sheppaid 
et al 1991). Apart from the decrease in energy intake caused by consuming a diet low 
in fat there are indications that fat and CHO may be different in the regulation of body 
fat. The storage of dietary carbohydrates in adipose tissue is a less-energy efficient 
process requiring 23% of energy intake, as compared with only 3% of energy required 
to store dietary fat as fat (Schaefer et al 1995). Any dietary fat eaten in excess is 
therefore more likely to be stored as fat, whereas excess CHO intake is mostly 
oxidised (Acheson et al 1982; Flatt et al 1985). However, the long term weight loss 
associated with consuming diets lower in fat and higher in carbohydrates is 
disappointing, producing decreases in body weight from 0.4 to 2.6 Kg (Katan, 1998) 
with much larger decreases needed to affect improvements in fasting lipoprotein 
levels.
Results of the red blood cell phospholipid analysis were in agreement with the results 
of the nutritional analysis data and therefore served as a good indicator of volunteer 
compliance. There was a significant reduction in the level of both SFA and MUFA 
with an increase in the PUFA component of membrane phospholipids. Data indicate 
that peripheral insulin sensitivity may be influenced by phospholipid fatty acid 
composition and that changes in the fatty acid composition of the cell membranes 
may modulate the action of insulin (Borkman et a l  1993). Increasing the content of 
PUFA within cell membranes in cultured cells increases membrane fluidity, the 
number of insulin receptors, and the action of insulin (Thomson et al 1987): converse 
effects occur when the concentration of SFA in the membranes is increased (Ginsberg 
et al 1982). In a study by Folsom et al (1996) fasting serum insulin was associated 
positively with the percentage of SFA in fasting plasma phospholipids. The detected 
association was strong even after adjustment for BMI. In this study while there was 
no association between the levels of SFA in phospholipids and the levels of fasting 
insulin a positive association between the subjects weight and phospholipid SFA 
content was observed. This supports the perception that long term exposure to high
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levels of fat in the diet is associated with a greater degree of obesity and overweight 
and that chronic lifetime habits may modulate insulin action.
Despite the reduction in SFA intakes, the anticipated reduction in total and LDL- 
cholesterol levels was not observed. Levels of HDL-cholesterol were also unchanged 
following the intervention diet. Levels of total cholesterol were not clinically raised in 
this group of individuals (mean 4.71 mmol/l) and therefore a reduction in cholesterol 
concentration may have been more evident had cholesterol levels been above normal 
values. Furthermore, studies reporting a reduction in plasma cholesterol levels 
following the consumption of a low-SFA diet have often been accompanied by a 
considerable amount of weight loss. Other studies provide no information as to the 
effect of the consumption of low-SFA /high-CHO on body weight, thereby making if 
difficult to draw firm conclusions as to the effect of the diet alone on improvements in 
lipoprotein metabolism (Vélez-Carrasco et al. 1999). Katan (1998) has remarked on 
the detrimental effect of low-fat and high-CHO diets on levels of HDL-cholesterol. 
The mean HDL-cholesterol concentration in this group was below 1.0 mmoI/1, a 
concentration associated with IR. An increase in CHO intake may therefore have 
elicited little effect on the already lowered levels of HDL-cholesterol. In addition, no 
alterations in fasting TG were observed as a result of the low-SFA and high-CHO 
diet. Our findings are not in agreement with other studies that have reported an 
increase in fasting TG levels as a result of an increase in the CHO content of the diet 
(Ginsberg et al. 1976; Coulston et al. 1987; Borkman et al 1991; Vélez-Carrasco et 
al 1999). However, the amount of CHO consumed in this intervention (49 % of 
energy) is not as extreme as the level of CHO in other interventions where a 
hypertriglyceridaemic effect has been observed. In a large study conducted by 
Retzlaff et al (1995) the effect of four ranges of CHO intake varying from 45 % to 60 
% of energy on TG levels in a group of hypercholesterolaemic individuals was 
examined. The study was conducted over a period of 24 months and the authors 
concluded that a moderate but not extremely high-CHO diet (> 60% energy) can be 
used long term without deleterious effects on plasma TG levels. It has also been 
suggested that increases in the plasma TG level as a result of an increase in dietaiy 
CHO can be avoided if the increase in CHO is introduced gradually (Ullman et al 
1991). Other studies of low-fat, high-CHO diets have not found increases in plasma 
TG levels, however the majority of these studies did not control for energy intake and
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were therefore accompanied by weight loss (Thuesen et al 1986; Brown et al 1984). 
Another study conducted by Sacks et al (1986) reported that TG levels remained 
unchanged in a group of normolipidaemic men following 3 months feeding of a 60% 
CHO diet, however the baseline levels of CHO intake were already high at 51% of 
energy in this gi’oup of semi-vegetarian men. Although the weight loss observed in 
the present study was small it may have been enough to offset any deleterious effect 
on fasting TG levels of the increase in CHO feeding.
While fasting levels of TG remained unchanged there was a 20% increase in 
postprandial TG concentrations following the low-SFA / high-CHO diet. The greatest 
increase in the postprandial TG concentration was observed between 6 and 9 hours 
following the consumption of the high fat breakfast. The postprandial investigation 
conducted in this study consisted of one test meal only, whereas the consumption of 
two meals and one snack is more representative within a nine-hour time frame. It 
would be expected that had more than one meal been ingested over the 9 hour period 
that the day-long TG level would have been raised as a result of the intervention diet. 
The accumulation of TG-rich lipoproteins was also greater following the low-SFA / 
high-CHO diet. TRL consist of chylomicrons, chylomicron remnants and VLDL TGs. 
To distinguish between chylomicrons of intestinal and hepatic origin, analysis of apo 
B-48 particles was conducted with subsequent indirect measurement of apo B-lOO 
concentration. Concentrations of apo B-48 were significantly lowered as a result of 
the intervention diet indicating that the increase in postprandial TG concentration was 
not as a result of an increase in exogenous TG-rich lipoproteins. This would confirm 
the findings of several other studies that have suggested that the increase in plasma 
TG concentration in response to low-fat, high-CHO diets is due to an increase in 
hepatic VLDL production. It has been argued that the CHO-induced 
hypertriglyceridemic effect of low-fat, high-CHO diets can be attenuated if such diets 
are enriched with dietary fibre. However, it is thought that the amount of dietary fibre 
needed to stunt the hypertriglyceridemic effect of high-CHO feeding is five to seven 
times the amount currently consumed in the UK and as such would be an amount that 
most individuals would find unacceptable (Simpson et al 1982; Hollenbeck et al 
1983). It has also been argued that CHO-induced hypertriglyceridemia is a transient 
phenomenon however, several studies do not support this conclusion. In the present
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study postprandial TG increases were evident after two months of the low-fat, high- 
CHO diet suggesting that the increase in TG was persistent.
Increasingly it is thought that higher concentrations of both fasting and postprandial 
plasma NEFA are risk factors associated with CHD and IR (Frayn, 1998) and for the 
development of NIDDM (Paolisso et al 1995). In this study there was a significant 
reduction in the levels of fasting NEFA and also a greater suppression of postprandial 
NEFA release following a high fat meal as a result of the low-SFA / high-CHO diet. 
The reduction in NEFA levels was more pronounced during the late postprandial 
period, which is somewhat contradictory to the observed concomitant increase in TG 
levels. It would be expected that the rise in TG would be accompanied by a rise in 
NEFA levels as plasma NEFAs aie the major substrate for hepatic TG synthesis, and 
it has been shown that there is a close correlation between NEFA and VLDL-TG 
secretion (Kissebah et al. 1974). In a study by Byrne et al (1997) the relationship 
between TG and NEFA concentrations was examined and it was shown that the most 
important determinants of plasma TG concentrations in a group of 1122 subjects was 
the area under the non-esterified fatty acid suppression curve. Plasma NEFA 
concentrations are largely determined by the action of insulin to suppress adipocyte 
lipolysis. Postprandial suppression of NEFA availability is one of the mechanisms 
through which insulin enhances glucose disposal and Roust & Jensen (1993) showed 
that postprandial release of NEFAs in upper-body obese women is not suppressed 
normally compared to that in lower-body obese and non-obese women. In this study 
was observed that fall in NEFA levels was associated with a reduction in the intake of 
energy following the low-SFA / high-CHO diet. No association between measures of 
fasting insulin or insulin sensitivity and NEFA levels was observed. The reduction in 
energy following the intervention diet was associated with in a reduction in body 
weight. It is possible that the reduction in weight which occurred during the 
intervention may have led to a decrease in the number of fat cells resulting in a 
decline in the rate of lipolysis and therefore the concentration of plasma NEFA. 
Certainly in obese individuals the converse effect has been observed and it has been 
shown that as the net rate of lipolysis increases with increasing fat mass, there is an 
increase in the plasma NEFA concentrations. In addition, it has been shown by 
Lillioja et al (1986) that it is the size of the fat depot rather than the basal rate of 
lypolysis per se that determines NEFA availability. Less is known about the effect of
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individual fatty acids in the diet on NEFA. It is known that if rat adipocytes are 
cultured with (non-esterified) SFA, a reduction in the sensitivity to insulin of glucose 
transport is observed (Stoiiein et al 1991). More information needs to be obtained 
from human studies in order to have a greater understanding of the effects of changes 
in the fatty acid composition of diets on the regulation of NEFA.
Hyperinsulinaemia is frequently associated with hypertension (Modan et al 1985), 
hyperlipidaemia (Zavaroni et al 1989), CHD (Fontbonne et al 1988) and the 
development of type II diabetes (Stout, 1985). In the present study the mean fasting 
insulin concentration was 92.8 pmol/1. From the analysis of the food records a 
positive congélation between levels of fasting insulin and habitual intake of SFA was 
found. This finding concurs with the study of Marshall et al (1997) that showed that 
diets high in total and SFA and low in starch and fibre were significantly associated 
with fasting hyperinsulinaemia. In a study of men with type II diabetes Maron et al 
(1991) also showed that the intake of SFA was significantly related to elevated fasting 
insulin concentration independently of body mass index. Mayer et al (1993) also 
demonstrated that the usual intake of total dietaiy fat was positively related to fasting 
insulin concentration in a group of healthy women twins. In the present postprandial 
study, while the overall concentrations of glucose and insulin in response to the test 
meal were unchanged, there was a significant reduction at the 60 min time point in 
both insulin and glucose levels following the low-SFA, high-CHO diet. In recent 
studies the 30-min insulin concentration during the oral glucose tolerance test has 
been shown to be a good marker of insulin secretion (Phillips et a l 1994). In the 
present study there was also a positive association between the extent of the 
postprandial glucose response and the level of SFA consumed during the subjects 
habitual high fat diet. A study conducted in Italy also showed that increased 
consumption of butter, a food rich in SFA, was associated with higher glucose 
concentrations in both men and women (Gatti et al 1992). In healthy men, glucose 
stimulated insulin secretion is increased after the acute ingestion of SFA, and the 
authors suggest that this may be due to a rise in plasma gastric inhibitory polypeptide 
(Collier et t7/.1988). Another suggestion is that the increase in free fatty acids due to 
the consumption of a high SFA diet leads to an increase in glucose levels caused by 
the glucose-fatty acid cycle as originally proposed by Randle et al (1963). In this 
study the levels of circulating NEFA were higher during the subjects’ habitual SFA
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diet and may have played a role in the observed positive association between the usual 
intake of SFA and postprandial glucose concentrations.
No changes in post-heparin LPL or HL activities were observed following the low- 
SFA / high-CHO diet. Little consistent information is available from previous studies 
regarding the effects of high-CHO and low-fat diets on LPL and HL activities. It has 
been proposed that high-CHO diets may reduce post-heparin LPL and HL activities 
and thus contribute to the rise in TG concentrations following these type of diets 
(Blades & Garg, 1995). In a study by Jackson et al. (1990), a high-CHO diet was 
reported to lower post-heparin LPL activity in a group of healthy individuals within 1 
week. In contrast, in a group of NIDDM patients Chen et al (1995) reported an 
increase in post-heparin LPL activity but not HL activity, following a high-CHO diet. 
The increase in LPL activity occurred alongside an increase in fasting TG 
concentration. The effects of liigh-CHO diets on adipose tissue LPL activity have not 
been studied. Studies looking at the effects on skeletal muscle LPL activity report a 
lowering of activity following high-CHO feeding (Lithell et al 1982; Kiens et al 
1987). In terms of a mechanistic effect of CHO induced triglyceridaemia, it is 
generally thought that a reduction in total plasma post-hepaiin LPL activity does not 
contribute to the increase in plasma TG concentrations associated with high-CHO 
diets during long-term studies (Blades & Garg, 1995). In this study there was a 
positive association between levels of fasting TG and LPL activity. A higher level of 
LPL activity was also associated with a greater increase in the postprandial area under 
the TG curve following the low-SFA / high-CHO diet. This suggests that in this study 
the increase in postprandial TG concentration was not as a result of a decrease in the 
activity of plasma LPL activity. Greater evidence for an increase in hepatic VLDL 
production as an explanation for CHO-induced triglyceridaemia exists. However, 
more information regarding the effect of low-fat and high-CHO diets on LPL activity 
in plasma and adipose tissue is required to make firm conclusions as to the role of 
LPL in modifying lipoprotein response.
Previous work has implicated that a higher habitual intake of dietary fat is associated 
with a worsened insulin sensitivity (Feskens & Kromhout, 1990; Lovejoy & 
DiGirolamo, 1992). In contrast to work that has been done in animals, studies that 
have looked at the effect of reducing intakes of dietary fat on insulin sensitivity in
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humans, are equivocal Few of those studies have measured insulin sensitivity using 
the short insulin tolerance test and related this to changes in the dietary intake of SFA 
and CHO. In this study subjects were selected on the basis of fasting insulin levels. 
Fasting insulin levels were shown to be associated with the intake of SFA in this 
group of subjects. As was observed with the fish oil study (chapter 3.0) insulin 
sensitivity was improved following the intervention diet in the individuals with the 
greatest degi*ee of IR at the outset of the study. It was also observed that there was an 
association between the extent of the reduction in the intake of SFA and the 
improvement in insulin sensitivity. This indicated that the individuals with the 
greatest improvement in insulin sensitivity were also the individuals with the greatest 
reduction in the intake of SFA. The reduction in dietary SFA was confirmed in this 
study by a reduction in red blood cell phospholipid SFA content. The hypothesis of 
this study was that insulin sensitivity would improve as a result of a reduction in the 
intake of SFA. This was based on the finding that the fatty acid composition of 
phospholipids influence insulin sensitivity and that a reduction in the SFA content of 
phospholipids would induce positive changes in insulin responsiveness. It would 
appear therefore, that the improvement in insulin sensitivity in this study was related 
firstly to the degree of IR at the outset of the study and secondly to the extent of the 
reduction in the intake of SFA. As with the fish oil study (chapter 3.0) there was no 
association between measures of insulin sensitivity and postprandial lipoprotein 
metabolism in this study.
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CHAPTER 5.0
REPLACEMENT OF SATURATED FAT WITH MONOUNSATURATED FAT 
AND THE EFFECT ON POSTPRANDIAL LIPAEMIA AND INSULIN
SENSITIVITY
5.1 BACKGROUND
Since the 1950s evidence has been growing that Mediterranean countries display rates 
of chronic disease, particularly CHD, that are among the lowest in the world and life 
expectancies that are among the highest (Nestle, 1995). The Mediterranean diet is 
characterised by large intakes of MUFA in the form of olive oil, with correlating low 
intakes of SFA. As discussed in chapter 4.0 dietary recommendations aimed at 
reducing the risk of CHD however, are still heavily dhected towards a decrease in 
total and SFA and an increase in CHO intake. While there is little doubt that there is a 
positive association between the intake of SFA and CHD there is as yet little trial 
evidence to support the notion that decreasing intakes of SFA alone will lead to a 
reduction in CHD (Oliver et al. 1997). As yet only those trials with parallel 
interventions such as reduction of cigarette smoking (Hjermann et al. 1981), or those 
in which the unsaturated components of dietary fat was altered have had an effect on 
the incidence of CHD (Frantz et al. 1989).
A diet rich in CHOs and fibre but low in fat has also been widely recommended for 
those with type II diabetes and impaired glucose tolerance. However, debate exists as 
to whether a high-CHO, low-fat diet is the optimal diet therapy for all subjects with 
type II diabetes. Garg (1998) has recently conducted a meta-analysis of the metabolic 
effects of diets high in MUFA or high in CHOs in the management of diabetes. On 
the basis of the meta-analysis the author concludes that it is clear that compared with 
high-CHO diets, high MUFA diets improve lipoprotein profiles as well as glycaemic 
profiles. Overall it was estimated that high MUFA diets reduce fasting TG and 
VLDL-cholesterol concentrations by 19% and 22% respectively, and cause modest 
increases in HDL-concentrations without adversely affecting LDL-cholesterol 
concentrations. The meta-analysis also revealed a significant net lowering of plasma 
glucose concentrations by 0.23 mmol/1. Fewer studies have looked at the effect of
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high monounsaturated diets in individuals who do not have diabetes but may be 
insulin resistant.
Since obesity is a strong risk factor for CHD, lowering the intake of total and SFA has 
also been promoted on the basis that such dietary measures will lead to a reduction in 
body weight through a decrease in energy intakes. Long -term trials of low-fat diets 
are however discouraging, in that weight loss is generally achieved in the first few 
months of an intervention but typically cease thereafter (Katan, 1997). This is usually 
as a result of poor compliance to this type dietary advice. Also, as discussed by Katan 
(1997) while the emphasis of dietary guidelines on diets low in total rather than just 
SFA rest partly on scientific data, non-scientific issues may also have played a role. 
The author comments that firstly the low-fat concept is simple to communicate and 
secondly a campaign against total fat will receive wider support in society because 
various economic interests are more or less equally affected. However, with intakes of 
fat in the region of 30-40 % of total energy, low-fat diets are considered by many as 
unpalatable and unsustainable in today’s affluent society. Decreasing the intake of 
SFA by increasing the intake of MUFA may be a more acceptable and effective 
dietary change.
5.1.2 STUDY OBJECTIVES
Studies looking at the effect of high MUFA feeding on insulin sensitivity are 
inconclusive with some reporting no effects (Garg et al. 1992b) and others reporting 
an improvement in insulin mediated glucose disposal with consumption of a high- 
MUFA diet (Parillo et al. 1992). Studies have tended to focus on effects in glucose 
intolerant or diabetic subjects. The aim of this intervention was to examine the effect 
of lowering the intake of SFA by increasing the intake of MUFAs in healthy subjects 
with indications of insulin resistance. MUFA intakes were to be increased via 
supplementation of the volunteers’ diets with rapeseed oil. Most studies that analyse 
the effects of dietary MUFA in humans have used olive oil or oleic acid-rich variants 
of sunflower or safflower oil. None of these oils are widely consumed in north­
western Europe or America where there is greater availability of the less expensive 
rapeseed oil (Valsta et al. 1992). In addition, rapeseed oil differs fi*om olive oil in its 
content of the «-3 PUFA, a-linolenic acid: 10-13 % in rapeseed oil versus 0% in olive
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oil (Valsta et al. 1992). This dietary intervention was designed to lower SFA intakes 
to less than 10% of energy and increase MUFA intakes to approximately 18% of 
energy intakes. The metabolic investigations conducted included, measuiement of 
insulin sensitivity using the short insulin tolerance test and measurement of 
postprandial lipaemia following a high fat meal. Compliance was determined from the 
measurement of red blood cell phospholipids. Fasting measuiements of glucose, 
insulin, cholesterol fractions and TG were also analysed. To explore the mechanism 
by which an alteration in dietary fat composition may improve insulin sensitivity, 
LPL activity and gene expression was also measured.
5.2 STUDY DESIGN AND SUBJECTS
5.2.1 EXPERIMENTAL DESIGN
The study consisted of a single dietary intervention with the subject’s pre-intervention 
diets acting as a control phase. Prior to the subjects receiving advice on how to reduce 
their intake of SFA and increase the consumption of MUFA the first set of metabolic 
investigations was conducted. Subjects then adhered to the intervention diet for a 
period of 4 weeks, at the end of which the second set of metabolic investigations was 
conducted. From our previous studies 4 weeks was considered sufficient to detect 
changes in the fatty acid composition of membrane phospholipids following the 
introduction of a fatty acid altered diet. The metabolic studies conducted pre and post­
diet included two study days, the measurement of postprandial lipaemia and insulin 
sensitivity using the short ITT. No stable isotope studies were carried out in this 
study. All subjects had refrained from strenuous exercise and abstained from alcohol 
on the day prior to each investigation. A description of each of the metabolic 
investigations conducted is provided in chapter 2.0, section 2.3.
Fasting blood samples were also collected during the study at week 0 and week 4 of 
the intervention. Samples were analysed for triglyceride, total cholesterol, HDL- 
cholesterol, glucose, insulin and red blood cell phospholipid fatty acids.
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5.2.1.1 Subject numbers and power calculations
As with the fish oil and SFA-CHO exchange trials, the initial intention was to 
establish a cohort of 12 on the basis of feasibility and the short ITT var iability (see 
section 3.2). However, for a variety of reasons it proved difficult to recruit sufficient 
numbers for screening to yield 12 subjects and some who were recruited dropped out 
of the trial at an early stage. For this reason only 9 completed the trial.
5.2.2 SUBJECTS
The Ethics Committee of the University of Surrey, Guildford, approved the study. 
The study days were carried out in the Clinical Investigation Unit in the School of 
Biological Sciences at the University of Surrey. All volunteers provided witnessed 
informed consent before participating in the trial.
Nine healthy male volunteers were recruited to the study fi*om a cohort who were 
identified via advertisements in the local media as well as posters placed with 
companies in the Guildford area. The volunteers had a mean age of 47 (SD 4.8) years 
(range 41-55 years) and a mean body mass index of 28.7 Kg/m^. The subjects were all 
non-smokers with a low level of physical activity and they all habitually consumed at 
least 13% of energy as saturated fat. All of the volunteers were free fi^ om medication 
and did not have any previous medical history of coronary artery, endocrine or liver 
disease. None of the volunteers were following any type of therapeutic or specialised 
diet or taking any form of dietary supplements.
All subjects had a fasting blood sample collected prior to inclusion in the study for 
screening. The criteria for inclusion were glucose <7.0 mmol/1, total cholesterol <7.0 
mmol/1, TG> 1.9 mmol/1, insulin > 40 pmol/1 and haemoglobin> 130g/l. Volunteers 
also had a waist circumference greater than 90 cm. The screening biochemical and 
anthropometric data are shown in table 5.1.
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Table 5.1. Baseline characteristics o f  study volunteers.
Age (years) 47 ± 4.8
BMI (Kg/m^) 28.7 ± 2.8
Waist cfrcumference (cm) 104 ± 7.6
Total plasma cholesterol (mmol/1) 5.67 ± 1.01
LDL cholesterol (mmol/1) 3.70 ± 0.98
HDL cholesterol (mmoFl) 0.82 ±0.11
Triglyceride (mmol/1) 2.55 ± 0.60
Insulin (pmol/1) 103.6 ± 53.0
Glucose (mmol/1) 5.31 ± 0.60
Data presented as means ± Standard deviation (n = 9).
5.3 DIETARY INTERVENTION
Upon entry into the study each volunteer completed a seven-day food record, as used 
in the Epic study, to determine usual dietary intakes of energy and fat (Bingham et al. 
1997). Nutritional analysis was completed using Dietplan 5 for windows (Forestfield 
Software Ltd.). The aim of the study was for volunteers to increase the intake of 
MUFA fi*om an average of 10 to 18 % of energy and reduce the intake of SFA ftom 
16 to less than 10 % of energy.
On the basis of their habitual intakes volunteers were given individual advice on how 
to reduce SFA. SFAs were derived predominantly from dairy products, meats and 
meat products and convenience foods. Volunteers were also asked to increase their 
intake of MUFA by changing to monounsaturated based margarine, using rapeseed oil 
(Goldenfields Ltd.) for cooking and by consuming specially prepared foods which 
were made using rapeseed oil as the source of fat. The fatty acid composition of the 
rapeseed oil is shown in table 5.2. The food items provided were biscuits, cakes, 
breads and pasta sauces. A local catering company, who was supplied with rapeseed
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oil, prepared the foods. The volunteers were asked to incorporate the foods into their 
habitual diet, exchanging them for then usual snacks or as part of their main meals, in 
an attempt to maintain their habitual energy intakes. A ‘unit’ system was devised to 
aid the volunteers in aiming for a daily intake of the MUFA-enriched foods. Each 
food portion was assigned a unit value where one unit was equivalent to 10 g of 
rapeseed oil. Each food item was made using either 10 g or 20 g of rapeseed oil i.e. 
equivalent to 1 or 2 units and volunteers were asked to consume 2-3 units daily on the 
basis of their habitual energy and fat intake. The amount of MUFA-enriched foods 
that volunteers consumed was adjusted throughout the intervention on the basis of the 
volunteers’ weight measurements.
During the study, volunteers’ attended the University of Surrey weekly to meet with 
investigator and to collect foods. This allowed investigator’s to answer any queries, to 
resolve any problems encountered with the study foods and to aid volunteer 
motivation. Weight measurements were also taken at each visit. At week 2 of the 
intervention volunteers were asked to complete a 7-day food record in order to 
monitor compliance and to analyse the nutrient composition of the intervention diet.
Table 5.2 Fatty acid composition o f rapeseed oil
Fatty acid % content
Total SFA 5.6
Total MUFA 68.1
Total PUFA 263
Linoleic acid 15.7
a  - Linolenic acid 10.6
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5.4 ANALYTICAL PROCEDURES
Plasma glucose concentrations, total cholesterol, HDL cholesterol, and triglycerides 
were assayed on a COBAS-MIRA autoanalyser (Roche Products Ltd, Welwyn 
Garden City, Herts) by enzymatic colorimetric methods using commercially available 
kits supplied by Roche Diagnostic Products Ltd (Welwyn Garden City, Herts) and 
Randox Laboratories (Co. Antrim, N.Ireland). LDL-cholesterol concentration was 
estimated using the Friedewald equation (Friedewald, 1972). Plasma NEFA 
concentrations were also measured using the COBAS-MIRA analyser by a standard 
enzymatic colorimetric method (Wako Chemicals, GmbH, Germany supplied by 
Alpha laboratories Ltd., London). Appropriate quality controls with pre-defined 
reference ranges were run with each assay in order to determine intra and inter assay 
variability. The within and between CV’s are outlined in Chapter 2.0 section 2.1. 
Serum insulin levels were measured by radioimmunoassay. Samples from each 
intervention period were analysed together in the same run at the end of the study 
period.
The fatty acid composition of red blood cell phospholipids was determined after the 
extraction of lipids with a mixture of chloroform and methanol (2:1 vol/vol), 
containing 0.01% BHT as antioxidant, according to the Folch method (Folch et al, 
1957). The fatty acids were separated and quantitated using gas chromatography. 
Fatty acids were identified by comparing retention times with those of a known 
standard mixture.
Triglyceride-rich and triglyceride poor fractions of plasma were separated using an 
adapted method of that described by Grundy & Monk (1976). 3.5 ml of plasma was 
overlayered with an equal volume of saline (1.006g NaCl/ml), and ultracentrifuged 
for 5.0 X 10^  g at 24°C in a 10-ml centrifuge tube. The top 1.2 ml of the upper layer, 
the TRL fraction was removed, aliquoted and frozen at -20°C for later analysis. TG 
levels were measured in the TRL fraction using an enzymatic, colorimetric kit 
supplied by Roche Diagnostic Products Ltd (Welwyn Garden City, Herts).
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Lipoprotein lipase activity was measured in 10 p.1 portions of plasma taken 5 and 15 
minutes after the administration of an intravenous dose of heparin. LPL activity was 
measured by a modified method described by Nilsson-Ehle & Schotz (1976).
5.5 STATISTICAL ANALYSIS
For most data tabulated results are presented as mean values and standai'd deviations; 
individual time points on graphs are presented as mean values with their standard 
errors. Statistical analysis was performed using the windows compatible computer 
package, Statistica (version 5, StatSoft Inc.) and the Excel (Microsoft Excel 97) 
computer programme.
The effect of the intervention diet on fasting values was analysed using the student’s t 
test for paned data. The postprandial data was expressed in summary form as an area 
under the postprandial response curve. The areas under the postprandial response 
curves were calculated using the Trapezium rule (Matthews et ah 1990). Differences 
in postprandial metabolism were calculated by comparing areas under the curve pre- 
and post-intervention. Values of P < 0.05 were considered statistically significant.
5.6 RESULTS
5.6.1 DIETARY INTERVENTION DATA
Data for energy and macronutrient intakes are presented in Figure 5.1. There was an 
increase in energy intake as a result of the intervention diet (p = 0.037) although this 
was not reflected in an increase in body weight, which remained stable for the 
duration of the study (91.4 ± 10.4 Kg Vs 91.2 ± 10.4 Kg). The increase in energy 
intake was as a result of an increase in CHO intake from 39.6% to 43.8% of total 
energy intake (p = 0.002). Total fat intakes were unchanged as a result of the 
intervention however the proportion of energy derived from individual fatty acids was 
altered. The aim of the dietary intervention was achieved, in that there was a 
significant decrease in SFA from and average of 15 % to 8.2 % of energy (p = 0.0003)
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and a significant increase in MUFA fi-om 13 % to 18.4 % of energy intake (p = 
0.0026). There was also an increase in the percentage of energy derived fi’om PUFA 
fi-om 6.6 % to 8.8 % of energy (p = 0.022). The intakes of protein were unchanged as 
a result of the low SFA / high MUFA diet.
Baseline diet Intervention diet
c 25.0
Figure 5.1. Nutritional intake measured during the habitual and intervention diet. 
Data are means of 9 subjects ± SE.
Significance of difference following the intervention diet * p < 0.05,
**p< 0.001.
5.6.2 RED BLOOD CELL PHOSPHOLIPID DATA
Table 5.3. shows the results of the red blood cell phospholipid data. There was no 
difference in the levels of any of the major fatty acids as a result of the dietary 
intervention. Therefore the change in the composition of fat intakes to a decrease in 
SFA and an increase in MUFA was not reflected in a change in red blood cell 
phospholipids.
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Table 5.3. Levels o f fatty acids in red blood cell phospholipids measured prior to 
and at the end o f the MUFA enriched diet.
Fatty acid (% area) Habitual diet MUFA-enriched diet F value
Saturated 46.7 ± 8.8 44.8 + 7.3 NS
Monounsaturated 23.5 + 3.9 28.9 ± 8.5 NS
Polyunsaturated 28.8 ± 11.5 25.1 + 5.7 NS
Total n-6 fatty acids 22.5 ± 7.6 19.8 ± 5.9 NS
Total n-3 fatty acids 3.9 ± 4.6 2.9 ± 1.4 NS
Arachidonic acid 9.0 ± 5.7 8.3 + 4.6 NS
Values are expressed as the percentage of the total area of all fatty acids measured and 
are presented as means of 11 subjects ± SD.
NS ~ non significant.
5.6.3 FASTING BIOCHEMICAL DATA
The fasting plasma concentrations of lipids, glucose and insulin are presented in table 
5.4. As a result of the low SFA / high MUFA diet there was a significant reduction in 
the fasting levels of TG and cholesterol. There was a 13 % reduction in LDL- 
cholesterol levels although this did not reach a level of significance. There was no 
change in HDL-cholesterol levels. The ratio of total cholesterol to HDL cholesterol j
was lowered following the intervention diet although again this did not reach a level i
of significance. No alterations in fasting NEFA, glucose or insulin measurements '
were observed as a result of the consumption of the MUFA-enriched diet.
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Table 5.4. Fasting concentrations o f plasma lipids (mmol/l), glucose (mmol/l) and
insulin (pmol/l) measured during the habitual diet and at the end o f the 
intervention diet.
Biochemical
Measurement
Habitual diet Intervention diet P value
Triglyceride 2.43 ± 0.87 2.06 ± 0.53 0.021*
Cholesterol 5.42 ± 1.27 4.81 ± 0.97 0.03*
HDL-Cholesterol 0.76 ± 0.08 0.77 ± 0.10 NS
LDL-Cholesterol 3.55 ± 1.45 3.10 ± 1.04 NS
CHOLrHDL ratio 7.1 ± 1.4 6.2 ± 0.86 NS
NEFA 0.28 ±0.11 0.29 ± 0.10 NS
Glucose 5.24 ± 0.67 5.19 ± 0.42 NS
Insulin 110.87 ± 69.78 100.76 ± 63.33 NS
Data are presented as means ± SD.
Significance of difference pre and post intervention * p < 0.05. NS = non-significant.
5.6.4 POSTPRANDIAL DATA
Postprandial TG data are presented in figure 5.2. There was a significant reduction in 
the TG response, measured by the total area under the curve, from 2088.5 (SD 565.9) 
mmol/lmin during the habitual diet to 1726.6 (SD 485.2) mmol/l.min following the 
low SFA / high MUFA diet (p = 0.013). There was also a significant attenuation in 
the 6-9 hour TG profile, measured by the 6-9 hour ai*ea under the curve as a result of 
the low SFA / high MUFA intervention diet (p = 0.018). Taking account of the fasting 
TG values there was no difference in the incremental area under the curve during the 
habitual diet and the intervention diet (p = 0.162). No significant differences were 
observed in the peak TG and the time to peak over the 9-hour study between the pre­
intervention and the post-intervention diet.
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Fig 5.2. Postprandial Triglyceride response following the test meal (80-g fat) 
during the habitual diet and following the low SFA / high MUFA diet. 
Data are presented as means of 9 subjects ± SE,
Figure 5.3. shows the postprandial TRL TG profile prior to and at the end of the 
intervention diet. There was no significant change in the clearance of TRL TG 
following the low SFA / high MUFA diet compared to the subjects habitual diet.
Concentrations of apo B-48 were attenuated following the low SFA / high MUFA 
intervention diet (p = 0.0001) as measured by the total AUC and shown in fig 5.4. The 
incremental AUC was also lower as a result of the intervention diet (p = 0.0059). 
There was also a significant variation in apo B-48 concentrations during the late 
postprandial phase (6-9 hour) with a reduced response following the low SFA / high 
MUFA diet (p = 0.0008).
Figure 5.5. shows the postprandial NEFA profile. As expected there was an inhibition 
of NEFA release directly after the consumption of the test meal with NEFA levels 
gradually increasing to a level almost twice that above baseline at the end of the 9- 
hour study. There was no change in the total area under the NEFA curve following the 
low SFA / high MUFA diet.
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Fig 5.3. Postprandial TRL TG response following the test meal (80-g fat)
during the habitual diet and following the low SFA / high MUFA diet.
Data are presented as means of 9 subjects ± SE.
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Fig 5.4. Concentrations of apo B-48, measured in individual subjects prior to 
and at the end of the intervention diet, following the test meal (80-g 
fat).
Subjects are ranked in order of decreasing apo B-48 AUC on the 
control diet.
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Figure 5.5. Postprandial NEFA concentrations following the test meal (80g fat) 
measured prior to and at the end of the low SFA / high MUFA diet. 
Data are presented as means ± SE.
Fig 5.6. shows the glucose and insulin levels following the test meal. They follow an 
expected contour with glucose rising following ingestion of the test meal and insulin 
released in response to the rise in glucose. There was no change in overall glucose and 
insulin concentrations as measured by the total area under the curve over the 9-hour 
study period. Two hours following the consumption of the test meal, the concentration 
of insulin was lower following the low SFA / high MUFA diet (p = 0.039). The 
reduction in insulin at this time point was not reflected in a reduction in glucose 
concentration at the same time point.
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Figure 5.6. Plasma glucose and insulin levels following the test meal (80g fat) 
measured prior to and at the end of the low SFA / high MUFA diet. 
Data are presented as means ± SE.
5.6.5 POST-HEPARIN LPL ACTIVITY DATA
Plasma levels of LPL activity in individual subjects, measured 5 and 15 minutes 
following the administration of heparin are shown in figs 5.7. and 5.8. respectively. 
There was a wide range of LPL activity among the study group, ranging from 0.62 to 
13.22 umol.oleate.ml.hr measured at the 15-minute time point during the habitual diet. 
At the 5 minute measurement there was a significant increase in LPL activity in the 
group overall from 3.39 (S D  3.49) umol.oleate.ml.hr during the habitual diet to 5.46 
(S D  3.62) umol.oleate.ml.hr following the low SFA / high MUFA diet (p = 0.03) as 
shown in fig 5.9. The increase in LPL activity was not sustained through to the 15- 
minute measurement and there was no change in LPL activity in the group overall at 
the 15-minute time point as a result of the low SFA / high MUFA diet. Despite 
repeated analysis, two subjects had a greater level of hepatic lipase than total lipase
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activity, resulting in negative levels using the method of measuring LPL activity 
employed in this study.
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Figure 5.7. LPL plasma activity levels in individual subjects, 5 minutes after 
heparin administration.
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Figure 5.8. Plasma LPL activity in individual subjects 15 minutes, following the 
administration of heparin.
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Figure 5.9. Mean LPL activity in 9 subjects, 5 minutes following the 
administration of heparin. The vertical bars represent standard error 
bars.
5.6.6 INSULIN TOLERANCE DA TA
Figure 5.10. shows the fall in blood glucose concentration over 15 minutes following 
the administration of a bolus dose of insulin (O.IU / Kg of body weight) on both the 
habitual diet and the intervention diet. Insulin sensitivity was calculated from the 
slope of the fall in log-transformed glucose between 4 and 15 minutes following 
insulin administration and the range of insulin sensitivity measured in the study group 
is show in figure 5.11. There was a wide range of insulin sensitivity among the study 
group with glucose Kitt varying from 2.8 (%/min ‘‘) to 5.33 (%/min'') during the 
habitual diet. It was observed that there was no alteration in insulin sensitivity as 
measured by the short insulin tolerance test following the low SFA / high MUFA diet 
in the group overall.
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Figure 5.10. Mean plasma glucose concentrations following the administration of a 
bolus dose of insulin (O.lU/Kg), measured during the habitual diet and 
following the low SFA / high MUFA diet.
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Figure 5.11. Kitt measurements in individual subjects during the habitual diet and 
following the low SFA / high MUFA diet. Subjects are ranked in order 
of increasing insulin sensitivity measured during the habitual diet.
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The fractional rate of fall in plasma NEFA levels between 4 and 15 minutes following 
insulin administration served as a measure of insulin mediated inhibition of hormone 
sensitive lipase. The fall in NEFA concentrations following the administration of 
insulin is shown in figure 5.12. There was an acceleration in the rate at which plasma 
NEFA levels fell following insulin administration as a result of the low SFA / high 
MUFA diet as shown in fig 5.13. although this did not reach a level of statistical 
significance (p = 0.068).
Figure 5.14. shows the lack of association between changes in postprandial lipaemia 
and changes in insulin sensitivity measured by the glucose Kur as a result of the low 
SFA / high MUFA diet.
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2 H*— Habitual dietÜ 0.20 
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Figure 5.12. Mean plasma NEFA levels measured over 15 minutes following the 
administration of a bolus dose of insulin (O.IU / Kg).
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Figure 5.13. Change in mean calculated NEFA Km following the low SFA / high 
MUFA diet.
Data are presented as the mean of 9 subjects ± SE.
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Figure 5.14. The relationship between changes in postprandial lipaemia and 
changes in insulin sensitivity following the low SFA / high MUFA diet 
(r = 0.563, p = 0.114).
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5.7 DISCUSSION
This study is novel in its use of rapeseed oil enriched foods as a means of increasing 
the MUFA content of subjects’ diets. Analysis of the food records showed that the 
volunteers were successful in reducing the intake of SFAs to less than 10 % of energy 
and increasing the intake of MUFAs to 18 % of energy intake. Substitution of dietary 
SFAs with MUFAs resulted in a 11 % decrease in total cholesterol and a 15.4 % 
reduction in the levels of TG. Body weight was unaffected by the dietary intervention 
indicating that the subjects were successful in adapting their habitual energy intakes. 
The dietary intervention was well tolerated by the subjects and suggests that as a 
dietary strategy this may be more acceptable than the low-fat, high-CHO diet 
currently recommended in most national and international nutritional guidelines. 
However, red blood cell phospholipid measurement pre- and post-intervention did not 
reflect the change in the intake of dietary fatty acids.
The purpose of the study was to evaluate the effects of MUFAs on plasma lipoprotein 
levels and insulin sensitivity. The data confirm that MUFA substitution for SFA is an 
effective dietary approach for reducing plasma cholesterol and TG concentrations. 
The 13 % reduction in LDL-cholesterol did not reach a level of significance and 
differs from other studies which have shown convincing reductions in plasma LDL- 
cholesterol levels following a high MUFA enriched diet (Vasta et al. 1992; Roche et 
al. 1998). Plasma HDL-cholesterol concentration was unaffected by the diet. Levels 
of fasting and postprandial NEFA were also imchanged as a result of the low-SFA / 
high-MUFA diet. It is widely accepted that MUFA, and especially oleic acid when 
substituted for SFA, decrease total cholesterol levels. The habitual high SFA intakes 
of the subjects was halved during the intervention diet and is thought to have induced 
the fall in plasma cholesterol levels. This is supported by the findings of other studies, 
which have shown that substitution of SFA with MUFA results in cholesterol 
lowering whereas, supplementation of diets with MUFA alone has not procured a 
lowering of cholesterol concentrations (Vicario et al. 1998). While the aim of this 
intervention was to maintain habitual energy intake and weight interestingly 
Gumbiner et al. (1998) reported that weight loss therapy can more effectively 
ameliorate cardiovascular risk in obese type II diabetes patients if MUFAs are 
incorporated into a hypocaloric diet. It would appear therefore, that increasing the
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MUFA content of diets’ has favourable effects on lipoprotein response in conditions 
of both low fat and high fat feeding.
Alongside the reduction in fasting TG levels this study also showed a significant 
decrease in postprandial TG concentrations. The TG attenuation was more 
pronounced during the late postprandial phase i.e. 6-9 hours following the high fat 
meal. This study was of relatively short duration however, the effect of long term 
ingestion of MUFAs on postprandial lipaemia was highlighted in a study by Zampelas 
et ah (1998) who showed a more advantageous postprandial pattern in response to a 
high fat meal in Southern Europeans compared with Northern Europeans. Blades & 
Garg (1995) investigated the mechanisms of TG lowering with high MUFA diets in 
subjects with type II diabetes and reported that TG lowering was due to reduced 
hepatic production of VLDL TG and not due to increased lipolysis or greater 
postprandial clearance of TRL. In this study levels of TRL-TG were unchanged as a 
result of the high MUFA intervention diet. The reduction in TG levels during the late 
postprandial phase was therefore not due to a greater clearance of postprandial TRL. 
However, the concentration of apo B-48 within the TRL fraction was significantly 
attenuated following the high MLTFA diet. This would suggest that the reduction in 
TG was due to a decrease in the secretion rate of intestinally derived chylomicrons. 
This is in contrast to the outcomes reported by Roche et al. (1998) who found an 
increase in levels of apo B-48 following 8 weeks of a low SFA / high MUFA diet 
using olive oil as the source of MUFA. Other studies have reported reductions in apo 
B levels following high MUFA feeding although they have not looked specifically at 
apo B-48 content (Valsta et al. 1992; Becker et al. 1983). A greater number of studies 
are required to learn more about the effects of high MUFA feeding on apo B-48 
concentration.
Measurement of LPL activity was conducted to provide insight into the possible 
mechanisms for the TG lowering observed with the high MUFA feeding in this study. 
Few studies have examined the effects of a greater MUFA intake on plasma LPL 
activity. A study by Williams et al. (1999) failed to show any effect on plasma LPL 
activity with high MUFA feeding, however TG levels were also unchanged following 
their intervention diet. In the present study there was a suggestion of an increase in 
LPL activity following the high MUFA diet through a significant increase in the 5-
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minute measurement however this was not sustained through to the 15-minute 
measurement. There is no direct evidence therefore that the reduction in fasting and 
postprandial TG observed in the present study was due to an increase in the rate of 
lipo lysis, mediated through an increase in plasma LPL activity.
There was no effect of the MUFA enriched diet on glucose or insulin concentrations 
measured in the fasting state. Two hours after the consumption of the high fat meal 
there was a significant reduction in insulin levels following the low SFA / high 
MUFA intervention diet. This was not matched by a significant reduction in plasma 
glucose levels at the 2-hour time point. Studies in those with type II diabetes have 
reported lower 2-hour postprandial plasma glucose concentrations with consumption 
of a high MUFA diet compared with a high CHO diet (Parillo et al. 1992; Parillo et 
al. 1996). Sarkinen et al. (1996) have also observed improvements in glucose 
tolerance in glucose-impaired subjects following a high MUFA diet. A similar finding 
has been reported in subjects of normal glucose tolerance (Pelikanova et al. 1989; 
Uusitupa et al. 1994) as well as in those with type II diabetes (Parillo et al. 1992). 
Garg (1998) reported a significant net lowering of fasting plasma glucose 
concentrations by 0.23 mmoFl with consumption of a high MUFA diet in a meta­
analysis of studies centred on subjects with diabetes. He found no change in plasma 
insulin levels. Few studies have measured insulin sensitivity directly and related this 
to changes in the intake of MUFA. Studies in diabetics have in some cases reported 
improvements in insulin mediated glucose disposal with consumption of a high 
MUFA diet (Parillo et al. 1992). In this study there was no observed effect on insulin 
sensitivity following the MUFA enriched diet. The MUFA enriched diet was not 
associated with an increase in the unsaturated component of red blood cell 
phospholipids, which may have accounted for the lack of hnprovement in insulin 
action. In common with the previous dietary intervention studies discussed in chapter
4.0 & chapter 5.0 there was no association between measures of insulin sensitivity 
and lipoprotein metabolism both before and following the intervention diet. Further 
studies however, are needed to confirm whether high MUFA diets can improve 
insulin sensitivity.
In conclusion this study, albeit short-term and of limited power has shown a clear 
benefit of substituting MUFA for SFA in the diets of overweight middle-aged men.
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Fasting and postprandial lipid levels were improved as a result of 4 weeks feeding 
with a rapeseed oil-enriched diet. There was a significant reduction in the intake of 
SFA and the study confirms that this the replacement of SFA for MUFA is a more 
favourable alternative to the strategy of replacing SFA for CHO recommended by 
most Western countries. The study is novel in it’s approach of using rapeseed oil 
enriched foods as a means of increasing the MUFA component of diets. The study has 
proved that it is possible to increase MUFA intake to levels comparable to that 
consumed in Mediterranean countries using foods commonly consumed in this 
country. The findings of the study could provide valuable information to the food 
industry keen to promote the ‘health benefits’ of particular foods. This study was 
conducted in a small group of individuals and for a relatively short duration. A greater 
number of studies, of greater duration are needed to confirm the long-term effects of 
consuming a rapeseed oil-enriched diet. Further work is also needed to examine the 
effect on insulin sensitivity and also to explore the associated mechanisms between 
postprandial lipid metabolism and insulin sensitivity.
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CHAPTER 6.0
MEASUREMENT OF LPL GENE EXPRESSION USING A 
COMPETITIVE RT-PCR METHOD
6.1 BACKGROUND
The polymerase chain reaction (PCR), originally described by Saiki et al. (1985), has 
developed from a highly specialised research tool into a routine procedure, which is 
now widely employed in many laboratories. In essence, PCR is a powerful copying 
system, which is used to target a specific nucleotide sequence within a sample of 
tissue and then produce millions of identical copies of this sequence. These copies 
provide ample nucleic material for fijrther analysis, or can be used simply to confh'm 
the presence of the target sequence in the sample. Deoxyribonucleic acid (DNA), 
extracted from a specimen e.g. blood or a sample of tissue, is the usual template in 
PCR. RNA can also be examined following reverse transcription by employing a 
reverse transcriptase enzyme. Reverse transcriptase PCR (RT-PCR) therefore, 
involves an initial reverse transcription step in order to produce a complimentary 
DNA (cDNA) copy of the original RNA under investigation. This technique can be 
used to detect or quantify the presence of specific messenger RNA (mRNA).
The key components of PCR are the oligonucleotide primers. For a standard PCR 
there are usually two primers. One primer matches one strand of the target DNA and 
the second primer matches the complementary strand. The 5’ ends of the primers 
mark the boundaries of the DNA sequence to be investigated therefore primers are 
sometimes labelled to as up-stream primer and down-stream primers. Primers can be 
designed against a specific target DNA of known sequence or they can be designed in 
order to amplify unknown sequences. The PCR procedure entails adding small 
amounts of extracted DNA/RNA to a reaction mixture containing a buffer solution, 
carefully optimised levels of ions (especially magnesium), single nucleotide bases and 
primers. If RT-PCR is being conducted a reverse transcription step is included to 
produce a double stranded cDNA sequence, otherwise only a DNA polymerase 
enzyme is added. PCR amplification is then achieved by repeated cycles of heating 
(denaturing), cooling (annealing) and extension using either a solid temperature 
cycling block or less often using a water bath. The components of the RT-PCR
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reaction are described in fig 6.1. Following the transcription of RNA to cDNA, the 
temperature is raised to 95°C, allowing the double-stranded template cDNA to 
denature into two single strands. This is followed by cooling to around 50-55°C 
which facilitates annealing of the primers to the appropriate cDNA strands. Finally, 
heating to 68-72°C allows the extension of a complementary strand of cDNA along 
each strand of substrate DNA in the 5'-to-3' dhection. The temperature then reverts to 
95 °C and the cycle is repeated. There is an exponential increase in cDNA and after n 
cycles there are theoretically 2" copies of the sequence being amplified. However, in 
practice only the first 20 or so cycles result in exponential increase of product.
Competitive PCR and competitive RT-PCR is used to obtain the most precise 
quantitation of DNA and RNA. This assay is based on competitive co-amplification 
of a specific target template (of unknown concentration), together with known 
concentrations of an internal standard in one reaction tube. The internal standard has 
to share recognition sites with the target template. The target template and internal 
standard must be amplified with the same efficiency and separate analysis of the PCR 
products of both should be possible. Quantitation is then performed by comparing the 
PCR signal of the target template with the PCR signals obtained with the known 
concentrations of the internal standard. Several dilutions of standards are used to 
quantify the target DNA. The PCR signal or relative amount of target DNA to the 
internal standard can be measured by densitometric analysis. The easiest way to 
distmguish between the target template and internal standards is by differences in the 
size of the two products. This can be achieved, for example, by constructing standards 
having the same sequence as the specific target but containing a deletion or insertion. 
The construction of suitable standards is extremely important, as this will determine 
the accuracy of the measurement of the target template. It is also essential that the 
concentration of the internal standard is deteraiined accurately.
PCR is hampered by a number of variations that can occur during sample preparation 
or in the course of the reaction, and minor variations in the reaction conditions aie 
greatly magnified during the amplification process. Such variability may be partly 
overcome by relating the amount of PCR products of the target template to an internal 
reference template (‘ housekeeping’ gene) such as the cellular gene p-globulin.
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Figure 6.1. Schematic of the reverse-transcription polymerase chain reaction.
Single stranded RNA is reversed transcribed to cDNA, which is then 
denatured. Primers anneal to their complementary sequences in the 
target DNA and extend. The process is repeated for each cycle of PCR. 
PI = primer 1, P2 = primer 2.
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The PCR technique is of interest in Human Nutrition because it can be employed to 
investigate the effect of nutrients at the level of gene expression. The technology can 
potentially provide us with more information as to the mechanisms involved in, for 
example, improvements in lipoprotein metabolism following changes in dietary fat 
intakes. Various genes play a role in lipoprotein metabolism, one of which is the LPL 
gene. As previously described LPL is an enzyme produced predominantly by adipose 
tissue and muscle and is a central enzyme in TRL metabolism. Although there is only 
one gene for LPL, there are important differences between adipose tissue and muscle 
LPL gene expression (Ranganathan et al. 1994). The regulation of LPL in different 
tissues is due to nutritional as well as hormonal influences. LPL gene expression has 
been measured in a number of studies in both animals and humans, however the effect 
of changes in nutrient intakes in relation to LPL gene expression has been relatively 
under-explored. In a study by Murphy et al.{\993>) male rats who were fed a diet 
enriched with fish oil were shown to have a greater amount of LPL mRNA in 
epididymal adipose tissue compared with maize-oil fed rats. In an extension of that 
work to human studies Murphy and colleagues examined the effects of the 
consumption of fish oils on the expression of LPL (Murphy et al. 1999). They found 
no significant difference in the levels of LPL expression following an «-3 PUFA 
enriched diet, however changes in LPL expression were significantly correlated with 
changes in TG concentrations as a result of the intervention. As yet no such similar 
studies have been reported in the literature. Studies involving dietary «-3 PUFA are of 
interest because of their effect on TG metabolism. However, no studies have to date 
explored the effect of other dietary fat components such as SFA and MUFA on 
adipose tissue LPL gene expression.
In this laboratory a competitive RT-PCR method had been developed by Brooks 
(1998) in order to facilitate the measurement of LPL mRNA from samples of human 
adipose tissue. That method was subsequently employed in this study to measure the 
effect of the dietary interventions described in chapters 3.0, 4.0 and 5.0 on the 
expression of LPL mRNA within adipose tissue samples, obtained by needle biopsy 
fi’om the human subjects. The aim of this work therefore was to examine the effect of 
changes in SFA, MUFA and PUFA intakes on the expression of LPL within 
subcutaneous adipose tissue using a competitive RT-PCR method.
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6.2 METHODS
6.2.1 RNA EXTRACTION
6.2.1.1 Total RNA extraction from fresh human adipose tissue
Adipose tissue samples from the fish oil study (chapter 3.0) were extracted at the time 
of biopsy described in section 2.2.9 using a technique based on a method reported by 
Chomczynski & Sacchi (1987). All solutions and pipette tips were autoclaved before 
use and all glassware was baked at 180°C for at least 12 hours to destroy RNases. The 
denaturing and phenolic solutions used in the extraction procedure were autoclaved 
before use.
The denaturing solution was prepared by dissolving 50 g of Guanidine isothyocyanate 
(GTC) in 63.4 ml of DEPC water and 3.52 ml of 0.75 M sodium citrate (pH 7.0) to 
which 528 pi of Sarkosyl had been added (10 % v/v). The reagents were mixed and 
held at 65°C to completely dissolve the GTC.
The required amount of phenolic solution was prepared by combining Chloroform : 
Isoamyl alcohol (24:1) ,2 M Sodium acetate (pH 4.0) and Phenol in the ratio of 1:2:10 
respectively.
Immediately upon extraction as described in section 2.2.9 the human adipose tissue 
was placed into a falcon tube containing 3 ml of denaturing solution and 21.6 pi of (3- 
mercaptoethano 1. 3.9 ml of pre-chilled phenolic solution was added. The tube was 
shaken vigorously for 10 seconds in order to ensure that the tissue was completely 
disrupted.
The tubes were kept on ice for 30 minutes before centrifriging in a Camlab 
refrigerated high-speed centrifuge (model number 4239R) at 6595 x g for 20 min at 
4°C. Following centrifugation, the aqueous top layer containing the RNA, was 
transferred into a sterile falcon tube and an equal volume of isopropanol added. The 
tubes were stored at -20°C overnight to precipitate the RNA.
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The following day the tubes were re-centrifuged at 6595 x g for 20 min at 4°C and the 
alcohol was poured off. The remaining pellet was dissolved in 300 pi of the 
denaturing solution and transferred to a sterile 1 ml eppendorf tube. 600 pi of ethanol 
was added and the tubes stored at ~20°C for one hour.
The tubes were centrifiiged in a microcentrifuge at 4135 x g for 20 minutes at room 
temperature and the supernatant discarded. The RNA-containing pellet was washed 
with 50 pi of 75% (v/v) ethanol and centrifuged as before in the microcentrifuge. The 
ethanol was removed and the tubes left to air-dry on a clean surface for 5 minutes. 
The RNA pellet was re-suspended in 50 pi of 0.5% (w/v) sodium lauryl sulphate 
(SDS) and stored at -80^C until required for analysis.
6.2.1.2 Preparation o f human frozen tissue for RNA extraction
Adipose tissue samples, not extracted at the time of collection, and stored in plastic 
tubes at -80°C were placed in liquid nitrogen immediately prior to the extraction 
procedure. Tissues samples collected by needle biopsy contained a mixture of blood 
and lignocaine, making it difficult to obtain an accurate weight of adipose tissue. 
Attempts to weigh the recommended amount of tissue (50-100 mg) led to 
unsuccessful RNA extraction’s as the actual amount of adipose tissue may have been
too little to obtain the required amount of RNA. Therefore, an unweighed amount of
material, amounting to approximately half the contents of the tube (approx. 250 mg) 
was removed using a spatula in order to ensure that a sufficient amount of adipose 
tissue was obtained. Standardisation of the tissue weight used for RNA extraction 
was therefore not possible.
6.2.1.3 Total RNA Extraction procedure for Frozen Human Adipose Tissue.
RNA was extracted from frozen adipose tissue collected during the SFA study as 
described in section 2.2.9 using the RNAgents® Total RNA Isolation System, 
(Promega Ltd, UK). The system contains:-
♦ 120 ml Denaturing solution
- 26mM sodium citrate, pH 4.0
- 0.5% N-lauryl sacrosine
182
- 0.125M P-mercaptoethanol
- 4M guanidine thiocyanate
♦ 10 ml 2M Sodium Acetate, pH 4.0
♦ 100 ml Phenol:Chloroform:Isoamyl Alcohol (125:24:1), pH 4.7
♦ 100 ml Isopropanol
♦ 25 ml Nucleus free water
600 pi of denaturing solution was dispensed into a pre-baked glass homogeniser tube 
and chilled on ice for 5 minutes. The tube containing the tissue sample was removed 
from the liquid nitrogen and a section of material placed into the denaturing solution 
using a pre-baked-cooled spatula. The tissue was then disrupted using a glass 
homogeniser, ensuring that no clumps of tissue were visible.
60 pi of 2M Sodium Acetate, pH4.0 was added and mixed thoroughly by inverting the 
tube 4-5 times. 600 pi of pheno 1:chloroform:isoamyl alcohol was added care having 
been taken to remove only from the lower organic phase of the bottle. The tube was 
capped, and carefully mixed by inverting 3-5 times and then shaken vigorously for 10 
seconds. The samples were chilled on ice for 15 minutes and centrifuged at 2065 x g 
for 20 minutes at 4°C using a refrigerated bench top centrifiige.
The top aqueous phase containing the RNA was carefully removed and transferred to 
an autoclaved plastic eppendorf tube. As DNA and proteins remain in the organic 
phase and at the interface care was taken to avoid taking material from this area. An 
equal volume of isopropanol was added to the aqueous phase and the sample was 
incubated at -20°C overnight to precipitate the RNA.
The next day the sample was removed from the freezer and the RNA pelleted by 
centrifuging at 2065 x g for 10 minutes at 4°C. The pellet formed was washed using 1 
ml of ice-cold 75% ethanol (95% or 100% ethanol diluted to 75% with DEPC-treated 
water). The sample was then centrifiiged again at 2065 x g for 10 minutes at 4°C.
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The pellet was air-dried in an RNase-free environment for 5 minutes. Care was taken 
not dry the pellet completely as desiccated RNA is extremely difficult to re-suspend. 
The RNA isolated was dissolved in 250pl of nucleas-free water and stored at -20°C.
6.2.1.4 Measurement o f concentration and A260/A280 ratio o f total RNA isolated.
Pure RNA exhibits an A260/A280 ratio of 2.0. However, due to variations between 
individual starting materials and in perfoiming the procedure, the range of RNA by 
A260/A280 ratio was expected to be 1.7-2.0.
Total RNA concentration was measured by absorption at 260nm using a Gene Quant 
II micro spectrophotometer (Pharmacia Biotech, St Albans, UK). A 70 pi cell was 
used to measure samples and the background reading of the spectrophotometer was 
set with nucleas-free water. To measure RNA the dilution factor was set at 2 (35 pi of 
nucleas free water and 35 pi of sample). The cell was inserted and removed when 
indicated and the concentration, ratio and absorbance of each sample read and 
recorded. Yields of total RNA from the adipose tissue biopsies ranged from 38.6 
ng/pl. The absorption ratio (260:280) was between 1.79 and 2.0 for all preparations.
6.2.2 GENERAL RT-PCR METHOD AND CONDITIONS
Adipose tissue RNA samples were amplified in an Omn-E thermal cycler (Hybaid, 
Middlesex, UK ) using the Access RT-PCR System kit (Promega Ltd,UK). The kit is 
designed for the reverse transcription and PCR amplification of a specific target RNA 
from either total RNA or mRNA. The system uses AMV Reverse Transcriptase 
(AMV RT) from Avian Myeloblastosis Virus for first strand cDNA synthesis, and the 
thermostable Tfl DNA Polymerase from Thermus Flavus for second strand cDNA 
synthesis and DNA amplification.
Working on ice, the reaction mixture, labelled as a mastermix, was prepared by 
combining the components of the kit in the following ratio.
Nucleas-Free Water xpl (to a final volume of 49pl)
AMVITfl 5x Reaction Buffer 1 Opl
dNTP mix 1 pi
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downstream primer 
upstream primer 
25mM MgS04 
AMV Reverse Transcriptase 
Tfl DNA Polymerase
1 pi (SOpmol)
Ipl (50pmol)
2pl
lul
iHl
RNA sample xpl (volume equivalent to 100 ng/pl)
The components were mixed by vortexing gently for 10 seconds and 49pl of 
mastermix was transferred into each of 7 thermocycler tubes.
Ipl of standard was added to each reaction tube (in a separate area to PCR set-up 
area) to cover a range of concentrations i.e. 10-fold , 5-fold or 2-fold dilution of 
standard concentration. The tubes were then transferred to a Hybaid Omn-E thermal 
cycler and cDNA synthesis amplified under the conditions shown in fig 6.2.
Reverse transcription step
V
48°C -  45 min 1 cycle
94°C -  1 min
Amplification step
V94°C -  30 seconds (denaturing)
62°C -  1 min (annealing) 27-35 cycles
68°C -  2 min (extension)
Figure 6.2. Conditions of PCR amplification.
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6.2.2.1. PCR primers
The primers described by Laville et al. (1996) were supplied by Gibco BRL custom 
primers, Life Technologies Ltd. The primers used to amplify the LPL and P2- 
microglobulin (p2-pglob) target genes as well as standards are listed below.
♦ LPL Upstream oligonucleotide primer (CBLPLU).
5' CACTGGGTAATGCTCCTGAG 3'
♦ LPL downstream oligonucleotide primer (CBLPLD). Sequence 5' to 3'.
5' ACACAGCTGAGGACACTTGC 3'
♦ P2-pglob upstream oligonucleotide primer (CBGLOBU).
5' GATGCTGCTTACATGTCTCG 3'
♦ P2-pglob downstream oligonucleotide primer (CBGLOBU).
5' CCAGCAGAGAATGGAAAGTC 3'
6.2.2.2 Internal Standards
The internal standard for LPL and P2-pglob was prepared by another investigator as 
described in Murphy et al. (1999). Briefly a vector (containing the multispecific 
internal standard) was cloned in E-Coli, cultured in LB-media and ampicillin and the 
resulting culture extracted using the Wizard Plus SV Minipreps DNA Purification 
System (Promega, Southampton, UK). The concentration of the synthetic RNA 
standard was measured spectophotmetrically by absorbance at 260 nm. The size of the 
standard was confirmed by running the RNA on an agarose gel (1.8 % w/v) alongside 
a known marker.
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6.2.3 SEPARATION AND ANALYSIS OF PCR PRODUCTS 
6.2.3.IAsarose 2 elpreparation and sel electrophoresis
RT-PCR reaction products were visualised using ethidium bromide stained agarose 
gels. In this work 3% (w/v) agarose gels were used. The materials used in the 
preparation and running of gels aie outlined below.
1 X Tris acetate (TAE) buffer
Trizma base 48.4 g
0.5MEDTA,PH8.0 20 ml
Glacial Acetic Acid 11.42 ml
Made up to 10 litres with distilled water. PH adjusted to 8.3.
Orange G loading dye
Orange G dye 0.02 g
Formamide 10 ml
0.5M EDTA, PH 8.0 200 pi
Mixed and stored at room temperature m a foil-covered container. 3 pi of Orange G 
loading dye per 15 pi of sample was used for gel electrophoresis.
1 Kb DNA ladder mixture
1 Kb DNA ladder (1 pg/pl) 10 pi 
Nucleas-free water 90 pi
Orange G loading dye 30 pi
The agarose gel was made by adding the appropriate amount of agarose to 100 ml of 1 
X TAE buffer and heating in a microwave for 3-4 minutes until completely dissolved. 
The molten agarose was left to cool slightly before adding 3 pi of ethidium bromide 
(10 mg/ml), swirling to mix. The agarose was cooled to a hand-hot temperature and
poured into a gel mould. The gel was allowed to set at room temperature, wrapped in
Clingfilm, and stored at 4°C until required for use.
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When PCR products were to be loaded the gel cast was inserted into an 
electrophoresis gel tank and over-layered with TAE buffer. 15 pi of each amplified 
PCR product was mixed with 3 pi of the orange G loading dye and loaded using a 
finpipette. A 1 Kb DNA ladder was run in an adjacent lane to confirm the size of the 
PCR product.. The tank was filled with sufficient TAE buffer and gel was run at a 
constant current of lOOmV over a period of 2-3 hours.
6.23.2 Quantification o f PCR products
The agarose gels were visualised under UV light and a positive and negative 
photograph (665 film; Polaroid) of the gel was obtained. An example of a typical 
photograph obtained following competitive RT-PCR is shown in figure 6.3. The 
density of the standard and target template was measured on the negative film using a 
dual-wave length, flying spot scanner (Shimadzu Europa GMBH, Duisberg, 
Germany). To determine the point of equivalence (the point at which the density of 
the target and internal standard products were equal), the log of the ratio of the 
internal standard to the target template was plotted against the log of the internal 
standard concentration. Figure 6.4 shows that the resultant curve was rectilinear with 
a slope of one demonstrating that the internal standard was amplified with the same 
efficiency as the target mRNA. The point of equivalence lies at log (standard/target) = 
0 .
Figure 6.3. Example of LPL and p2-pglob standard and target products visualised 
under UV following the PCR reaction.
188
1
I  ^
M
3  gr
?
y = -0.9207X + 5.9039 
R2 = 0.9856
1.4 
1.2 4 
1 
0.8 
0.6 
0.4 
0.2
_4..g0p+00 4.50E+00 5.00E+00 5.50E+00 6.00E+00 6. 
-0.4
- 0.6
7.00E+00
L og  n o . o f  m o le c u le s  o f  RNA s ta n d a r d
Figure 6.4. Example of plot of log of ratio of corrected target to standard band 
density to log no. of molecules of RNA standard.
The majority of the RNA samples were analysed using either a 2-fold or a 5-fold 
serial dilution of the standards. A series of 2-fold and 5-fold dilutions of standard 
were prepared in advance of the PCR procedures and ranging in a starting 
concentration of between 1 ng/pl to 1 fg/pl. In order to compare samples as 
accurately as possible, the target mRNAs from both the pre-intervention and post- 
mtervention studies were measured in the same run, using the same mastermix of 
reagents.
The specific calculations used to estimate the number of molecules of LPL mRNA per 
molecule of Pa-pglob mRNA in each sample is outlined below.
1. The target and standard RNA templates differed in size i.e. in the number of base 
pairs (BP) that they contain. The greater the number of base pairs the more 
ethidium bromide that is taken up. To correct for this the ratio of the size of the
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target to standard was calculated for each gene to determine a correction factor as 
shown.
LPL correction factor
LPL target (BP = 227) : LPL standard (BP = 267) = 0.85 
p2-pglob correction factor
p2-pglob target (BP = 269) : p-MG standard (BP = 306) = 0.88
Having measured the target and standard band densities (using the dual wave 
scanner) it was necessary to correct for the difference in the size of the mRNA 
templates by multiplying the target band densities by the appropriate 
correction factor as calculated above.
2. The number of molecules of mRNA in each concentration of standard was 
determined from the calculations below.
1 mole of LPL/ P2-pglob target = 6.023 X 10^  ^ molecules (i.e. Avogadro’s 
number)
Molecular weight (MW) of 1 RNA base = 343
Weight 1 mole of LPL target = 343 X 267 (number of BP) = 91581 (g)
Weight 1 mole of P2-pglob target = 343 X 306 (number of BP) = 104958 (g)
1 (g/mole) LPL target = 6.58 X 10^  ^molecules mRNA 
1 (g/mole) p2-pglob target = 5.74 X 10^  ^molecules mRNA
3. The log of the ratio of the corrected target to standard band density was plotted 
against the log of the number of molecules of target RNA used in the PCR 
reaction.
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4. The number of molecules of target mRNA was calculated from the equation of the 
line i.e. Y = MX + C, where y = 0.
5. Finally the results were expressed as the number of molecules of LPL mRNA per 
molecule of P2-pglob mRNA.
6.2.4 STATISTICAL ANALYSIS
The paired Students t test was used to compare levels of target LPL mRNA 
expression in adipose tissue obtained prior to and following each dietary intervention 
study. The Pearson’s correlation was used to compare measures of LPL mRNA 
expression with all other parameters measured during the intervention studies.
6.3 RESULTS
The mean level of LPL mRNA expression (number of molecules of LPL mRNA / ng 
mRNA) following the n-3 PUFA, low SFA / high CHO and low SFA / high MUFA 
intervention studies, measured using the competitive RT-PCR method are shown in 
figs. 6.5., 6.6. and 6.7. respectively. There was a wide variation in the level of LPL 
mRNA expression both between and within each intervention diet. In the fish oil 
intervention the mean LPL expression value was 1.61 x 10"^  molecules of LPL mRNA 
per ng total RNA on the control diet and 2.51 xlO"^  molecules of LPL mRNA per ng 
total RNA on the n-3 PUFA enriched diet. There was no significant difference in the 
level of LPL gene expression as a result of the w-3 PUFA enriched diet (p = 0.10). In 
the second intervention mean LPL expression values were higher than the fish oil 
intervention at 1.11 x 10^  molecules of LPL mRNA per ng total RNA on the habitual 
diet and 2.95 x 10^  molecules of LPL mRNA per ng total RNA on the low SFA / high 
CHO diet. No significant difference in LPL gene expression was detectable following 
the low SFA / high CHO diet (p = 0.58). In the MUFA mtervention LPL gene 
expression was higher as a result of the low SFA / high MUFA diet at 9.05 x 10"^  
molecules of LPL mRNA per ng total RNA compared with 2.79 x lO'^  molecules of 
LPL mRNA per ng total RNA on the habitual diet, however this did not reach a level 
of significance (p = 0.07).
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Figure 6.5. Mean LPL mRNA expression (molecules LPL mRNA / ng total 
mRNA) measured in adipose tissue biopsy samples obtained at the end 
of the control diet and at the end of the fish oil diet (n = 11).
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Figure 6.6. Mean LPL mRNA expression (molecules LPL mRNA / ng total 
mRNA) measured in adipose tissue biopsy samples obtained prior to 
and at the end of the low SFA / high CHO diet (n = 11).
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Figure 6.7. Mean LPL mRNA expression (molecules LPL mRNA / ng total
mRNA) measured in adipose tissue biopsy samples obtained prior to 
and at the end of the low SFA / high MUFA diet (n = 9).
To control for variations in the PCR technique the results were expressed as the 
number of molecules of LPL mRNA per molecule of p2-pglob and these results are 
presented for each intervention study in table 6.1. There was no change in the 
expression of LPL mRNA expressed as the number of molecules of LPL mRNA per 
molecule of p2-pglob as a result of any of the dietary interventions.
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Table 6.1. LPL gem expression expressed as no. o f molecules o f LPL mRNA per 
molecule o f pi-microglobulin mRNA for each intervention study.
Study Control diet Intervention diet P value
n-3 PUFA 0.28 ± 0.21 0.47 ± 0.36 0.17
Low SFA / high CHO 1.18 ±1.54 0.76 ±1.50 0.27
Low SFA / high 
MUFA
0.54 ± 0.48 0.86 ±1.15 0.43
Data are presented as means ± SD.
There was no association with the level of mRNA LPL gene expression and post­
heparin LPL activity in either the w-3 PUFA intervention or the low SFA/ high CHO 
intervention. In the MUFA intervention study there was a positive association 
between the level of post-heparin LPL activity and the level of LPL gene expression 
following the low-SFA / high-MUFA diet as shown in figure 6.8. In the MUFA 
intervention study there was also a positive association between levels of fasting 
insulin and levels of LPL gene expression prior to the intervention as shown in fig 
6.9. It is interesting to note that in the low-SFA / high-CHO intervention the levels of 
LPL activity as well as LPL mRNA expression were higher when compared to the w-3 
PUFA enriched diet and the low SFA / high MUFA intervention diet.
An association between TG concentrations and LPL gene expression was detectable 
only in the n~3 PUFA intervention. As shown in figure 6.10. the change in fasting TG 
concentration was negatively correlated with the change in LPL gene expression (r = - 
0.6918, p = 0.02). In addition, the change in postprandial TG concentrations was also 
associated with the change in LPL gene expression following the w-3 PUFA enriched 
diet as shown in fig 6.11. (r = -0.6031, p = 0.05). This would indicate that the greater 
the improvement in TG concentrations following the n-3 PUFA enriched diet the 
greater the level of LPL gene expression. In the w-3 PUFA study the change in LPL
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gene expression was also associated with the change in the postprandial insulin 
response as shown in fig 6.12. (r = -0.6179, p = 0.04). Those subjects therefore, with 
the greatest reduction in postprandial insulin concentrations also had the greatest 
increase in LPL gene expression levels following the «-3 PUFA enriched diet. There 
was no association between the level of LPL gene expression and either TG or insulin 
concentrations in the low SFA / high CHO diet.
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Figure 6.8. The association between post-heparin LPL activity levels 
(pmole.oleate.ml.hr) and the level of LPL gene expression (no. of 
molecules of LPL mRNA per ng total RNA) following the low SFA / 
high MUFA diet (r = 0.6874, p = 0.04).
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Figure 6.9. The relationship between fasting insulin levels and LPL gene
expression measured prior to the low SFA / high MUFA diet (r = 
0.774, p = 0.01).
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Figure 6.10. The association between the change in fasting TG concentration and 
the change in LPL gene expression following the n-3 PUFA enriched 
diet (r = -0.6918, p = 0.02).
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Figure 6.11. The association between the change in postprandial TG AUC and the 
change in LPL gene expression following the n-3 PUFA enriched diet 
(r = -0.6031, p = 0.05).
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Figure 6.12. The association between the change in postprandial insulin AUC and 
the change in LPL gene expression following the n-3 PUFA enriched 
diet (r = -0.6179, p = 0.043).
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6.4 DISCUSSION
The development of a competitive RT-PCR method in this laboratory, facilitated the 
measurement of LPL gene expression in small amounts of subcutaneous adipose 
tissue. In this study, three separate dietary intervention studies were conducted and 
adipose tissue biopsy samples were obtained prior to and following each dietary 
intervention. The aim of the study was to measure LPL gene expression using the RT- 
PCR method to investigate whether changes in lipid metabolism as a result of the 
dietary interventions were related to the regulation of LPL in adipose tissue.
In order to correct for any imprecision’s in the RT-PCR method the results were 
expressed in relation to a reference gene i.e. Pz-microglobulin. There was no 
difference in the expression of LPL gene, expressed as the number of molecules of 
LPL mRNA per molecule of p2-Iiglob mRNA following any of the dietary 
interventions. There was also no change in the absolute levels of LPL mRNA 
(expressed without the reference gene) as a result of any of the dietary intervention 
studies. LPL gene expression was therefore unaffected by either an increase in n-3 
PUFA intake, a decrease in SFA intake or an increase in CHO or MUFA intalce in this 
group of middle aged men. The expression of the results against a reference gene (P2- 
pglob) was designed to account for variations in the RT-PCR method however, as 
pointed out by Murphy et aL (1999) there is no universally accepted reference gene 
for adipose tissue. In addition, it is expected that the reference gene will remam at a 
constant level of expression regaidless of cell cycle state, age of cell or external 
stimuli, however as pointed out by Zimmerman & Mannhalter (1996) it cannot be 
assumed that the housekeeping gene will maintain a steady state of expression under 
all circumstances. While the p2~Iiglob gene has been utilised as a reference gene in 
many studies the expression of p2-Iiglob has not been tested under conditions where 
dietary fat has been altered and it is recommended that future studies should address 
this.
Post-heparin LPL activity levels were not associated with measurements of LPL gene 
expression in either the n-3 PUFA or the low-SFA / high-CHO dietary studies. In the 
MUFA intervention while no changes occuiTed in either the level of post-heparin LPL
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activity or adipose tissue LPL gene expression as a result of the intervention there was 
a positive association between each measure of LPL following the low SFA / high 
MUFA diet. This would indicate that any change in post-heparin LPL activity was 
reflected in a change in the level of LPL gene expression. Few studies have related 
measurement of post-heparin LPL activity to LPL gene expression, however it 
accepted that measurement of post-heparin LPL activity alone is a rather crude 
indication of the regulation of LPL in the human body. For example a number of 
tissues, including muscle, contribute to the LPL released into plasma in response to an 
injection of heparin. Post-heparin LPL activity measurements alone therefore, do not 
provide information as to tissue specific effects in the regulation of LPL.
The significant negative relationships between the change TG levels (fasting and 
postprandial) and the change in LPL gene expression in the «-3 PUFA intervention is 
in common with the finding of Murphy et al. (1999). This association was not 
detected in the other intervention studies conducted in this project and suggests that 
the relationship between the consumption of fish oil and changes in TG concentration 
are in part determined by changes in the expression of LPL in adipose tissue. The fact 
that the changes in LPL expression were correlated to changes in plasma TG and not 
changes in post-heaprin LPL activity suggests that LPL expression is a longer term 
regulator of plasma lipid levels. Further studies involving larger numbers of subjects 
are requhed to provide more information as to the effect of fish oil feeding on LPL 
gene expression.
In conclusion the evidence provided firom this work suggests that changes in plasma 
TG in response to an alteration in the intalce of dietaiy fatty acids are related to 
changes in LPL gene expression only when the intake of long chain n-3 PUFA are 
increased. We found no relation between the expression of adipose tissue LPL and 
changes in any of the lipid parameters measured following the low-SFA / high-CHO 
or the low-SFA / high MUFA inteiwentions suggesting that alternative mechanisms 
are involved in the observed changes in lipid metabolism following a reduction in 
SFA. The method of increasing long chain «-3 PUFA intake in this intervention was 
via foods enriched with fish oil. Greater TG lowering effects have been observed in 
interventions using capsule supplementation. To explore the relationship between 
LPL gene expression and alterations in n-3 PUFA intake it is recommended that
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filture studies involving a greater number of subjects and an intervention using fish oil 
capsules alone aie conducted. In addition these studies were conducted in genetically 
uncharacterised men and it is now known that individuals differ in their response to 
alterations in the intake of fatty acids as a result of genetic influences e.g. those with 
an apo E4 phenotype have a greater cholesterol lowering response. Greater insight 
into the regulation of LPL gene expression following alterations in the intake of 
dietary fatty acids could be obtained in studies involving groups of individuals that 
have been genetically characterised.
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CHAPTER 7.0
OVERALL FINDINGS
7.1 STUDY DESIGN
Derangements in postprmidial lipid metabolism are increasingly recognised as a risk 
factor for CHD, primarily due to the association between an enhanced postprandial 
response and the risk of developing atherosclerosis (Boquist et al. 1999). Oui’ 
understanding of the fectors involved in the regulation of postprandial lipaemia is 
continually evolving however many aspects of the postprandial process remain to be 
elucidated. As discussed in the introduction, the relationship between insulin 
resistance with respect to glucose disposal and disturbances in postprandial lipid 
metabolism has been relatively under-explored (Guerci et ah 2000). It has long been 
recognised that resistance to the action of insulin is associated with various metabolic 
abnormalities including; hypertriglyceridaemia, a greater number of small dense LDL 
paiticles, low levels of HDL-cholesterol, elevated NEFA concentrations, and in some 
instances hyperinsulinaemia (Frayn, 1993). Few studies however, have measured the 
insulin sensitivity of glucose disposal diiectly and conq)aied this to measures of 
fasting and postprandial lipid metabolism. The majority of the studies conducted have 
relied on fasting insulin concentrations as a suiTogate measiu’e of insulin resistance 
(Jeppesen et ah 1995; Boquist et ah 2000). While many studies have demonstrated 
that there is an association between fasting insulin concentrations and lipoprotein 
fractions including VLDL, HDL and LDL levels the value of using measures of 
fasting insulin and glucose levels to interpret the interrelation between insulin 
sensitivity and lipoprotein metabolism is questionable (Jensen, 2000). In 
consideration of this observation, the focus of this study was to investigate the 
relations of insulin sensitivity measured using the short insulin tolerance test to 
postprandial lipaemia, when dietaiy fat composition is altered in the diets of middle- 
aged men.
201
7.ÎJ STUDY DESIGN LIMITATIONS
Three separate dietary intervention studies were conducted over the course of this 
project. The first intervention was designed to investigate the effect of an w-3 PUFA 
enriched diet. The second intervention involved a decrease in SFA intakes and an 
increase in CHO intakes. The final intervention was designed to examine the effect of 
replacing SFA with MUFA. The studies conducted were intense, expensive metabolic 
studies involving 3 days of investigation conducted pre-and post-intervention (2 of 
which are reported on in this thesis) some of which could only be applied to two 
subjects at any one time. The effect of this is that the number of subjects that could be 
studied was limited in each intervention: 32 were studied in all.
In addition, these subjects were genotypically uncharacterised. When this study was 
originally planned the importance of genotype was not considered in the selection of 
subjects. As discussed in chapter 1.0 population studies have shown that not only do 
genetics play a role in determining an individuaTs lipid profile, but it can also 
influence then response to a lipid-altering intervention (Williams et al. 1995; Ordovas 
& Schaefer, 2000). For example, it has been shown that plasma cholesterol, LDL- 
cholesterol and apo B levels are highest in subjects carrying the apo E4 isoform, 
intermediate in those with the apo E3 isoform, and lowest in those with the apo E2 
isoform and that the response to dietaiy fat intake may differ among individuals with 
different apo E phenotypes (Schaefer et ah 1986; Ordovas et al. 1987; Wilson et al. 
1994). In particular, it is thought that subjects with an apo E4 isoform have a greater 
response to cholesterol-lowering diets. The effects of TG-lowering interventions 
across different apo E genotypes have produced conflicting reports, however it has 
been observed that carriers of the apoE2 isoform have a hyper-TG response to low-fet 
and high-CHO diets (Ordovas et al. 1995). The genetic factors influencing insulin 
sensitivity and changes in insulin sensitivity are less well defined. Within this study 
we observed a great deal of individual vaiiation both in response to the high fat meal 
and the insulin tolerance test. Genotypic heterogeneity may have accounted at least in 
part for these observed differences. Had genotyping been incorporated into the 
screening progiamme for subject selection more information could have been 
obtained as to the effect of manipulating dietary fat intakes on the insulin sensitivity 
of glucose and lipid metabolism in individual’s within specific genotypes. In addition,
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it may have been possible to identify cleai*er relationships between the insulin 
sensitivity of glucose disposal and postprandial lipaemia.
Finally the method of measuring insulin sensitivity in this study was with the short 
ITT and while several studies have found that the short ITT compares favomably to 
other more sophisticated methods of measuring insulin sensitivity a recent study 
conducted by Hermans et ah (1999) found that the ITT performed less well than other 
tests due to it’s poor reproducibility. This differs from the work of Hirst et ah (1993) 
who found that the short ITT compared favoui’ably with other measures of insulin 
sensitivity including the euglycaemic clamp technique. Hirst et ah (1993) found that 
the intra CV varied from between 6 and 13 % across a number of studies, which had 
used tlie ITT to measure insulin sensitivity. The intra-individual vaiiation of glucose 
Kitt measured using the short ITT, was determined by another investigator within this 
laboratory in 6 young men on 4 occasions (unpublished data). The CV was 15 %, 
similar to the variation in fasting TG (14.5 %) and total cholesterol (10 %). Thus 
while some reports have indicated that the ITT performs poorly against other 
measures of insulin sensitivity others have not found this however, more studies are 
necessary to confirm that using the short ITT does not present a methodological 
problem.
7.2 OVERALL RESULTS
The findings from the «-3 PUFA, low-SFA / high-CHO, and low-SFA / high-MUFA 
interventions have been discussed sepaiately in chapters 3.0,4.0, and 5.0 respectively. 
Since the same set of measuiements were conducted in each intervention study it is 
possible to combine the data sets to compare overall findings in order to test the 
original hypotheses which were that;
> Insulin resistance with respect to glucose disposal also extends to deranged 
postprandial fat metabolism, with consequent increased risk of CHD.
> The insulin sensitivity of these pathways is improved by either increased 
dietary w-3 PUFA or reduced SFA in normal adults.
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7.2.1 INFLUENCE OF DIETARY INTERVENTIONS ON FASTING BLOOD 
BIOCHEMISTRY
There were few overall changes in the mean values for any of the blood biochemistry 
measures obtained prior to and following each dietary intervention study. The mean 
fasting blood biochemistry results for the combined data set is shown in table 7.1. 
Fasting TG was marginally lower in the post-intervention phase at 1.85 (SD 0.53) 
mmol/1 compaied with 2.03 (SD 0.69) mmol/1 in the pre-intervention phase (p = 0.09). 
This was mainly as a result of the higlily significant reduction in TG as a result of the 
low-SFA / high-MUFA trial (p = 0.02) and the mean (non-significant) fell in TG 
levels in the fish oil group. While a TG lowering effect was most evident with the 
low-SFA / high-MUFA diet, this group of subjects also had a higher mean baseline 
fasting TG concentration and may therefore have been more responsive to a change in 
dietary fat intake. In addition, the non-significant reduction in mean fasting TG in the 
fish oil group was influenced by one individual with an un-explained increase in 
fasting TG following the fish oil intervention. Fasting NEFA concentration was 
significantly reduced for the post-intervention groups overall (p = 0.01) mainly due to 
the significant fell in the low SFA / high CHO intervention (p ~ 0.01) and the non­
significant fell in the fish oil group. There were no changes in insulin, glucose, 
HOMA, total-cholesterol, HDL-cholesterol or LDL-cholesterol levels as a result of 
any of the dietary interventions.
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Table 7.1. Overall fasting biochemical measurements obtained prior pre^ and 
postAnterventions.
measurement Pre-intervention Post-intervention P value
n 32 32 -
TG (mmol/i) 2.03 ± 0.69 1.85 ± 0.53 0.09
Total cholesterol (mmol/1) 5.40 ± 1.28 5.23 ± 1.03 0.36
LDL-cholesterol (mmol/1) 3.63 ± 1.39 3.55 ± 1.13 0.59
HDL-cholesterol (mmol/1) 0.88 ± 0.18 0,88 ± 0.17 1.00
NEFA (mmol/l) 0.48 ± 0.20 0.39 ± 0.14 0.01
Insulin (pmol/1) 96.9 ± 56.0 92.7 ± 43.9 0.54
Glucose (mmol/l) 5.39 ± 0.54 5.41 ± 0.45 0.79
HOMA 3.19 ± 0.54 3.02 ± 1.49 0.48
Values are presented as means ± SD.
7.2.2 INFLUENCE OF DIETARY INTERVENTIONS ON POSTPRANDIAL 
LIPAEMIA
In each intervention study postprandial lipaemia was studied over a 9h period 
following a standardised high fat breakfest (80 g fat). The results for each 
intervention and for the group overall me shown in table 7.2. It was observed that 
there was a wide degree of vmiation in initial dietary lipid tolerance among the study 
gi'oup. While there was vmiability in the TG and apo B-48 postprandial levels within 
the group overall, it was also clear that the responses to the three dietary interventions 
were quite different. Both the «-3 PUFA and the low-SFA / high-MUFA interventions 
were associated with improvements in dietary lipid tolerance in terms of both TG 
AUC and Apo B-48 AUG. In contrast the low-SFA / high-CHO dietmy intervention 
was associated with a worsening of TG AUC but not with a worsening of apo b-48 
AUC indicating that there was an additional adverse influence of CHO on VLDL 
which negates any benefit when SFA is replaced by carbohydrates. This would 
indicate that either an increase in «-3 PUFA intake or a decrease in SFA intake is
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associated with an improvement in postprandial lipaemia at the level of chylomicron 
clearance, however replacement of SFA with CHO has an adverse effect on VLDL 
TG levels which is not observed when SFA is replaced by MUFA.
Since postprandial TG clearance can be assumed to reflect insulin levels and action, 
the TG AUC/insulin AUC ratio is to some extent a measur e of the insulin sensitivity 
of TG clearance, A low ratio would indicate increasing insulin sensitivity, especially 
where it reflects a lower TG in relation to the insulin level rather than an increasing 
insulin in relation to the TG level. Table 7.2. shows the change in TG AUC/insulin 
AUC ratio as a result of the interventions. Thus, in the fish-oil trial insulin sensitivity 
increased since the TG AUC/insulin AUC ratio fell by 24 % (p = 0.02) with no 
change in the insulin AUC. In contrast, in the low SFA / high CHO intervention, the 
TG AUC/insulin AUC ratio increased by 27 % (p -  0.01) with no change in the 
insulin AUC indicating a fall in insulin sensitivity. In the low-SFA / high-MUFA 
intervention the mean value fell indicating an increase in insulin sensitivity but the 
change was not significant.
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1.2.3. INFLUENCE OF DIETARY INTERVENTIONS ON THE INSULIN 
SENSITIVITY OF GLUCOSE DISPOSAL.
As with the fet tolerance test, there was a wide degree of variation in insulin 
sensitivity among the study groups, with glucose Kjtt varying between 1.20 and 6.17 
%/min * prior to the dietary intervention studies. Table 7.3. shows the interTelations 
between glucose Km and fasting glucose and insulin. The data are organised into 
quartiles of increasing insulin sensitivity and shows that in subjects at baseline 
glucose Kitt correlated with fasting glucose (r = -0.39, p ~ 0.03), fasting insulin (r ~ - 
0.36, p = 0.04) and HOMA (r = -0.38, p = 0.03). In addition, glucose Kitt was 
associated with Insulin AUC following the high fat meal (r = -0.37, p = 0.04). NEFA 
Kitt was unrelated to glucose K m  at baseline in the group overall (r -  0.14, p -  
0.44). ANOVA of quartiles showed no significant differences for any of these 
parameters. Initial fasting insulin was used as a predictor of insulin sensitivity in this 
study however caution is necessary when using fasting insulin alone as a predictor of 
insulin sensitivity. The relationship between fasting insulin and glucose K m  is shown 
in figure 7.1.
In terms of improvements in the insulin sensitivity of glucose disposal no intervention 
induced a significant change. Overall, 15 individuals improved, 5 worsened and 12 
varied by less than 15% (the intra-individual var iation in this test measur ed by another 
investigator in this research group). Improvements in glucose Km  were related to the 
initial glucose K m  and those individuals with the lowest insulin sensitivity at the 
outset had the greatest improvements in insulin sensitivity following the intervention 
diets. The association between the change in glucose K m  (pre-interwention glucose 
K m  / post-intervention glucose K m  ) and the initial glucose K m  measurements is 
shown in fig 7,2. Recommendations for future studies would therefore be to include 
measurements of glucose Km  at baseline in order to ensure that a more homogenous 
group, in terms of the insulin sensitivity of glucose disposal, is studied.
The fall in NEFA was used as a measure of the insulin sensitivity of HSL inhibition. 
Pre-intervention NEFA Kitt values predicted post-intervention NEFA Kitt values (i*^  
= 0.35) however, there were no significant changes in NEFA K m  following any of 
the dietary interventions.
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Figure 7.1. The correlation between 6sting insulin and glucose Krrr in the group 
overall (n = 32) measured pre-intervention (r = -0.36, p = 0.04).
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Figure 7.2. The association between glucose Krrr (%/min‘‘) and the change in 
glucose K i t t  i e. ratio of glucose Krrr post-intervention to pre­
intervention (Delta glucose K i t t ) -  r = -0.78, p < 0.0001.
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7,2A. INTERRELATION BETWEEN INSULIN SENSITIVITY OF GLUCOSE 
DISPOSAL AND POSTPRANDUL LIPAEMIA
As previously discussed few studies have measured insulm sensitivity directly and 
related this to measures of postprandial lipid metabolism. To test the hypothesis that 
insulin resistance with respect to glucose disposal also extends to deranged 
postprandial fat metabolism, insulin sensitivity as Kgiucose was compared with all 
variables of postprandial lipaemia by correlation across the pre-intervention data set. 
The data was organised into quartiles ranked in order of increasing insulin sensitivity 
(i.e. Kgiucose) and the results of the analysis is shown in table 7.4.
TG AUC was positively correlated with Kgiucose (r = 0.35, p = 0.05) with a 35 % 
difference in TG between the top and bottom quartiles. ANOVA of quartiles however 
showed that the significance of this difference was low for TG (p ~ 0.14). The 
relationship between Kgiucose and postprandial TG may have reflected an increased TG 
clearance due to increasing hyperinsulinaemia with insulin in-sensitivity since there 
was also a positive relationship of Kgiucose with the TG AUC/insulin AUC ratio (r = 
0.52, p = 0.02). There was no association between Kgiucose and festing TG, 
Cholesterol, LDL-cholesterol and HDL-cholesterol. Neither LPL activity nor niRNA 
LPL level were related to Kgiucose as shown in table 7.5.
This data shows that in genotypically uncharacterised middle aged men, the insulin 
sensitivity of glucose disposal as measured by the short ITT does not predict the 
apparent sensitivity of lipid-related targets of insulin action in a simple way.
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Table 7.5. Analysis o f  quartiles ranked in order o f decreasing insulin sensitivity
in relation to measures LPL activity and gene expression( n -  32)
Quartile l^glucose LPL activity 
(umole.oleate.itil.ltr)
LPL mRNA 
(no. of molecules)
LPL : p-pglob 
ratio
1 1.84 8.59 2.47 X 10® 0.86
2 3.06 7.49 1.51 X10® 0.26
3 3.85 7.91 1.49x10® 0.97
4 5.05 6.58 2.14x10® 0.69
ANOVA 0.79 0.41 0.53
r -0.07 -0.06 -0.05
P 0.69 0.74 0.76
7.2.5 RED BLOOD CELL PHOSPHOLIPID DATA
7.2.5.1 Relationship between the dietary intake o f fatty acids and the fattv acid 
content o f red blood cell phospholipids
Red blood cell fatty acids were measured and the levels of &tty acids compared to the 
intake of fatty acids from food. Combining the data for each intervention and for each 
dietary phase it was shown that there was a positive congélation between the dietary 
intake of SFA , MUFA and PUFA and the corresponding levels of SFA, MUFA and 
PUFA measured in the RBC phospholipids. These relationships are depicted in 
figures 7.3., 7.4., and 7.5, respectively. Red blood cell phospholipid measurement 
was therefore a usefiil marker of the dietary intake of fatty acids.
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Figure 7.3. The relationship between the dietary intake of SFA and the level of 
SFA in RBC membrane phospholipids in individual subjects measured 
pre-and post-intervention (n = 64). r = 0.34, p = 0.005.
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Figure 7.4. The relationship between the dietary intake of MUFA and the level of 
MUFA in RBC membrane phospholipids in individual subjects 
measured pre-and post-intervention (n = 64). r = 0.36, p = 0.003
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Figure 7.5. The relationship between the dietary intake of PUFA and the level of 
PUFA in RBC membrane phospholipids in individual subjects 
measured pre-and post-intervention (n = 64). r = 0.36, p = 0.003
7.2.5.2 The relationship between red blood cell fattv acid content and measures of 
insulin sensitivity and lipid tolerance.
Having established that the red blood cell fatty acid levels were a reliable indicator of 
the dietary intake of fetty acids we examined the relationship between all outcome 
variables and RBC fetty acids. The purpose of this was to test the hypothesis that the 
insulin sensitivity of pathways of both glucose and lipid homeostasis is improved by 
n-3 PUFA and impaired by SFA. Analysis was performed both on the pre­
intervention data set (n = 32), the post-intervention data set (n = 32) for total n-3 fetty 
acids and SFA in RBC membranes.
For the pre-intervention data saturated fet in terms of palmitate (Cl6:0), the main 
saturated fetty acid present in the RBC membrane was inversely related to Kgiucose and 
was the only significant fatty acid (r = -0.44, p = 0.01) in a forward stepwise multiple 
regression which accounted for 28 % of the variance in Kgiucose (p = 0.012). The 
dependent variable used was Kgiucose and the independent variables were C l6:0,
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C18:0, C18:l, C:18:2, C22:4, C20:3, C20:4, C20:5 & C22:6. This significant 
correlation (r = -0.44) shown in figure 7.6. means that increasing C l6:0 in RBC 
membranes is related to decreasing insulin sensitivity. Stearic acid (C l8:0) was also 
inversely related to HDL-cholesterol indicating that increasing C l8:0 is related to 
decreasing HDL-cholesterol, both adverse influences (r = -0.52, p = 0.002). These 
influences when examined in terms of quartiles of variables ranked for either Cl 6:0 or 
C l8:0 indicate a 21 % improvement in Kgiucose and a 26 % increase in HDL- 
cholesterol from between the top and bottom quartiles of the SFAs as shown in figs 
7.7. and 7.8. respectively. In the pre-intervention data therefore it is evident that a 
high level of saturated fet represented as either C l6:0 or C l8:0 is associated with a 
decreased insulin sensitivity and a low level of HDL-cholesterol, both adverse 
influences in terms of CHD risk.
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Figure 7.6. The relationship between RBC phospholipid palmitate content and 
Kgiucose (r = -0.44, p = 0.01).
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Figure 7.7, Insulin sensitivity (Kgiucose) examined in quartiles of increasing RBC w- 
3 PUFA content (n = 32).
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Figure 7.8. HDL-cholesterol ranked by increasing RBC C l8:0 (stearic acid)
content.
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In the post intervention data measures of lipid tolerance were generally associated 
with total n-3 PUFA content of RBC membranes. Thus, there was an inverse 
association between TG AUC (r = -0.37, p = 0.034) and RBC n-3 PUFA and a direct 
correlation between RBC n-3 PUFA content and HDL-cholesterol (r = 0.51, p = 
0.002). The improvement in HDL-cholesterol with increasing RBC n-3 PUFA content 
is shown in fig 7.9. where the data is organised into quartiles ranked in order of 
increasing RBC n-3 PUFA content. Figure 7.10. shows the TG AUC ranked by 
decreasing total RBC n-3 fatty acids and overall there was a 32 % improvement in the 
TG AUC between the top and bottom quartiles. The improvement in TG AUC with 
increasing n-3 PUFA content of RBC membrane phospholipids was not mediated by 
an increase in LPL activity as LPL activity was inversely related to RBC n-3 PUFA (r 
= -0.345, p = 0.05) as shown in figure 7.11.
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Figure 7.9. The relationship between HDL-cholesterol and RBC phospholipid n-3 
PUFA content (n = 32). The data is ranked in quartiles of decreasing 
RBC n-3 fatty acid content (r = 0.51, p = 0.002).
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Figure 7.10. The relationship between TG AUC and RBC phospholipid w-3 PUFA 
content (n = 32). The data is ranked in quartiles of decreasing RBC /î-3 
fatty acid content (r = -0.37, p = 0.034).
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Figure 7.11. The inverse association between RBC «-3 PUFA content and LPL 
activity (r = -0.35, p = 0.05).
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7.3. DISCUSSION OF OVERALL FINDINGS
Understanding the biology of insulin resistance is important to facilitate the 
development of new therapies, to optimise current therapies and to identify causative 
genes and their products. The aspect of insulin resistance, which has been most 
extensively studied in man, is the defective insulin-mediated uptake and utilization of 
glucose. However insulin is associated with many more processes other than glucose 
metabolism including lipid and protein metabolism (American Diabetes Association: 
Consensus Development Conference on Insulin Resistance, 1997). Insulin inhibits 
adipose tissue lipolysis, muscle protein catabolism, and the synthesis of some hepatic 
proteins. Insulin also stimulates the synthesis of the enzyme LPL which is known to 
play a central role in lipoprotein metabolism. Conditions related to insulin resistance 
therefore abound (Bonora et al. 1998) and research into the &ctors associated with IR 
and how to reduce the risk of developing conditions such as diabetes and CHD, 
morbidities associated with IR, is ongoing.
Both genetic and environmental factors play a role in the development and 
progiession of insulin resistance. Dietary factors undoubtedly influence insulin action 
(Storlein et al. 2000) however, contioversy exists as to the best dietary approach in 
the treatment of insulin resistance. Type II diabetes is the metabolic disease most 
commonly associated with insulin resistance and is characterised by the inability to 
handle carbohydrate. Storlein et al. (2000) therefore ask ‘why advocate a high- 
carbohydrate diet to individuals whose core problem is that macronutrient'? Pai’t of 
the answer relates to the macronutrients available to substitute for carbohydrate. There 
is limited ability to manipulate the intake of protein, and therefore reducing 
carbohydiate generally comes at the cost of increasing fat. Since obesity is also part of 
the metabolic syndrome disease cluster, and insulin resistance is closely linked with 
adiposity, there is a geneml reluctance to advocate any dietary therapy likely to 
increase the intake of fet (Katan, 1997). However, dietaiy fat is not a single entity, 
with saturated and unsaturated fatty acids exerting very differing metabolic effects in 
the body. Recently there has been greater focus on the composition of dietary fet 
rather than total fat intake per se with regard to effects on insulin action. Saturated fet 
is generally negatively associated with insulin action whereas polyunsaturated fet is 
thought of as beneficial. Less evidence exists on the impact of monounsaturated fet.
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In addition it has been suggested that saturated and unsaturated fats have veiy 
differing effects not only on energy storage and utilisation, and in their function as 
structur al components of cell membranes but also in their role as regulators of gene 
expression (Storlein et aL 2000). There are also gaps in the literature on the optimum 
type of carbohydrate in the diet, the impact of dietary fibre and the role of the 
glycaemic index in insulin resistance (Riccardi & Rivellese, 2000). In this study we 
attempted to identify the effect of changes in the composition of dietaiy fet through an 
increase in the intake of «-3 PUFA or a decrease in the intake of SFA on measures of 
insulin sensitivity. To address the question of whether it is of greater benefit to 
increase the intake of caibohydrate or increase the intake of MUFA in order to reduce 
the intake of SFA one intervention was designed to decrease the intake of SFA in 
favour of an increase in CHO while a second was designed to decrease the intake of 
SFA in favour of an increase in MUFA.
Nutritional recommendations have placed a greater emphasis on the need to reduce 
percentage of fet in the diet, rather than a need to decrease the absolute amount of fat 
or to alter the composition of fat in the diet. Accordingly, this recommendation has 
taken hold in many sectors of the food industry and the number of low-fat or %-fat- 
fiee labelled products has increased on oui* supermarket shelves. In addition, despite 
more than a decade of public health messages aimed at the promotion of lower fat 
diets this has not resulted in a decrease in the prevalence of obesity nor in the 
occurrence of metabolic disorders. Achievement of a low-fat diet among many 
populations would require a dramatic shift in eating liabits and it is not altogether 
surprising that in today’s affluent society this has been difficult to achieve. What may 
be more attainable is to change the composition of that fat intake towards a greater 
amount of unsaturated fet and a lower intake of saturated fat. In consideration of this 
the intervention studies discussed in this thesis were designed to focus on altering the 
composition of fat in the diet and not decreasiag the intake of total fet alone. The 
method of altering the composition of fat in the diets of the volunteers was through 
foods in which the type of fat used to make the food was altered or in the case of the 
low-fet/ high-CHO intervention thiough the use of commercially available low-fat 
foods. A strength of this study therefore, is that it was conducted under normal free- 
living conditions, using femiliar foods such as sauces, cakes and biscuits. The study 
demonstrates that it is feasible to achieve alterations in the composition of dietary fet
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intakes in men habitually consuming a western style diet, without the consumption of 
unfamiliar foods or without the use of liquid formula diets or capsule supplements 
alone.
Assessing dietaiy conqiliance in the free-living population is often difficult and most 
studies rely on the inteipretation of food records (Livingstone, 1995). Participants in 
this study reported energy and macronutrient intakes that were extremely close to the 
target intakes. Confidence in the accuracy of the dietary assessment is also increased 
by the observation that lower energy intakes were associated with a reduction in body 
weight (mean 1.7 Kg) during the low-SFA/ high-CHO intervention, where a reduction 
in total fat intakes also occuned. A significant weight loss following the consumption 
of low-fat diets of this nature has also been observed in other studies (Kasim et al, 
1993; Shah et al. 1994). Apart form the analysis of food diaries, a second measure of 
compliance in this study was the measurement of red blood cell phospholipid fatty 
acid composition. Across all of the intervention studies pre- and post-intervention 
there was a positive association between the intake of individual dietary fatty acids 
and the measmement of individual fetty acids in the red blood cell phospholipids. 
Measurement of red blood cell phospholipid fatty acid composition therefore proved 
to be a usefril marker of the intake of dietary fatty acids.
Changes in fasting biochemical measurements were most evident in the low SFA/ 
high MUFA diet where there was an 11 % reduction in total cholesterol and a 15.4 % 
reduction in the levels of festing TG. In the «-3 PUFA intervention study the 
reduction in fasting TG was influenced by one individual who had an increase in 
fasting TG as a result of the intervention, making the fall in TG non-significant (p = 
0.06). The increase in fasting TG, which might have been expected to occur as a result 
of the increase in CHO during the low-SFA/ high-CHO diet, was not evident 
however, this did not hold true in postprandial measurements of TG. Overall no 
changes were observed in the levels of LDL-cholesterol and HDL-cholesterol or in 
the festing measures of glucose and insulin as a result of any of the intervention diets. 
There was however, a significant decrease in the level of fasting NEFA when the 
results of each intervention were combined, mostly as a result of the highly significant 
reduction in NEFA concentrations following the low-SFA / high-CHO diet. NEFAs 
have been shown to be an important stimulus to hepatic TG secretions and that
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inadequate suppression of NEFAs may result in increased TG concentrations 
(Mckeigue et al. 1993; Byrne et al, 1994), Byrne et al, (1995) conducted a study in 
which individuals were studied using a glucose tolerance test and subsequently 
divided into quartiles based on 2-hour glucose measurements. They observed that 
individuals in the upper quartile of glucose tolerance (i.e. most glucose intolerant) 
also had the highest mean TG concentrations and the highest mean NEFA 
concentrations. In addition, Paolisso et al, (1995) have also demonstrated that large 
fat cells and the resulting increased plasma NEFA concentrations are independent risk 
factors for the development of type II diabetes. In terms of CHD risk, Frayn (1998) 
speculates that feiluie to regulate the plasma NEFA concentiation normally both in 
the fasting and postprandial state, might be associated with development of a number 
of risk factors for CHD, including insulin resistance, hypertriglyceridaemia, hyper- 
apoB and increased coagulant activity. Plasma NEFA concentrations are however 
inherently variable from subject to subject and also within subjects from day to day 
(Frayn, 1998). In addition, there are no population derived reference ranges within 
which to define a raised or normal NEFA level The reduction in fasting NEFA levels 
obseiTed in this study were not associated with a reduction in either festing or 
postprandial TG and the benefit of reducing NEFA levels alone is not known since 
few studies have examined the effect of reducing NEFA levels on CHD risk. 
Therefore, while there seems to be good evidence to suggest that plasma NEFA 
concentration may play a central role in the risk fectors associated with insulin 
resistance more studies are needed to gain a greater understanding of the effects of 
alterations in fasting NEFA levels as a result of alterations in dietaiy fat intake.
The short ITT was the method of measuring insulin sensitivity employed in this study. 
Across all of the intervention studies there was a wide degree of insulin sensitivity 
among the subjects, with initial fasting insulin levels predictive of the degree of 
insulin resistance. Overall, there was no change in insulin sensitivity as a result of any 
of the dietary interventions, however it was evident that the improvements in insulin 
sensitivity occurred in individuals with the greatest degree of insulin resistance at 
baseline. When the pre-intervention data for the combined studies was organised into 
quartiles based on glucose Krrr it was observed that those in the lowest quartile (le. 
most insulin resistant) also had the highest levels of fasting glucose, fasting insulin 
and the highest insulin AUC measmements following the high fat meal The HOMA
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model is another measure of insulin sensitivity, which is determined from fasting 
insulin and glucose levels (Matthews et al, 1985), and there was also an association 
between insulin sensitivity measured using the short ITT and HOMA. It appears 
therefore that the short ITT provided a good measure of the insulin sensitivity of 
glucose disposal in this study. A fasting insulin level greater than 40 pmol/1 was 
included in the screening criteria for the selection of subjects for this study, however 
those subjects who had a low insulin sensitivity measured using the ITT the mean 
fasting insulin was 112.4 (SD 58.5) pmol/1. It is recommended for future studies of 
this nature that a fasting insulin level of at least 90 pmol/1 is used to predict insulin 
resistance or that baseline assessments of insulin sensitivity me included to select a 
more homogeneous group.
As far as the hypothesis that glucose Kitt would predict postprandial lipaemia, the 
opposite was observed with TG AUC positively correlated with glucose K i t t . This 
indicates that the greatest TG response following the ingestion of a high-fat meal was 
observed in individuals who were the most insulin sensitive. The TG AUC to insulin 
AUC ratio, which could be used as a measure of the insulin sensitivity o f TG 
clearance, was also positively associated with glucose Kitt. 
In addition, there was also a marginal association between glucose K i t t  and apo B-48 
AUC (p = 0.08). No associations were evident for fasting TG, cholesterol, HDL- 
cholesterol, LDL-cholesterol, LPL activity or LPL mRNA expression. These findings 
are in contrast to those of Graci et al. (1999) who found that when subjects (n = 40) 
were divided into quartiles of insulin sensitivity, measured using the short ITT, the 
concentrations of TG and cholesterol were progressively increased from the most 
insulin sensitive quartile to the least insulin sensitive quartiie. Relationships between 
fasting insulin levels, as a surrogate measure of insuhn resistance, and fasting plasma 
lipoprotein levels have also been established in many population based studies 
(Laakso et al 1990; Ostlund et al. 1990; Haffiier et al. 1993). In a recent study by 
Boquist et al. (2000) fasting insulin was found to be associated with the TG response 
to a high fat meal independently of BMI, waist-to-hip ratio, blood glucose and festing 
TG. The differences between the study of Boquist and colleagues and this study 
however, is that firstly subjects in that study were selected on the basis of their Apo E 
genotype (all participants were homozygous for the apo E3 allele) and secondly the 
range of fasting insulin was much lower in the Swedish study with the majority of the
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subjects would being judged as insulin sensitive according to then fasting insulin 
values (only 15 % had a fasting insulin > 60 pmol/1). In addition, the range of mean 
fasting plasma TG concentrations in quartiles of glucose Kitt was from 1.06 -  1.79 
mmol/1 in the Swedish study whereas in our study the fasting TG concentrations were 
higher and ranged from 1.79 -  2.26 mmol/1 across quartiles of insulin sensitivity. 
Fasting concentrations of TG above 1.9 mmol/1 have been shown to be associated 
with an unfavourable lipoprotein profile, the ALP and an ALP has been shown to be 
strongly associated with the insulin resistance syndrome. Few of the Swedish subjects 
would therefore have been classified as having an ALP whereas tlie majority of our 
subjects would have fallen into this categoiy. It is possible therefore that associations 
between insulin sensitivity and measures o f fasting lipid metabolism are appar ent only 
within relatively normal or low concentrations of fasting TG and low concentrations 
of festing insulin, both of which are unlikely to indicate any metabolic disturbances.
The argument against recommending car bohydrate as a source of replacement energy 
for saturated fet hinges largely on the observation that high-carbohydrate diets are 
associated with an increase in TG and a reduction in HDL-cholesterol. Several 
authors have argued strongly in favour* of replacing saturated fats with unsaturated 
fats (Grundy, 1986, Mensink & Katan, 1987; Katan et al, 1997) an argument which is 
supported by epidemiological studies e.g. the low CHD rates in people habitually 
consuming a Mediterranean diet (Kushi et al. 1995). In this study while fasting levels 
of TG and HDL-cholesterol were unchanged following the low-SFA/high-CHO 
intervention there was a 20 % increase in levels of postprandial TG with the most 
acute increase in the late postprandial phase (6-9 hour* TG response). In addition, the 
levels of TRL-TG were significantly accentuated following tlie low-SFA / liigh-CHO 
diet. The results of this study therefore substantiate the view that a high-CHO diet is 
detrimental in terms of causing unfavourable changes in lipoprotein levels. In 
contrast, the low-SFA / high-MUFA diet was associated with an improvement in 
postprandial TG, TRL-TG and apo B-48 concentrations, frirther endorsing the 
findings of previous studies that replacement of SFA with MUFA is more beneficial 
than replacement with dietary CHO. In the w-3 PUFA intervention, while there was no 
change in postprandial lipaemia as a result of fish oil feeding in the group overall, it 
was evident that the greatest improvements in postprandial TG concentrations 
occuiTed in subjects who had the greatest degree of postprandial lipaemia at the outset
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of the study. Similarly Harris et al. (1988) demonstrated that in a group of non­
diabetic hypertriglyceridaemic subjects, a higher initial TG level was associated with 
a greater TG reduction as a result of fish oil administi ation. In addition, Connor et al. 
(1993) foimd that fish oil incorporated into the diet of hypertriglyceridaemic subjects 
had a more profound hypolipaemic effect than had been observed in normal subjects. 
In the «-3 PUFA intei*vention while the concentration of TG was not significantly 
attenuated over the entiie 9-hour postprandial study there was a significant lowering 
of TRL TG in the late (6-9 hour) postprandial phase. Many investigators have 
highlighted that an accentuated lipoprotein profile in the late postprandial phase is 
potentially more atherogenic (Groot et al 1991; Putsch et al 1992; Uiterwaal et al 
1994; Karpe, 1997) therefore the reduction in lipaemia in the late postprandial phase 
observed in this study is favourable in terms of reducing CHD risk.
It is known that peripheral insulin sensitivity can be influenced by phospholipid fatty 
acid composition and that changes in the fatty acid composition of the cell membranes 
may modulate the action of insulin (Borkman et al. 1993). Increasing the content of 
PUFA within cell membranes in cultured cells increases membrane fluidity, the 
number of insulin receptors, and the action of insulin (Thomson et al 1987); converse 
efifects occur when the concentration of SFA in the membranes is increased (Ginsberg 
et a l 1982). Animal studies have shown that in rats made insulin resistant with a 
high-fet diet, the resistance can be prevented by the inclusion of «-3 PUFA in the diet 
which have been incorporated into the phospholipid component of muscle cells. In 
humans, insulin sensitivity has been correlated with the ratio of n-6 PUFA to SFA in 
serum phospholipids (Field et al. 1988). In this study we examined the association 
between red blood cell phospholipid fatty acid content and measures of insulin 
sensitivity and lipid metabolism. In the pre-intei-vention data it was observed that 
there was a significant inverse association between palmitiate (Cl6:0), which was the 
main saturated fatty acid present in the RBC membranes, and glucose Kitt. In 
addition there was an inverse relation between stearic acid (€18:0) and HDL- 
cholesterol levels. This data indicates that there is a detrimental influence of high 
levels of SFA in membrane phospholipids on both insulin sensitivity and HDL- 
cholesterol levels. This finding is similar to the finding of other workers who have 
examined the relationship between phospholipid fatty acid content and insulin 
sensitivity. For example, in a study by Vessby et al, (1994) insulin sensitivity was
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measuied by the hyperinsulinaemic clamp technique in a group of 70 year old men 
and it was found that peripheral insulin sensitivity was significantly and negatively 
correlated to the proportion of palmitic acid in the skeletal muscle phospholipids. 
Their study differs from this study in that we examined the effect in RBC membranes 
and not skeletal muscle, which is the main insulin-sensitive tissue (Borkman et al.
1993). However the majority of fatty acids within membranes are derived from 
dietaiy souices and it is assumed tliat fatty acids present in muscle cell membranes 
would be reflective of fatty acids present in erytlirocyte cell membranes. In the post 
intervention data the main associations between RBC membrane phospholipid fatty 
acid content were with measures o f lipid metabolism and total w-3 fatty acid content. 
Total n-3 PUFA content was inversely correlated with TG AUC and positively 
correlated with HDL-cholesterol. When the data was ranked into quaitiles of 
membrane n-3 PUFA content, it was obsei*ved that TG AUC decreased and HDL- 
cholesterol levels increased with the progressive increase in «-3 PUFA content. The 
majority of studies conducted have compared membrane w-3 fatty acid composition 
with measures of insulin sensitivity or festing insulin level. In this study an 
association between measures of insulin sensitivity and membrane total «-3 fatty acid 
content were not detected and one explanation could be that the proportion of total «-3 
fatty acids were too low to detect significant relationships between insulin sensitivity 
and n-3 PUFA content. Only one intervention in this study was designed to increase 
the dietaiy intake of «-3 PUFA and in experimental studies, the content of w-3 fatty 
acids in the diet, as well as in the tissues, has been shown to be critical for the 
maintenance of good insulin sensitivity. The mechanism by which membrane fatty 
acids influence insulin sensitivity is thought to be due to the close contact of the 
insulin receptor and glucose transporter with membrane lipids. Certainly in animal 
studies, rats fed a high fat diet have a decreased capacity to transport and metabolise 
glucose. Similarly in human studies, while membrane fetty acids have not generally 
been measured it has been shown that that a higher SFA intake is associated with 
impaiied insulin action (Maron et a\. 1991; Marshall et al. 1997), Other studies have 
shown that decreased insulin sensitivity is associated with decreased concentrations of 
PUFA in skeletal muscle phospholipids (Borkman et al. 1993). An increase in the 
unsaturated component of cell membranes is thought to increase membrane fluidity 
and as a consequence the residence time of glucose transporters is increased with a 
resultant increase in the disposal of glucose. The mechanism by which an increase in
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the w-3 PUFA content is associated with a lower postprandial TG in this study is not 
thought to be related to increase in the activity of the enzyme LPL, since LPL activity 
was found to be negatively correlated with membrane w-3 PUFA content. Since the 
TG to insulin AUC ratio was also inversely coiTelated with RBC w-3 PUFA it is 
assumed that this is associated with an improved insulin action, however the exact 
mechanisms are unclear and warrant frirther investigation.
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7.4 SUMMARY AND RECOMMENDATIONS FOR FUTURE STUDIES
The aim of this study was to investigate the effects of modifying the composition of 
dietaiy fat in the diets of a gi’oup of middle-aged men on the insulin sensitivity of 
glucose disposal and postprandial lipid metabolism. To explore some of the 
mechanisms by which alterations in dietary fat can influence insulin action and 
lipoprotein metabolism, measurements of the post-heparin activity and the gene 
expression of the insulin sensitive enzyme LPL were conducted.
The insulin sensitivity of glucose disposal was not affected by any of the dietary 
interventions conducted in this study. The lack of effect on insulin sensitivity with 
alterations in dietary fat is similai* to the finding of the majority of studies conducted 
in non-diabetic subjects to date (Schwab et ah 1995; Fasching et ah 1996; Louheranta 
et ah 1998; Louheranta et ah 1999). In common with other studies we also found an 
association between the fatty acid composition of phospholipid membranes and the 
degree of msulin resistance at baseline. It was postulated therefore, that alterations in 
the intake of dietary fatty acids would influence insulin sensitivity, however this was 
not the case. One reason for the lack of any observed effect in this study may have 
been due to the wide variation in insulin sensitivity among the study group at the 
outset. In addition, the number of subjects studied in each intervention was small and 
therefore the study may have had too low statistical power to demonstrate a 
significant effect. It is recommended for friture studies that an assessment of insulin 
sensitivity is conducted at screening in order to ensure that individuals are msulin 
resistant and secondly that a greater number of subjects are included.
With respect to postprandial lipaemia, improvements were observed following tlie 
low-SFA/ high-MUFA diet and the w-3 PUFA enriched diet. In contrast the low-SFA/ 
high-CHO diet was associated with a worsening of postprandial lipaemia through a 
increase in TRL-TG following the intervention diet. From the results of this study 
therefore, it is would appear that it is more beneficial to increase the intake of fet fi*om 
unsatuiated souices as opposed to reducing total fat intakes and increasing the intake 
of carbohydrate. However as stated in the introduction to this work most Nutritional 
Recommendations are directed towai'ds decreasing the intake of all fat and increasing 
the intake of carbohydrate. Low-fat, high-CHO diets have been recommended for
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several reasons but were primarily based on the effect of such diets on total plasma 
cholesterol concentrations (Kromhout et a/. 1995). However unsaturated fats have 
been shown to be equally effective at lowering plasma cholesterol levels (Mensink,
1994). Other workers have also argued strongly against the use of high-CHO diets in 
the prevention of the development of or attenuation of the manifestations of the 
insulin resistance syndrome. The main argument against the use of high-CHO diets in 
both normal and diabetic subjects is that they increase the concentration of both 
fasting and postprandial TG levels, and that they can lower the concentration of HDL- 
cholesterol (Reaven, 1997; Grundy, 1999; Katan, 1997). Our work supports the 
finding that postprandial TG levels are increased as a result of high-CHO feeding and 
adds to the consensus that dietary fat quality is the important deteitninant of CHD risk 
, with SFA increasing risk and MUFA and PUFA posing little risk and in some cases 
reducing risk. The work suggests that dietary fat composition should be changed 
towai'ds a lower SFA intake a higher MUFA intake and a lower w-6 : w-3 ratio thiough 
an increase in the intake of long chain w-3 PUFA. Recommendations for friture studies 
are that dose response studies are conducted to determine the optimum dietaiy levels 
of each of the main fatty acid groups.
There was no change in the measurement of LPL activity or LPL gene expression 
following any of the dietary intervention studies. Few other studies Imve shown any 
effect of w-3 PUFA enrichment on post-hepaiin LPL activity (Harris et al 1988; 
Weintraub et a l 1988; Nozaki et a l 1991). In addition, little consistent information is 
available fr om previous studies regarding the effects of high-CHO and low-fat diets 
on LPL and HL activities (Blades & Garg, 1995) and few studies have examined the 
effects of a greater MUFA intake on plasma LPL activity (Williams et ah 1999). We 
also found no change in the levels of mRNA gene expression following any of the 
intervention diets. Again, few studies have looked at the effect of manipulating 
intakes of dietary fet and the eiqjression of LPL. Our results are in agreement with 
those of Muiphy et al. (1999) who found no effect of fish oil feeding on the 
expression of LPL in subcutaneous adipose tissue, however as with our study the 
number of subjects was small (n = 6). Further studies involving larger numbers of 
subjects are required before any firm conclusions can be reached as to the effect of 
altering dietai y fet intakes on the activity and expression of the enzyme LPL.
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The relationship between insulin sensitivity and postprandial lipaemia was 
complicated and in the group overall there was a positive association between the 
insulin sensitivity of glucose disposal and TG AUC at baseline. The impact of insulin 
resistance on postprandial metabolism has not been extensively analysed however our 
results aie not in agreement with other studies that have indicated that 
hyperinsulinaemia and/or decreased insulin sensitivity is involved in altered 
lipoprotein metabolism (Graci et al. 1999; Boquist et al. 2000; Jeppesen et al. 1999). 
The results of this study warrant fuither investigation as a sufficient number of similar 
studies have not been completed from which to make adequate comparisons.
Finally these studies were completed in a group of genetically unchaiacterised 
subjects. The importance of genotype was not considered when these studies were 
originally planned however, since then it has become cleai* that not only can genetics 
play a role in determining an individuaFs lipid profile, but it can also influence then 
response to a lipid-altering intervention. Less is know about the effect of particulai’ 
genetic phenotypes on insulin sensitivity. Had a larger number of subjects that had 
been genetically chaiacterised been included in the study it may have been possible to 
observe cleaier associations between alterations in dietaiy fat intake on measures of 
lipid metabolism, insulin sensitivity and LPL gene expression.
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APENDIXî Stable isotope studies conducted by other investigatoi's during 
dietary interventions (not described in thesis)
INSULIN SENSITIVITY OF GLYCEROL RELEASE AND NEFA 
SUPPRESSION
i.e. insulin sensitivity of fasting HSL inhibition (stable isotope study of glycerol 
production rate in response to insulin infiision).
This involved measuiements of insulin, glycerol and NEFA concentrations and 
glycerol production rate during the fasting (3h) and low-insulin infusion phase (3h) of 
a 6 hr infusion of [1,2,3,^H5]glycerol (see protocol Fig la).
In each study the insulin inftision resulted in a very small but significant increase in 
serum insulin and significant reductions in glycerol and NEFA (see Fig 2b appendix),. 
In the FO study there were no differences in fasting or low insulin glycerol or NEFA 
concentrations between the FO and the control group. In contrast both festing and low 
insulin glycerol and NEFA levels were lowered by the reduced SFA diet compared 
with the control diet, significantly so during the insulin infiision (glycerol, 29.3 {sd 
10.2) V. 20.4 {sd 11,6) mmols/1, p=0.01 ; NEFA 0.42 {sd 0.10) v. 0.29 {sd 0.08) 
mmols/1, p=0.01 for the control v. the reduced SFA diet respectively. The insulin- 
induced fall in glycerol concentrations reflected a significant fall in the glycerol 
production rate and the extent of the All in glycerol concentration was highly 
correlated with the 611 in the appearance rate {R  ^= 0.71).
Fish oil intervention
There is no effect of the fish oil intervention on glycerol kinetics. Appearance rate 
was not influenced by the intei-vention in the fasting or low insulin state. The 
appearance rate fell significantly with the low level insulin infusion (p~0.015 before 
and p= 0.034 after reduced fat intake but the extent of the reduction did not change. 
Reduced SFA intervention
There was an effect of the intervention on glycerol kinetics since the appearance rate 
was marginally lowered in fasting (p=0.061), and with insulin (p=0.022) by the 
dietary intervention. The appearance rate fell significantly with the low level insulin 
infusion (p-0.01 control, p= 0.001 intervention) but the extent of the reduction did not 
change.
If the glycerol production rate is assumed to reflect the activity o f HSL which 
is primarily a toction of insulin activity then these results suggest that the insulin 
sensitivity of HSL is not altered by increased FO. However the significant fall in the 
glycerol Ra during 6sting and with insulin suggests that the insulin sensitivity of this 
step is improved by decreased SFA intake.
Fish oil study SFA study
glycerol Ra (mmols/kg/h) fall in Ra glycerol Ra(mmols/kg/h) fall in Ra
control Fish oil control fish oil control Low SFA control Low SFA
Fasting +insulin fasting +insulin Fasting +insulin fasting +insulin
Mean 113 90 113 88 23 25 86 76 80 60 16 20
Sd 39 30 40 35 24 31 20 22 21 17 17 14
p insulin effects 0.015 0.034 0.013 0.000
p dieteffects fasting 0.996 0.061
p diet effects insulin 0.814 0.022
pdiet on fall in Ra 0.866 0.223
Fig 1 INSULIN SENSITIVITY OF GLYCEROL RELEASE AND NEFA 
SUPPRESSION
Figure la  ProtocolGlycerol release protocol
constant Infusion of I1,2,32H5] glycerol +/* Insulin 
Blood sampling: insulin, giyceroi and NEFA
\  i l l !  U H
lasting Low insulin infusion
after overnight fast O.OOSU.kg*^  h*L
Q 3hm 6hrsTime (hours)
primed constant infusion of 11,2,32H5] giyceroi 
glycerol enrichment measured by GCMS
glycerol appearance rate (Ra)
Ra -  infusion rate/isotope dilution.
Fig lb Glycerol and NEFA concentrations witli low insulin infusion
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